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Zusammenfassung und wissenschaftlicher Erkenntnisgewinn 
Biopharmazeutika sind potente Medikamente, welche häufig in zielgerichteten Therapien eingesetzt werden. 
Sie weisen bemerkenswerte Spezifitäten und geringe Nebenwirkungen auf, Aspekte, die unter anderem für die 
Behandlung von Autoimmunkrankheiten und Krebs von großer Relevanz sind. Allerdings stellen die Generierung 
und die aufwendige funktionelle Validierung von neuen Molekülen heutzutage immer noch einen Engpass in 
dem Entwicklungsprozess von neuen biopharmazeutischen Medikamenten dar. Die Durchführung von 
funktionellen Assays in einem frühen Entwicklungsstadium wäre von großem Vorteil für die Identifizierung von 
neuen potenten Medikamenten und möglicherweise neuartigen Therapieansätzen. Dennoch sind klassische 
phänotypische Screens in Zusammenhang mit Proteinbibliotheken mit hoher Diversität limitiert durch den 
niedrigen Durchsatz der Funktionalitätsbestimmung und der erforderlichen Expression und Aufreinigung jedes 
einzelnen Wirkstoffkandidaten.  
Ziele dieser Arbeit waren die Etablierung und Validierung eines neuen generischen Verfahrens für die direkte 
Selektion funktioneller Proteinvarianten mit vorgeschriebener biologischer Wirkweise in einem Ultra-Hoch-
Durchsatz Prozess. Für diesen Zweck wurden S. cerevisiae Hefezellen als Sekretionswirt eingesetzt, da deren 
hohe Transformationseffizienz und Kompatibilität zu hoch-diversen Protein Bibliotheken ein wichtiges Merkmal 
darstellt. In Kombination mit den Hefezellen wurden Säugertier Reporterzellen verwendet, um 
aktivitätsabhängige fluoreszente Signale, welche auf einen erwünschten Wirkmechanismus hinweisen, zu 
erhalten. Diese Strategie bildet die Grundlage einer neuen Selektionsplattform, welche die Dursuchung einer 
hohen Anzahl verschiedener Proteine nach gewünschter biologischer Funktion ermöglicht. Die 
Kompartimentierung eines Gemisches aus Hefe- und Reporterzellen resultiert in Mikroreaktoren, in denen eine 
Phänotyp-Genotyp Kopplung gewährleistet ist. Durch das geringe Volumen, welches sich im Picoliter Maßstab 
bewegt, findet eine schnelle und effiziente Akkumulation von sekretierten bioaktiven Molekülen statt. Durch 
den Einsatz mikrofluidischer Verfahren können beide Zelltypen schnell und hoch-präzise in Mikrotröpfchen 
verpackt werden. Hydrogel-bildendende Polymere ermöglichen die Erzeugung von uniformen kugelähnlichen 
Mikroreaktoren, welche sowohl Hefe- als auch Reporterzellen in sich tragen. Diese Strategie macht das System 
kompatibel mit Ultra-Hoch-Durchsatz Fluoreszenz-aktivierter Zellsortierung und ermöglicht den Einsatz von 
herkömmlichen kommerziell erhältlichen Sortiergeräten zur Durchmusterung von Protein-Bibliotheken mit 
hoher Diversität.  
Der erste Teil dieser Arbeit befasst sich mit der Generierung von Hydrogel-Mikroreaktoren. Drei verschiedene 
Hydrogel-bildende Matrizes und Polymere wurden getestet und die Mikroreaktoren-Generierung sowie die 
Gellierungs-Konditionen wurden optimiert. Darauffolgend wurden die Lebensfähigkeit und die Aktivierung der 
Säugertier Reporterzellen unter diversen Bedingungen und unter Verwendung der drei verschiedenen Polymere 
untersucht. Kultivierungsbedingungen wie das verwendete Zellkulturmedium, die Kultivierungstemperatur und 
die Rotationsgeschwindigkeit während der Kultivierung wurden umfassend getestet und miteinander verglichen 
um optimale Bedingungen für beide Zellspezies (Hefe und Säugerzellen) zu identifizieren.  
Der zweite Teil der Forschungsarbeit fokussierte sich auf die Validierung des Konzepts. Immortalisierte Maus B-
Zellen wurden zusammen mit Zytokin-sekretierenden Hefezellen als Modell für erste funktionelle 
Selektionsversuche eingesetzt. In einer Reihe von Mischungsexperimenten wurden Hefezellen, welche ein 
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biologisch aktives Zytokin sekretierten in verschiedenen Verhältnissen mit einem Überschuss an Hefezellen 
gemischt, welche eine nicht-funktionelle Zytokin-Mutante sekretierten. Durch den Einsatz von Ultra-Hoch-
Durchsatz Fluoreszenz-aktivierter Zellsortierung konnten Mikroreaktoren isoliert werden, welche eine durch ein 
biologisch funktionelles Zytokin aktivierte Reporterzelle beinhalteten. Dieser Prozess führte zu einer schnellen 
und effizienten Anreicherung von Hefezellen, die das biologisch aktive Zytokin sekretieren. Diese ersten Erfolge 
gewährten einen Einblick in die Stärken und Schwächen dieses Verfahrens und warfen Licht auf die vielen 
verschiedenen ausschlaggebenden Faktoren, welche unumgänglich sind, um eine robuste und zuverlässige 
Selektionsplattform zu etablieren.   
Der letzte Abschnitt der Arbeit ist der Implementierung des Verfahrens zur Selektion agonistischer Antikörper 
gewidmet. Dazu wurde die T-Zell Aktivierung durch anti-CD3 Antikörper mithilfe einer immortalisierten T-Zell 
Reporterzelllinie nach Verkapselung in Mikroreaktoren untersucht. Im Zuge der Arbeiten hatte sich die Menge 
an durch die S. cerevisiae Hefezellen sekretiertem anti-CD3 Antikörper als zu niedrig herausgestellt. Dies 
resultierte in einer unzureichenden T-Zell Aktivierung, sowohl unter Standard-Zellkulturbedingungen, als auch 
in den miniaturisierten Mikroreaktoren. Aus diesem Grund wurde eine Adaptierung des Systems vorgenommen, 
um den Einsatz eines alternativen Sekretionswirtes, welcher besser für die Sekretion von großen und komplexen 
Molekülen wie Volllängen Antikörpern geeignet ist, zu ermöglichen. Dies wird als Teil eines Postdoktoralen 
Forschungsprojektes weiterbearbeitet. 
Diese Arbeit liefert eine methodische und konzeptionelle Grundlage für die weitere Entwicklung und möglicher 
Etablierung einer generischen Plattform zur Identifizierung und Selektion von Biomolekülen mit angestrebten 
biologischen Funktionen. Das bearbeitete Konzept hat sich als geeignet für die funktionale Durchmusterung 
Hefe-basierter Bibliotheken erwiesen und besitzt das Potential, die Entwicklung von neuen maßgeschneiderte 
Biopharmazeutika mit definiertem biologischem Wirkmechanismus, wie z.B. Zytokine, zell-penetrierende oder 
agonistische Antikörper, zu beschleunigen.  
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Scientific Novelty and Significance 
Biologics in targeted therapies often demonstrate remarkable safety and specificity, especially in case of 
autoimmune diseases and cancer. However, the discovery of novel molecules and the necessary functional 
validation still represent a bottleneck in the development of novel biopharmaceuticals. Implementation of 
functional assays in an early drug-discovery stage appears highly beneficial for the discovery of new potent 
biologic drugs or even first-in class medicines. Nevertheless, the low throughput and the need of individual 
expression and purification of the tested candidates, limit the applicability of the classical phenotypic screens 
for high-diversity protein libraries.  
Aim of this work was the establishment and validation of a novel generic functional screening approach for 
selection of protein variants with desired biological function in an ultra-high-throughput manner. This new 
process is based on the combination of a S. cerevisiae secretion host, capable of high transformation efficiencies 
and compatible with high-diversity protein libraries, with a mammalian-based reporter system for activity-
dependent fluorescence readout of functional molecules. This strategy represents the base of a straightforward 
selection platform for testing a high number of different protein molecules for desired biological function. 
Compartmentalization of the secretor and reporter cells in distinct microreactors enables phenotype-genotype 
coupling while miniaturization of the test assays to volumes in the picolitre range brings the advantage of rapid 
biochemical reactions by fast accumulation of secreted molecules. Microfluidic-assisted encapsulation of the 
two cell types supports the generation of microdroplets with high speed and precision and implementation of 
hydrogel-forming polymers enables the recovery of uniform hydrogel microbeads surrounding the encapsulated 
cells. This strategy makes the system compatible to ultra-high throughput fluorescence-activated cell sorting on 
a commercially available device and enables the screening of high diversity protein libraries.  
The first part of the work assessed the generation of hydrogel microbeads using different emulsification 
techniques. Three different hydrogel-forming matrixes and polymers were tested and droplet generation, as 
well as gelation conditions were optimised. Next, mammalian reporter cell viability and activation were 
examined under diverse conditions in hydrogel microbeads consisted of the three different polymers. 
Cocultivation conditions like culture medium, culture temperature, and rotation speed, were extensively tested 
and compared in order to identify conditions compatible with both species (S. cerevisiae and mammalian cells).  
The second part of the research was focused on validating the concept by conducting a proof-of-concept 
functional screening using a model secretor-reporter system. By means of mixing experiments of yeast cells 
secreting a biologically active cytokine with an excess of yeast cells secreting a non-functional mutant variant, 
the successful and efficient enrichment of biologically active variants following our novel functional selection 
approach was proven. These experiments gave insights into the strengths and limitations of the method and 
revealed which factors play a decisive role for a robust and reliable selection platform. 
The last part of the work was dedicated to implementation of the functional screening approach for selection of 
agonistic antibodies. By utilizing an immortalized T cell reporter cell line, T cell activation by anti-CD3 antibodies 
was examined after compartmentalization into microdroplets. However, the amount of secreted full-length anti-
CD3 antibody from S. cerevisiae cells was too low and was insufficient to induce reporter cell activation both in 
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standard cell culture and in miniaturized microdroplets. Therefore, adaptation of the system towards an 
alternative secretion host, more appropriate for secretion of large and complex molecules like full-length 
immunoglobulins, was envisaged and will be performed in the scope of a post-doctoral research.  
In summary, this work provides a methodical and conceptional basis for the development of a generic platform 
for discovery and selection of biomolecules with desired biological function. A comprehensive investigation of 
the effects of microfluidic co-encapsulation of living organisms from two distinct kingdoms was performed, 
giving insides into critical aspects like culturing conditions, which determine limiting factors like cell viability and 
protein expression and secretion. The strategy has proven suitable for functional screening of yeast-based 
libraries and has the potential to enable and accelerate the discovery of new functional biologics, including 
cytokines, agonistic or internalizing antibodies.  
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1. Introduction 
Historically, drug discovery and development dates back to the juvenility of human civilization. In ancient times, 
remedies were derived mainly from plant or animal products in form of ointments or potions and were most 
probably discovered through a trial-and-error experimentation1. Centuries of development and refinement led 
to the development of medicinal substances2, but it was not until the 1800s when the drug discovery started to 
follow scientific techniques3, beginning with the chemical isolation of active ingredients from plants (morphine 
from opium4, quinine from cinchona bark5, cocaine from coca leaves6 and many more). While in the 20th century, 
diseases were mainly controlled by small molecule-based medicines, with antibiotics being in the forefront2, the 
discovery of the DNA structure and function by Watson and Crick in 19537 set a new milestone in the 
pharmaceutical research and gave rise to modern molecular biology8. Combined scientific progress in the fields 
of biochemistry and molecular biology in the late 20th century enabled the development of the first biological 
drug - recombinant human insulin (Humilin®), which reached the pharmaceutical marked in 19829. Since then, 
the development of biologics (also called biopharmaceuticals) has become a focus of interest, opening the door 
to novel treatments with superior safety and specificity especially in case of autoimmune diseases10 and 
cancer11. Nowadays, the biologics represent a significant part of the medical arsenal with 17 novel 
biopharmaceuticals approved in 2018 by the FDA (US Food and Drug Administration) from a total of 59 new 
drugs12 and a continuous growth of the biologics market, predicted to reach nearly 400 billion USD/year by 
202513.  
 
1.1. Biologics: Definition and Classification 
Biological medicines represent a heterogenous class of drugs, which according to EMA’s (European Medicines 
Agency) definition “contain active substances from a biological source, such as living cells or organisms (human, 
animals, and microorganisms such as bacteria or yeast)”14. Vaccines, antitoxins, somatic cells, blood products, 
gene therapy, tissues, peptides and a broad range of recombinant therapeutic proteins (hormones, enzymes, 
cytokines, antibodies) represent the main entities which fall in the category of biopharmaceuticals up to date15. 
Due to their biological origin, those medicines often represent complex mixtures consisting of sugars, proteins, 
or nucleic acids or combinations of all those, making the characterization of the final product not trivial. Further 
characteristics, differing biologics from conventional small molecule drugs, are the higher molecular size, light 
and heat sensitivity, aggregation and degradation behaviour, which could affect the shelf life time of the 
products and, thus, often increase the final price of the medicines16. Nevertheless, together with higher 
complexity, the biologics bring advantages over conventional drugs, by exhibiting higher selectivity and potent 
therapeutic efficacy, paired with limited side effects. Today, biopharmaceuticals represent the cutting-edge of 
biomedical research and have the potential to offer not only novel treatment but also cure for a variety of 
challenging diseases.  
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1.2. Discovery and Development of Biologics 
The biologics market is up to date dominated by monoclonal antibodies (mAbs) and other recombinant proteins 
(Fig. 1). Generation of monoclonal antibodies was first established in 1975 by Köhler and Milstein by hybridoma 
technology17, enabling for first time in vivo antibody application as therapeutics. In the past decades, variety of 
antibody discovery platforms have been developed, which can be broadly divided into three categories: in vivo, 
in vitro, and in silico technologies.  
 
 
Figure 1. Global biologics market share of different biopharmaceutic products in 201818. Graph modified from 
https://www.mordorintelligence.com/industry-reports/biologics-market, accessed on 23.03.2020. 
 
1.2.1. In vivo antibody discovery technologies 
Hybridoma technology opened up the field of therapeutic antibody development. In the process of hybridoma 
generation, mice are immunized with the target molecule. Based on the in vivo humoral immune response of 
the animals, followed by natural antibody maturation processes in lymphoid organs, B cells producing highly 
specific and affine murine antibodies are stimulated to expand and differentiate to plasma cells, which represent 
the antibody-secreting reactors of the organism19. After sufficient immunogenic response, the maturated B cells 
are isolated from the spleen of the host animal and fused with myeloma cancer cells to generate immortalized 
hybridoma cell lines. Important factor in this step is to ensure monoclonality of the resulting cell lines, which is 
crucial for the following selection process. Generated hybridomas are then subjected to multiple rounds of 
screening and selection for isolation of mAbs with desired target specificity and affinity20, 21. Standard screening 
procedure is microplate-based antigen-immobilized enzyme-linked immunosorbent assay (indirect-ELISA)22. In 
this approach, the target molecule (antigen) is immobilized on the surface of a microtiter plate, culture 
supernatant of the different hybridoma cell lines is incubated in the wells in different dilutions and after washing 
steps, the antigen-bound monoclonal antibodies are detected using enzyme-conjugated (e.g. peroxidase) 
detection antibodies, where a chemical substrate is converted to a chromophore (a molecule with specific colour 
and absorption). Although this procedure has been successfully implemented, delivering the first approved mAb 
on the market – muromonab23, direct use of murine antibodies for human therapy resulted in immune response 
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against the drug (human anti-mouse antibodies or HAMAs) leading to rapid clearance of the murine antibodies24. 
This shortcoming of murine antibodies shifted the focus into the development of less immunogenic biologics by 
genetic engineering humanization strategies, giving rise to second-generation chimeric (rituximab25) and 
humanized (trastuzumab26) mAbs. In order to surpass the need of additional humanization of the isolated 
murine mAbs (resulting often in much lower antibody affinity than the parental antibody27) , the current state-
of-the art is to use transgenic host animals for the immunization, where the rodent immunoglobulin genes are 
replaced with those from human repertoire, leading to formation of fully human antibodies28.  
1.2.2. In vitro antibody discovery technologies  
Another approach for the production of fully human antibodies representing alternative to animal 
immunization, is implementation of in vitro display platforms like phage display29, yeast surface display30, 
bacterial31, or ribosome display32 for generation and screening of combinatorial antibody libraries. These 
libraries can be derived from immune human individuals, or contain the complete naïve human repertoire. For 
this purpose, the antibody heavy and light chain repertoire is obtained from mRNA from B lymphocytes, reverse 
transcribed to cDNA and the variable domains (for heavy (VH) and light (VL) chains) are randomly recombined 
to form antibodies or antibody fragments (single chain variable domain (scFv) or fragment antigen binding 
(Fab))33. Additionally, combinatorial libraries can be selectively mutated or randomized, generating semi-
synthetic antibody libraries with diversity beyond the scope of the immune system, which enhances the 
probability of isolating antibodies with desired properties significantly34. While immune libraries usually have 
sizes in the range of 108 clones, naïve libraries must be bigger than 109 in order to compensate for the fact that 
no affinity maturation and expansion of antigen-specific clones has occurred35. Nowadays, antibody libraries 
with sizes of over 5 x 1010 for phage display34-36 and up to 109 for yeast surface display37 are standard. 
In case of phage display, antibodies or antibody fragments are expressed and presented on the surface of phage 
particles by genetic fusion to one of the coat proteins of filamentous bacteriophage. The most common 
screening strategy is based on biopanning in multiple rounds, where in similar to ELISA manner, the target 
molecules are immobilized on the surface of 96-well polystyrene microtiter plates. Subsequently, the phage 
library is incubated in the microplate wells and the non-binding phages are washed away. Bound phages are 
eluted and amplified by infection of bacteria (mostly E. coli) and the cycle is repeated several times with 
increased selection stringency by more extensive washing steps to enable isolation of high-affinity phages. At 
the end, enriched clones are analysed by DNA sequencing, reformatted for mammalian expression as full-length 
antibodies and target binding and functionality are further characterized38, 39.  
Cloning of variable antibody genes could also easily be performed for the generation of yeast surface display 
(YSD) libraries. For this purpose, antibody genes are genetically fused N- or C-terminally to a cell wall anchor 
protein (e.g. Aga2p). Commonly, homologous recombination in S. cerevisiae yeast is implemented as cloning 
strategy, resulting in generation of large YSD libraries40. Following protein expression induction, the Aga2p-fused 
library is secreted by the yeast cells and displayed on the cell surface through a disulfide bond formation 
between Aga2p and Aga1p domains of the -agglutinin mating system41. In comparison with other display 
formats, YSD offers several advantages like comparability to fluorescence-activated cell sorting (FACS), where 
real time selection monitoring and quantitative measurements of equilibrium binding constants, stability and 
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specificity is possible, without soluble protein expression necessary42. Furthermore, yeast cells represent a 
eukaryotic expression system capable of incorporation of post-translational modifications like glycosylation. 
Implementation of protein tags on the displayed molecules enables normalization of the ligand binding to the 
surface expression levels, thus selection of variants exhibiting simultaneously high expression levels and high 
affinity is possible41.  
Common in all in vitro surface display platforms is the phenotype-genotype coupling, ensured by the display 
host which carries either the DNA (phage, yeast, bacteria) or the mRNA (ribosome) code of the enriched variants. 
This feature enables high-throughput selection of the display hosts either by biopanning (phage, ribosome) or 
by FACS (yeast) and has resulted in the generation of numerous diagnostic and therapeutic antibodies43-45.  
1.2.3. In silico antibody discovery technologies  
The youngest category antibody discovery approaches (third generation), is based on in silico computational 
antibody analysis and design. Computational antibody design is a complex process and involves different 
methods and approaches like structure and energy-based modelling, combinatorial design and machine 
learning. Among optimization of antibody affinity and/or physicochemical properties, these techniques enable 
also de novo antibody design, where structure and antigen-antibody complexes are modelled using a set of 
different algorithms (e.g. OPTCDR, AbDesign, RosettaAntibodyDesign)46. Current advances in next generation 
sequencing (NGS) of whole immunoglobulin repertoires (Ig-seq), enabled the generation of huge databases 
containing multiple Ig-seq datasets, representing enormous diversity of naturally occurring antibody variants. 
These databases build the base of antibody model libraries, where in silico high-throughput screenings with 
different targets can be performed and binding interactions (docking) between the antigen of interest and 
antibody variants is predicted. Furthermore, these antibody model libraries are used also for developability 
prediction by assessment of residues charge, hydrophobicity, or loops length47.  Although in silico antibody 
design has emerged as essential part of the discovery and development process of novel antibodies, 
computational methods are unlikely to replace the entire experimental process. Nevertheless, they represent 
cost-efficient analysis and optimization tools for guiding the experimental procedures and development of the 
lead antibodies48.  
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1.3. Functional Antibodies  
In the context of disease therapy, antibodies exhibit diverse mechanisms of action. Natural antibody functions 
like neutralization, antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity 
(CDC), and antibody-dependent cellular phagocytosis (ADCP) involve a complex interplay of the immune system 
for defence against pathogens and toxins, and are exploited by the majority of marketed therapeutic 
antibodies49. Additionally, antibodies have emerged as suitable tools for regulation of cellular processes by 
modulation of signalling pathways50. Inhibition of overactivated growth factor pathways in cancer cells can limit 
tumour progression and angiogenesis, and prevent metastasis51-53. However, in many cases cancer resistance 
against neutralizing and blocking antibodies can be observed, due to signal compensation by alternative cellular 
pathways54. Next generation antibody therapeutics (antibody-drug conjugates, radioimmunoconjugates 
bispecifics, multispecifics, BiTEs etc.) aim at surpassing  the limitations of a conventional antibody format, either 
by combination of the antibody target specificity with tumour killing by potent chemotherapeutics55 or 
radioisotopes56, or by immune system modulation by T cell engagement57. 
1.3.1. Blocking antibodies for therapy 
Neutralizing antibodies intercept antigens like allergens, viruses, and toxins and thereby negate downstream 
cellular effects like cell infection, chemotaxis or cell death. This mode of action has been exploited for therapy 
of infectious viral diseases (palivizumab58), cancer (bevacizumab59, durvalumab60), and autoimmune diseases 
(adalimumab61, infliximab62). 
On the other side, antagonistic antibodies inhibit directly the function of its target like receptor-ligand 
interaction or receptor activation by multimerization and block or dampen its biological function. Multiple 
disease-relevant receptors have been identified and targeted by antagonistic antibodies. Examples of approved 
therapeutic antibodies for various indications, targeting different receptors are listed in Table 1.  
 
Table 1. Examples for approved antagonistic antibodies used for therapy 63.  
Antibody Target Indication 
Ipilimumab (Yervoy®) 
Cytotoxic T-lymphocyte-associated Protein 
4 (CTLA4) 
Melanoma 
Cetuximab (Erbitux®) Epidermal Growth Factor Receptor (EGFR) 
Colorectal cancer, head and neck 
cancer 
Pertuzumab (Perjeta®) 
Human Epidermal Growth Factor Receptor 2 
(ERBB2/HER2) 
Breast cancer 
Nivolumab (Opdivo®) Programmed Cell Death Protein 1 (PD1) 
Melanoma, Hodgkin lymphoma, 
NSCLC and others 
Olaratumab (Lartruvo®) 
Platelet-Derived Growth Factor Receptor A 
(PDGFRα) 
Soft tissue sarcoma 
Natalizumab (Tysabri®) Integrins (41 and  47) 
Multiple sclerosis and Crohn’s 
disease 
Daclizumab (Zinbryta®) Interleukin 2 Receptor (IL-2R) Multiple sclerosis 
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1.3.2. Agonistic antibodies for therapy  
Opposite to receptor blocking, agonistic antibodies induce cellular pathway cascades by interaction with its 
target receptor in a manner that mimics binding of the native ligand. Generation and development of agonistic 
antibodies against co-stimulatory immune cell receptors (secondary signal for activation of immune cell 
response) has emerged as promising strategy to target cancer cells which otherwise remain “hidden” from the 
immune system64, 65. Numerous co-stimulatory agonistic antibodies are currently undergoing clinical trials as 
combination therapies for diverse cancer indications mostly in advanced-stage malignancies. Promising and 
well-characterized targets are TNF receptor superfamily members (e.g. CD40, OX40, GITR)66-68 and co-
stimulatory B7-CD28 superfamily members (e.g. CD28 and ICOS)69, 70. However, scientists are facing new 
challenges during discovery and characterization of new agonistic molecules, due to the complexity of immune 
checkpoint activation mechanisms, which often demand extensive antibody structure design and novel 
biophysical profiles, not been necessary for other antibody therapies65.  
1.3.3. Cell-penetrating antibodies – future tools for regulation of intracellular targets  
Monoclonal antibodies have empowered targeted disease therapy due to their high specificity and excellent 
pharmacokinetic properties. However, despite their huge success, antibodies are generally confined to the 
extracellular space remaining unable to penetrate cellular membranes. With a limited number of validated 
tumour-specific or disease-associated cell surface or soluble antigens, the target repertoire for novel mAbs is 
shrinking and the competition in the field is becoming very tough71, 72.  At the same time, intracellular proteins 
such as enzymes, transcription factors, or proteins involved in signal pathways, are becoming attractive drug 
targets. Although the intracellular space has been so far reserved by small molecule drugs, which in most cases 
are capable of free diffusion through cellular membranes, many intracellular targets have been considered 
undruggable by small molecules due to large flat contact areas in the active centres or protein interaction sites  
where specific inhibition by chemical molecules is not possible73. Oncoproteins like c-Myc and Ras74, 75 or 
intracellular immune checkpoints76 represent some examples for promising intracellular antibody targets. 
Diverse strategies for intracellular antibody delivery have been extensively studied, however the majority of 
them have not passed the proof-of-principle or preclinical research stage, yet77. 
Whereas cellular internalization can be achieved by specific binding of antibodies to cell surface receptors 
(receptor-mediated endocytosis), in this case the antibodies remain entrapped in enclosed intracellular vesicles 
(endosomes) where they are either subjected to degradation (lysosomes), recycling, or transcytosis (transport 
to the other side of the cell)78. Since the majority of potential therapeutic targets are located either in the 
cytoplasm or in the nucleus (e.g. transcription activators), cytosolic antibody delivery represents a high in-
demand branch in antibody development and engineering. Chemical modification of antibodies (e.g. 
conjugation of membrane transport peptides79 and cell-penetrating peptides (CPPs)80 or conjugation of 
phosphorothioated DNA oligonucleotides81), as well as utilization of lipid-based82, polymer-based83, inorganic84, 
or virus-like nanocarriers85 are examples for some of the most extensively studied intracellular antibody delivery 
approaches up to date. Additionally, natural autoantibodies occurring in some autoimmune diseases like 
systemic lupus erythematosus86 and multiple sclerosis87 have been observed to penetrate cytoplasm of living 
cells and even accumulate in the nucleus88. Such autoantibodies have been used as vehicles for the delivery of 
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different payloads like nanoparticles89 and proteins90. Nevertheless, natural anti-DNA autoantibodies lack cell 
specificity and often have cytolytic or cytotoxic effects. In order to address these problems, engineered cytosol-
penetrating antibodies (cytotransmabs) were generated by substitution of the variable domains (VL) of two 
approved therapeutic antibodies (adalimumab and bevacizumab) by a humanized VL from a mouse-derived 
lupus autoantibody (hT4)91. Both engineered antibodies demonstrated cytosolic penetration, however the 
antigen specificity of the parental therapeutic antibodies was lost. Instead, the cytotransmabs interacted with 
ubiquitously expressed heparan sulfate proteoglycans (HSPGs) on the cell surface and following endocytosis, 
dissociated from HSPG in the acidified endosomes. In the endosomal escape mechanism, proposed by the 
authors, conformational changes in the cytotransmab structure take place upon endosome acidification (pH 5.5-
6.5) and lead to formation of endosomal pores, enabling the release of the cytotransmabs in the cytoplasm92.  
Further engineering of the cell-penetrating antibody moiety (hT4) reduced the interaction of the cytotransmabs 
with HSPGs (which previously has rendered the cytotransmabs unspecific) and grafting of the endosomal escape 
motif W92Y93W94 on the VH resulted in enhanced endosomal escape efficiency93. 
With recent advances in the development of multispecific antibody formats94, grafting of endosomal escape 
motifs from autoantibodies and/or their combination with antibody domains addressing intracellular targets 
becomes more attractive. However, a reliable high-throughput selection system for both efficient cytosolic 
penetration and functional intracellular target engagement is required for successful screening and validation 
of engineered cytosol-penetrating antibody formats95. 
 
1.4. Functional Antibody Screening 
Affinity-based antibody discovery techniques (described in 1.2) stand out with high probability of finding a 
specific and highly affine binder and, hence, represent the approach-of-choice (also called “target-based 
approach”) in most antibody discovery campaigns nowadays. However, antibody discovery in this case often 
stumble upon the problem of limited validated therapeutic targets, leading to extensive generation of follow-
up drugs which differentiate only in the addressed epitopes, mechanisms of action, or simply are characterized 
by one improved property (“me better” antibodies)96. Alternatively, novel drugs can be identified based on their 
effects upon a disease-relevant model system (animal models, tissues, or cell models) in so called phenotypic or 
functional approach97. In this case no profound knowledge of the molecular target and mode of action are 
initially required and candidates leading to desired effects (e.g. cell death, pathway activation or inhibition) are 
further characterized as hit molecules. Function-based antibody discovery has the potential of engendering the 
development of first-in class antibody therapeutics against novel targets72, nevertheless bottleneck in this 
approach represents the last step of the discovery process - target deconvolution, where the molecular target 
and the mode of action are identified. Furthermore, in this case extensive clinical validation of the novel targets 
is required, which brings along high development risk and prolonged research time frames98. Comparison of the 
discovery process following either function-based, or target-based approach is illustrated in Figure 2. :  
phenotypic (function-based) screening starts with the establishment of accurate disease model. Here 
personalized medicine can be engaged by utilizing patient-derived primary cancer cells99. Library screening is 
performed in most cases in microtiter plate formats, where high-content microscopy plays often a significant 
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role in the assay analysis100. After identification of the hits and leads with desired properties and effects, the 
molecular target is deconvoluted and identified using proteomics and mass spectrometry techniques101.  
 
 
Figure 2. Function-based vs. target-based antibody discovery. Figure modified from Terstappen et al. 2007 102 
 
The target-based discovery approach begins with the identification and validation of disease-relevant drug 
target. Affinity-based screening of high-diversity antibody libraries can be performed in an ultra-high-throughput 
manner resulting in the generation of hits which specifically recognize the target antigen. However, often 
secondary and tertiary screens are necessary for examination and validation of desired functions (e.g. agonistic 
or antagonistic properties). For this purpose, isolated antibody molecules are subjected to various functional 
assays, where the lead molecules are individually tested in soluble form (after expression and purification)103. 
Although target-based antibody discovery often leads to isolation of highly affine and specific antibodies against 
various targets, in context of in vivo antibody functionality (e.g. agonism) antibodies with moderate affinities 
sometimes demonstrate superior agonist potencies than higher-affinity molecules104, 105. Thus, implementation 
of functional screens in an earlier selection phase could be beneficial for more precise isolation of lead molecules 
with desired functionalities. For this purpose, new more holistic approaches need to be established which, 
depending on the existing experimental models and disease information, incorporate both discovery models.   
 
1.5. High-Throughput Functional Screening  
Since the size of antibody libraries almost always extends those of chemical small-molecule libraries by multiple 
orders of magnitude106, 107, screening techniques with huge success in small-molecule phenotypic screening 
(e.g. high-content microscopy, multiplexed flow cytometry108) face limitations regarding the throughput of the 
phenotypic assays. As functionality of biologics is mediated by complex protein-protein interactions109, cell 
internalization110, receptor clustering111, or effector cell interactions (CDC, ADCC)112, functional validation of 
antibody variants derived by target-based screening is similarly mainly conducted in vitro in multi-well plate 
formats using mammalian cell cultures. This assays often require individual expression and purification of all 
candidates in soluble form. The following section describes and compares the most promising strategies up to 
date for increasing the throughput of in vitro cell-based functional assays.  
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1.5.1. High-content screening technologies  
Multicolour fluorescence microscopy is one of the most powerful tools to analyse spatiotemporal events in 
biological systems113. Image-based analysis of intracellular events and cellular morphology has been broadly 
implemented for defining the functions of genes, proteins and other biomolecules and for the early drug 
discovery in the context of high content screening (HCS) of small molecules114. Modern HCS platforms integrate 
automated cell-sample preparation, fluorescent labelling, image acquisition, image processing and image 
analysis by a combination of sophisticated hardware and software components. Automated microscopes with 
improved auto-focusing and sample positioning, together with artificial intelligence (AI)-based algorithms 
(machine learning, neural networks) enable the generation and management of huge image data sets113. Big 
advantage of the latest HCS platforms is that they permit quantitative analysis of the phenotypes of single living 
cells by cell segmentation algorithms, simultaneously combining observations of multiple parameters like 
cellular morphology, protein expression, localization and post-translational modifications115. The dramatic 
progress in the software field enabled the handling and analysis of huge data sets, as well as advanced data 
mining, modelling and prediction. Nonetheless, the bottleneck of HCS platforms remains the throughput of the 
image acquisition and processing which is performed by the hardware components (confocal microscopes). Up 
to date most of the commercially available devices support only 96- and 384-well plate formats116, which are 
not suitable for screening of high diversity libraries within the scope of phage or yeast surface display.  
1.5.2. High-throughput microtiter plate formats  
Since functional validation of hit molecules, derived from various screening campaigns, is a crucial step for the 
generation of new drug candidates, high-throughput screening (HTS) in microtiter plate formats has undergone 
a developmental revolution117. Adopted from standard methods for screening of small-molecule libraries where 
extensive robotics optimization enabled assay miniaturization in 384- and 1536-well formats, HTS approaches 
are now combined with new molecular biology methods and protein-expression technologies increasing the 
applicability for screening of biopharmaceuticals from protein libraries118. Sole HTS protein screening consists of 
three main stages: generation of cDNA library encoding all protein variants, expression of the DNA library to 
individual functional proteins, and screening for therapeutically relevant molecules in a suitable assay117. 
Furthermore, HTS is often applied as subsequent secondary and tertiary screens after ultra-high-throughput 
screening via phage or yeast surface display119. In contrast to high-content phenotypic screening (described 
above), HTS is a target-based approach which precisely focuses on single mechanism of action (biochemical or 
cell-based assays). Biochemical assays can be based on enzyme/substrate reactions, protein-protein 
interactions, or more complex in vitro transcription systems120. Substituting cell-based systems by biochemical 
assays permits in some setups sample miniaturization to assay volumes of 1-2 µL (3456-well microplates), which 
complies to screening of >100,000 variants per day in an ultra-high-throughput manner. However technical 
hurdles like liquid dispensing and sample evaporation often compromise the validity and reproductivity of such 
assays121. 
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1.5.3. Assay miniaturization techniques 
Miniaturization of functional assays for drug discovery and validation is highly desirable in order to accelerate 
the screening process and to reduce the associated costs. Reduced quantity of biological and chemical reagents 
used per sample enables higher assay throughput without massive increase of the material costs and at the 
same time sample parallelization permits the implementation of multiple detection modes. However, important 
for all miniaturization strategies is to ensure the stability of all assay components over the time course of the 
reactions and to exclude impact by the implemented automation devices (e.g. dispensers or readers)122. 
Miniaturization processes can be divided in three different scales:  
(1) mini-scale: several mm, corresponding to volumes in the µL range; 
(2) micro-scale: 50 µm to a few mm with sample volumes in the range of 10 nL to few µL; 
(3) nano-scale: 1 µm – 50 µm, sample size < 10 nL123. 
Assay development has split up in two main miniaturization approaches: batch-based systems (microplate, 
microarray, and nanoarray formats) and continuous, flow-based systems (lab-on-a-chip, microfluidic devices, 
and lab-on-valve (LOV))122.  
Microplate assays remain the most frequently used format, due to their easier handling, low costs, and simpler 
assay adaptation. However, as commercially available microtiter plates range from 96- to a maximum of 3456-
wells124, micro- and nanoarrays has emerged as novel analytical tools which overcome the scale and density 
limitations of microtiter plates by reaching densities of thousands of spots per cm2. In the past, microarrays have 
been extensively used for gene expression studies via cDNA or RNA analysis, additionally, modern applications 
include protein or small-molecule library screening125. Microarray assays are based on immobilization of 
biomolecules in high density and in a defined order on glass or silicon slides, alternative materials like aluminium 
and gold surfaces, as well as hydrophilic polymers are also being implemented126. Protein microarrays have been 
successfully used for identification, quantitation and functional analysis of a variety of proteins, such as 
biomarkers and potential target molecules127. While earlier microarray setups were mainly based on readout by 
colour change (chromophores) or fluorescence (fluorophores), recently label-free detection techniques have 
been broadly applied. Label-free detection methods are based on measurement of changes in molecular 
biophysical properties like molecular weight (mass spectrometry or microcantilevers), refractive index (e.g. 
surface plasmon resonance), and molecular charge which occur during a biochemical reaction or interaction 
between the molecules in the assay. The main advantage of the label-free detection strategies is that the 
involved methods use only native proteins and ligands, thus, unspecific cross-reactions with detection molecules 
are excluded128. Nanoarrays are further miniaturized microarrays and have been used for highly sensitive and 
selective detection of molecules in trace quantities (e.g. pathogens)129. Although micro- and nanoarray devices 
can dramatically increase the throughput (over 10,000 samples per single microarray), they demonstrate several 
weaknesses regarding the reliability of the assays, resulting from low accuracy and precision of the automated 
dispensing and detection devices122.  
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1.6. Microfluidic Technologies 
Technical progress over the past decades in the field of microfluidics130 has stimulated the development of a 
second branch of miniaturization techniques – flow-based systems. Microfluidic systems enable the control and 
manipulation of fluids that are geometrically constrained to the sub-millimetre scale in microchannels with 
wight/height dimensions between 100 nm and 10 µm131. Microscaling has several advantages in the context of 
fluidics, which have allowed one to screen for novel functionalities that were elusive for macroscale devices. By 
miniaturizing fluidic devices, a laminar flow regime is achieved, which is highly predictable and simpler to control 
than turbulent flow in macroscale devices. As surface tension, interfacial tension, and capillary forces dominate 
the physics of microfluidics, faster diffusion of molecules, due to smaller fluid volumes leads to much shorter 
reaction times130. Although the microfluidic discipline is still considered in its adolescence132, it has opened new 
possibilities for cell-based drug screening like simultaneous testing of compounds on different cell types133 
(continuous-flow microfluidics), more accurate tissue models for disease studies and drug testing134, 135 (3D cell 
culture on microchips and organ-on-a-chip), and facile generation of millions of individual microreactors with 
volume in the picolitre range136 (droplet-based microfluidics).  
1.6.1. Droplet microfluidics for high-throughput biological assays 
Droplet microfluidics enables the encapsulation of reactants in discrete compartments by using an inert carrier 
fluid (usually oil) for the generation of small-volume aqueous droplets in a water-in-oil (w/o) emulsion. In 
contrast to continuous-flow microfluidic systems, where entire reactions take place on a microfluidic chip, 
droplet microfluidics allows large number of reactions without increasing the size or complexity of the 
microfluidic device.  Thus, droplet microfluidics offers greater potential for increased throughput and scalability 
than other microfluidic approaches137. Droplet-based microfluidic devices are capable of producing 
monodisperse droplets with volumes in the range 0.05 pL – 1 nL (diameter 5-120 µm), which can encapsulate 
cells, DNA, and diverse other molecules, dissolved (or suspended) in the inner aqueous phase of the droplet136.  
Huge influence on the generation of stable aqueous droplets plays the carrier fluid (oil phase) which surrounds 
the droplets. The oil phase should prevent coalescence (fusion) of the droplets, it must not influence the reaction 
in the droplets, and should be biocompatible and permit sufficient gas permeability. Surfactants, mixed to the 
oil phase, stabilize the droplets and prevent coalescence by adsorbing to the oil-water interface and lowering 
the interfacial tension between the two immiscible phases138. Fluorocarbon oils are commonly preferred for 
biological applications using microfluidics, because they are characterized by low-viscosity and high gas 
permeability, which is essential for the viability of the encapsulated cells139. Additionally, fluorocarbon oils are 
biologically inert and, due to their simultaneous hydrophobicity and lipophobicity, exhibit excellent retention of 
reagents inside the droplets preventing cross-contamination between the drops140, 141. Alternatively, silicone, 
hydrocarbon, or mineral oils can be used, but all of them bring certain disadvantages either with respect to the 
viscosity of the oil or to the swelling properties of the microfluidic chip142. In accordance to the oil-of-choice, the 
appropriate surfactant should be selected. In the case of fluorocarbon oil, commercially available 
fluorosurfactants consist of mixtures of perflurinated polyethers (PFPE) or further modified (PEGylated) PFPE 
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derivatives and facilitate generation of “highly stable over a wide range of temperatures and biological 
conditions picodroplets”143.  
For the generation of monodispersed droplets, three different microchannel geometries (co-flow, T-junction, 
and flow-focusing) are most commonly used (Fig. 3).  
 
Figure 3. Microfluidic chip geometries commonly used for droplet formation. Figure modified from Damiati et al. 2018 144. 
 
In case of co-flow microfluidic chips, a small capillary for the aqueous phase (dispersed phase) is centered within 
a larger microfluidic channel in which the oil phase (continuous phase) is flowing. Thus, both phases are flowing 
in parallel directions and droplets are formed by the viscous shear of the continuous phase over the dispersed 
phase142, 145. Alternatively, the dispersed phase can be injected from a channel, which is placed perpendicularly 
to the continuous phase channel (T-junction). By T-junction geometry, in the majority of cases drop-formation 
is carried out at low capillary number (Equation 1) (surface forces >> viscous forces) of the continuous phase by 
a mechanism of plugging and squeezing. In this case, the pressure in the continuous phase is increased each 
time the tip of the dispersed phase emerges from the input channel, this leads to squeezing and pinching off 
droplets from the dispersed phase146. Due to the pressure fluctuations, which occur in the continuous and 
dispersed phases, the generated drops are larger than the downstream channel, hence they look spherical142. 
The third drop formation geometry is the flow-focusing device. Here, the dispersed phase is injected through 
one channel, while the continuous phase flows from two orthogonal directions. Similar to the T-junction, when 
the capillary number is low, a mechanism of plugging and squeezing takes place, resulting in big droplets. At 
high capillary numbers (surface forces << viscous forces) drop-formation is facilitated by viscous drag and 
interfacial tension147. Common to all three geometries is that the size of the generated droplets and the speed 
of droplet formation (frequency) depend on the ratio of the flow rates of the continuous and dispersed phases. 
Equation 1. Capillary number 148. 
𝐶𝑎 = µ ×
𝑈
𝛾
 
µ (Pa s) = viscosity of the continuous phase 
U (m s-1) = characteristic velocity of the continuous phase 
𝛾 (N m-1) = surface tension of the water-oil interface 
 
Droplet microfluidics offers an efficient high throughput technology for compartmentalization of single cell 
populations. Single-cell analysis provides information related to differences between individual cells in a 
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population149. Since heterogeneity of individual cells in genetically identical cell populations has been an issue 
limiting drug response and survival by cancer treatment150, single-cell analysis and screening has emerged as 
strategy to unmask differences in the responses of individual cells and to obtain deeper knowledge over the 
processes induced by a given compound151. The most common way to achieve single-cell droplet encapsulation 
is to use limiting dilution, where the cell density is adjusted in a way that statistically only one of ten droplets 
contains a single cell. The statistical distribution of the cells in the droplets follows the Poisson distribution 
(Equation 2). Parameters which influence the Poisson statistics in microfluidics are cell size, cell density and 
droplet size148.   
Equation 2. Poisson statistics 148.  
𝑝(𝑘, 𝜆) =  
𝜆𝑘𝑒−𝜆
𝑘!
; 
𝑝 = probability 
𝑘 = number of particles in a droplet 
𝜆 = average number of cells per droplet 
𝜆 =  
𝛷𝑠
𝛷𝑑
;              𝛷𝑑 =  
?̅?𝑐
?̅?𝑑
 
𝛷𝑠 = volume fraction of cells in the pre-encapsulation solution 
𝛷𝑑 = volume fraction of a droplet containing one cell 
?̅?𝑐 = average cell volume 
?̅?𝑑 = average droplet volume 
 
In case of limiting dilution  is adjusted to 0.1 (1 of 10 droplets contains a cell), resulting statistically in a small 
fraction (< 0.5 %) of droplets containing more than one cell, ~9 % containing exactly one cell and over 90 % 
empty droplets. The trade-off of minimal droplets occupied with more than one cell, with a huge amount of 
useless empty droplets is in most cases not a big issue due to the fast generation of a high number of droplets. 
However, depending on the capability of downstream droplet sorting and assay analysis, increasing  to 1, can 
be favourable, since this elevates significantly the fraction of cell-containing droplets (~37 % droplets with single 
cells and ~26 % droplets with more than one cell).  
1.6.1. Fluorescence-activated droplet sorting (FADS)  
Once encapsulated in water-in-oil droplets, the cells/reagents can be either further incubated and processed 
off-chip (in microtubes) or this can be performed directly on-chip by integration of delay lines152. Sophisticated 
microfluidic geometries allow for further post-emulsification manipulations, like droplet splitting153 or addition 
of new reagents by droplet fusion, electrocoalescence, or picoinjection154-157. Together with high-throughput 
analysis of the assays in the microdroplets, droplet sorting enables the selection of a subset of reactions for 
additional manipulation158. Fluorescence-activated droplet sorters are custom-made microfluidic devices which 
incorporate fluorescence detection and a dielectrophoretic sorting unit159. For droplet sorting, the w/o emulsion 
is re-injected in the FADS device (Fig. 4) where the re-injection inlet facilitates spacing of the individual droplets 
by intersection with a channel for the continuous phase. The spacing junction is followed by a Y-shaped sorting 
junction, where droplet separation is facilitated via dielectrophoresis. With the help of the detection unit, 
passing droplets are irradiated and emitted fluorescence is recorded. The sorting electric filed is turned on only 
in case the droplet has fluorescence intensity above a preselected threshold, resulting in a vertical electric 
gradient. A dielectrophoretic force attracts the droplets toward the region of high electric gradient on the side 
of the electrodes and they are diverted into the collection channel. When no electric field is applied, the 
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collection channel possesses higher fluidic resistance than the waste channel, leading to flow of all droplets into 
the waste channel159.  
 
Figure 4. Scheme of a custom-made FADS microfluidic device. Figure modified from Mazutis et al. 2013 159. 
 
Dielectrophoretic FADS devices can perform droplet sorting with a maximal speed of 2 kHz160, 161, alternatively, 
surface acoustic waves can be used for droplet deflection, reaching sorting rates of maximal 3 kHz162. Due to the 
Y-form of the sorting junction, flow rates need to be kept under a capillary number (Ca) of 0.1, which limits the 
throughput of the device. At faster flow rates, surface tension is dramatically reduced and the drops split at the 
divider between the collection and waste channels, contaminating the collection reservoir158. In order to 
overcome these shortcomings, new channel divider architectures have been developed, which prevent splitting 
of the droplets at very high flow rates and thus permit sorting rates of up to 30 kHz158.  
 
1.7. Fluorescence-Activated Cell Sorting (FACS)  
The first fluorescence-activated cell sorter (FACS) was introduced in the late 1960s by Herzenberg and co-
workers. It was developed as an instrument for separation of specific cell types from a complex biological sample 
(e.g. lymph nodes, bone narrow, or liver) based on fluorescence signal from a cell-specific fluorescent marker163. 
While significant improvements over the decades have taken place, enabling specific detection of 8-12 
fluorophores and sorting rates up to 200 kHz164, the analysis and sorting essentials of the FACS remain 
unchanged165:  
Living cells are treated with specific fluorescent markers (e.g. cell type-specific antibody-fluorophore 
conjugates). The stained cell suspension is placed into a pressurized cell reservoir, from where it is injected 
through an inner nozzle, while cell-free sheath fluid flows around the inner nozzle, resulting in acceleration and 
narrowing of the stream and generation of a cylindrical liquid stream emerging from an outer nozzle. The stream 
breaks up into identical droplets (jet stream). The liquid stream is illuminated directly after emerging from the 
nozzle (before breaking into droplets) by a laser beam with distinct wavelengths. When a cell crosses a laser 
beam, it is illuminated for several microseconds and emits a fluorescence signal which is collected by a detector 
and directed to a row of photomultipliers and filters. In case the fluorescent signal of a cell meets the sort 
criteria, the drop occupied by the positive cell is specifically charged at the moment of formation. The charged 
droplets are sorted as they pass through a transverse electrostatic field generated by two parallel deflection 
plates and are collected in a separate tube166.  
FACS technology has revolutionized many areas of biology, biotechnology, and medicine. Starting by separation 
of mixed cell populations, through antibody screening and single-cell hybridoma cloning167, to modern clinical 
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diagnostics168, the application area of flow cytometry and FACS has rapidly expanded, giving rise to automated, 
robust, and exceptionally specific FACS instruments. However, since standard FACS devices work with aqueous 
buffers as sheath fluid, direct implementation of w/o droplet emulsions for flow cytometric analysis and sorting 
is not possible. Thus, the advantages of FACS over FADS regarding the significantly higher throughput and 
multichannel detection, has so far not been fully exploited for analysis and processing of w/o emulsions.  
1.7.1. FACS of double emulsions (w/o/w)  
One strategy for combining droplet-based compartmentalization with FACS represents the generation of water-
in-oil-in-water (w/o/w) emulsions, also called double emulsions. In this case, the aqueous microdroplets 
containing cells and reagents are surrounded by a thin oil shell (oil and surfactant mix) and are dispersed in an 
aqueous phase (buffer), which makes them compatible with FACS processing169-171 (Fig. 5). For this purpose, the 
primary w/o emulsion, produced by droplet-based microfluidics (described in 1.6.1) is emulsified in a second 
step using an aqueous buffer as a continuous phase. The second emulsification can be performed as bulk 
emulsification by mixing with a carrier aqueous phase and applying shear stress by pipetting or vortexing172. 
Although this technique is time saving, the resulting double emulsion is highly polydisperse and consists of a 
huge fraction of very small empty oil droplets and oil droplets with multiple aqueous cores173, 174, which hampers 
the FACS selection. For controlled generation of monodispersed double emulsions, droplet microfluidics is 
favored175. Following initial w/o emulsification using a microfluidic chip with fluorophilic or lipophilic wall coating 
(depending on the oil-of-choice), the w/o emulsion is injected in a second droplet microfluidic chip with a 
hydrophilic coating and an aqueous continuous phase176. Stabilization of double emulsions necessitates addition 
of hydrophilic non-ionic surfactants to the outer aqueous phase like Tween 20170, Tween 80174, and sodium 
dodecyl sulfate (SDS)177. However, these agents have the ability to break lipid bilayers, inducing membrane 
damage in mammalian cells and thus exhibit cytotoxic effects even at very low concentrations178, 179. Since cell 
viability is a critical parameter in the context of mammalian cell – based assays, implementation of double 
emulsions is still mainly limited to cell-free assays170, 174, screening of enzymes in cell lysates180 or encapsulation 
of robust organisms with cell wall, like bacteria171, 181. 
 
 
 
 
Figure 5. Strategies for combination of droplet 
micro-compartmentalization and FACS. 
Primary w/o emulsion with encapsulated cells 
consists of aqueous droplets in an oil phase. After 
second microfluidic emulsification using an 
aqueous buffer as a continuous phase, the aqueous 
droplets are surrounded by an oil shell and are 
dispersed in the aqueous buffer. When hydrogel 
forming molecules are initially mixed to the cell-
containing encapsulation solution, the droplets in 
the primary emulsion can be solidified to 
hydrogel microbeads and after emulsion breakage 
can be recovered and resuspended in an aqueous 
buffer. (Image modified from Sukhorukov et al. 
2004182).    
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1.7.2. Gel microdroplet – FACS   
Gel microdroplets (GMDs) are aqueous microdrops containing a biocompatible matrix (hydrogel)183. GMDs can 
either be dispersed in a nonaqueous fluid as emulsion (“closed” GMDs), or they can be transferred to an aqueous 
medium (“open” GMDs). The big advantage of the GMDs over double emulsions is the easier handling and the 
option to switch from “closed” GMD system, where all reagents are retained and accumulated in the droplets, 
to “open” GMD system (Fig. 5), where rapid molecular exchange with the surrounding medium takes place, 
enabling manipulation of the encapsulated cells and simple addition of assay components183. Since GMDs can 
be readily recovered in an aqueous solution, they are compatible with an ultra-high-throughput flow cytometric 
analysis and sorting. GMD-FACS expands the types of assays compatible with flow cytometry, which is technically 
limited to measuring intracellular or cell-membrane-associated fluorescence184. Additionally, hydrogel matrixes 
structurally resemble extracellular matrix (ECM) and retain cell viability and growth. Hence, ECM-like gels have 
extensively been implemented in 3D cell culturing185 and hydrogel microbeads have emerged as promising 
technique for the generation of multicellular spheroids, as they combine high-throughput generation with 
efficient transport of oxygen, nutrients, and metabolites186-188.      
 
1.8. Hydrogel Microbeads 
Hydrogels are by definition macromolecular networks swollen in water or biological fluids189. Nowadays, 
hydrogel materials are implemented in different fields like drug delivery, tissue engineering, optics, diagnostics, 
and imaging190. Building blocks for hydrogels can be of natural or synthetic origin. Natural polymers like chitosan, 
alginate, collagen, agarose, cellulose, and gelatine, as well as synthetic polymers e.g. polyethylene glycol (PEG), 
hydroxyethyl methacrylate (HEMA) and derivatives of those are commonly used in the pharmaceutical filed190. 
Hydrogels can be classified in different categories depending on diverse parameters like physical structure (e.g. 
amorphous or semi-crystalline), ionic charge (anionic, cationic, neutral, or ampholytic), size (macro-, micro-, or 
nanogels), and bond formation (chemical or physical)191. These parameters dictate the functions of the different 
hydrogels and determine properties like swelling, elasticity, pore size, stability, and biocompatibility and 
degradation. For the purposes of this work, three different biopolymers with different crosslinking mechanisms 
have been exploited for encapsulation of viable cells in hydrogel microbeads.  
1.8.1. Alginate 
Alginic acid and its salts (commonly referred to as alginates) are derived from marine brown algae, where they 
play a role as a structure-giving element of the cell wall. Alginates are anionic, linear polysaccharides, composed 
of blocks of (1-4)-linked -L-guluronic or -D-mannuronic acid monomers (Fig. 6)192. Solubilized, they build large 
water-soluble polymers (hydrocolloids) enhancing the viscosity of the fluid dramatically193. Alginate forms 
soluble salts with monovalent metal ions, with sodium alginate being most commonly used. In presence of 
divalent cations, especially Ca2+, strong ionotropic hydrogels are formed (Fig. 6)193. Sodium alginate and Ca2+-
alginate gels are considered as generally non-toxic, biocompatible, and biodegradable and find wide application 
in the pharmaceutical, cosmetic, and food industries194. Encapsulation of different bioactive substances and 
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living cells in alginate beads have been largely exploited, due to the inert environment within the polymer 
network and the mild gelation conditions195, 196.   
 
Figure 6. Chemical structure of alginic acid and calcium alginate hydrogel. Figure was modified from Liang et al. (2015)192 and Lee 
et al. (2012)193. 
 
Different approaches for the generation of alginate beads and different gelation strategies have been 
published197. Utilizing a droplet-based microfluidic system for the generation of alginate beads has proven 
efficient for formation of discrete and uniform hydrogel structures198. However, on-chip gelation of alginate 
represents a significant challenge since rapid gelation can cause clogging of the chip. Gelation techniques can 
differ in the source of calcium ions and are broadly separated into external and internal gelation199. External 
gelation by dripping into a calcium-containing solution has been broadly applied200-202 since in this way chip 
clogging is prevented. Nonetheless, this often results in aggregation of alginate beads and non-spherical form 
of the hydrogels203. For internal gelation, non-soluble CaCO3 nanoparticles can be mixed to the dispersed phase 
and used as a crosslinking agent. In situ crosslinking is induced by acid, added to the continuous phase, and takes 
place directly after drop generation204. However, dissolution of solid calcium salt particles leads to a 
heterogeneous calcium ion distribution in the droplets, causing a non-uniform gel formation. Alternatively, ion 
chelating agents like ethylenediaminetetraacetic acid (EDTA), enable direct mixing of Ca2+ in soluble form to the 
dispersed phase by preventing gelation and allowing for homogenous and controlled crosslinking205. In this case, 
CaCl2 is equimolar mixed with EDTA where the free Ca2+ is completely complexed at pH of 8. Alginate 
solidification in the emulsified droplets can be performed at a desired time point (after incubation etc.) by 
addition of small volume (0.05 % v/v) acetic acid. This induces Ca2+ release and rapid gelation of the alginate, 
resulting in monodispersed, spherical and uniform alginate beads. High cell viability and cell proliferation in the 
generated microbeads were demonstrated, proving the compatibility of this method for encapsulation of 
mammalian cells205.  
1.8.2. Matrigel 
Matrigel® (or EHS matrix) is a basement membrane matrix extracted from Englebreth-Holm-Swarm (EHS) 
tumours, with a complex composition consisting mainly of the glycoproteins laminin and entactin, collagen type 
IV, a heparan sulfate proteoglycan (perlecan), as well as proteases, growth factors and other proteins like 
transferrin and clusterin206. Matrigel matrixes show remarkable biological activity by promoting differentiation 
of various cell types, as well as cell growth stimulation in tissue explants206. Furthermore, Matrigel is used to 
mimic extracellular matrix (ECM) for culturing of cancer and stem cells and maintain self-renewal and 
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pluripotency of stem cells207. For this reasons, Matrigel has been widely exploited for 3D cell culturing in 
microtiter plate formats208 or in gel microbeads209, 210. Microfluidic encapsulation of cells in Matrigel occurs 
similarly to standard droplet generation, with the difference that the microfluidic device needs to be 
permanently cooled at 4 °C, since the matrix solidifies at ambient temperatures above 20 °C. Hence, gelation is 
achieved by incubation at 37 °C for 15-30 min, depending on the size of the droplets and the volume of the 
emulsion. The advantages of Matrigel regarding the enhanced cell viability and non-complicated solidification 
process has not been exploited yet for functional screening on single-cell level, nor for FACS-based selection.  
1.8.3. Agarose 
Agarose is a linear, non-charged polysaccharide built up of disaccharide units of D-galactose and 3,6-anhydro-L-
galactopuranose (Fig. 7). It is extracted from red algae (Rhodophyta) and represents the major fraction in agar, 
besides agaropectin192. Similarly to agar, agarose is a thermal-responsive polymer which undergoes sol-gel 
transition upon cooling (thermal crosslinking)211 by aggregation of double helical structures formed by the 
physical entanglement of anhydro bridges on the individual molecules212 (Fig. 7).  
 
 
Figure 7. Chemical structure of agarose and agarose hydrogel. Image was modified from Zhang et al. (2015)211. 
 
Agarose hydrogels are widely used in biological, biochemical and medical fields, including cell culture, DNA 
analytical techniques (agarose gel electrophoresis), chromatography (gel filtration, affinity, and ion exchange 
chromatography), drug delivery, wound dressing, tissue engineering or cell encapsulation213. Advantageous 
physical properties of agarose, like physiological gelation temperature in the range of 31-36 °C which is 
reversible only after reaching the melting point (65-85 °C) and the uncomplicated handling of agarose hydrogels, 
make it attractive for encapsulation of live cells in agarose microbeads. Furthermore, it was demonstrated that 
agarose matrices allow for effective diffusion of big molecules such as antibodies, which is essential for many 
bioassays and screening procedures214. Chemical modifications of agarose, like hydroxyethylation215, reduces 
the number of intrastrand hydrogen bonds, decreasing the melting and gelling temperatures of standard 
agarose. Such low or ultra-low gelling temperature agaroses (below 20 °C) are suitable for microfluidic 
encapsulation of living cells since they allow for working at physiological temperatures, while reducing the risk 
of solidification and chip clogging during the droplet formation process216. 
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2. Objective 
The objective of this work in the frame of the doctoral research was the establishment and validation of a generic 
ultra-high-throughput screening platform for selection of novel biomolecules based on their desired 
functionality. The bioactive molecules should be produced by a secretor cell and sensed with respect to their 
biologic activity by a report cell line. To allow for high-throughput library screening, secretor cells should be 
yeast cells, while reporter cells should be mammalian cell lines. Functional screening procedures should be 
established for three different applications: 1) Identification of antibodies that are able to reach the cytoplasm 
of mammalian cells; 2) identification of small signalling proteins (IL-3, TNFα) to induce a reporter cell response; 
and 3) identification of agonistic antibodies that trigger prescribed cellular signalling pathways.  
In the context of screening of cytoplasm-penetrating antibodies, a robust secretor-reporter system needed to 
be generated and a technique for phenotype-genotype coupling needed to be established. To this end, 
microfluidic-assisted droplet generation was envisaged, since it facilitates generation of huge amount distinct 
microreactors. Different microfluidic systems (custom-made and commercially available), protocols and oil-
surfactant mixtures should be tested to achieve an efficient high-throughput droplet production. Furthermore, 
in order to enable FACS-based selection of desired candidates, generation procedure for hydrogel microbeads 
had to be developed. Three hydrogel-forming agents (alginate, agarose and Matrigel®) with different 
crosslinking mechanisms were chosen on the basis of their applicability for encapsulation of live cells. Hydrogel 
microbeads generation should be optimized and properties of the hydrogels regarding their stability, 
microfluidic compatibility and retaining of cell viability should be characterized and evaluated.  
A standard fluorescence activated cell sorting device should be adopted for analysis and sorting of cell-
containing hydrogel microdroplets (GMD-FACS). For this purpose, sorting parameters should be optimized in 
order to ensure integrity of the hydrogel microbeads during the FACS processing and accurate sorting process, 
at the same time. Technical optimizations and sorting parameters needed to be validated by sorting of hydrogel 
beads, containing different yeast populations, and sorting efficiency and yeast cell viability and growth should 
be investigated.  
Additionally, a functional read-out based on mammalian reporter cells was desired. Therefore, the 
encapsulation procedure needed to be adjusted for mammalian cells and appropriate co-cultivation conditions 
for yeast and mammalian cells should be identified. To this end, yeast growth and heterologous expression and 
secretion of candidate molecules from yeast cells should be assessed and optimized under conditions 
compatible with mammalian cell culture (temperature, media, etc.) in order to identify optimal conditions for 
both cell types.  
For validation of the functional screening and selection concept, proof-of-concept screens needed to be 
established and performed. Two different mammalian cell lines with fluorescent reporter systems were 
available: Ba/F3-CIS-d2EGFP (murine reporter cells), which respond to stimulation with murine interleukin 3 
(mIL-3) by expression of green fluorescent protein (GFP) and NF-B/Jurkat/GFP (human immortalized T 
lymphocytes), which can be stimulated by human tumour necrosis factor alpha (hTNF) or by T cell activation 
(anti-CD3 + anti-CD28) and express GFP as well. Yeast-based expression and secretion system needed to be 
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established and sufficient secretion of mIL-3 and hTNF for induction of reporter cell response should be 
realised. 
In case of Ba/F3-CIS-d2EGFP, a non-functional mIL-3 mutant should be generated with minimal sequence 
alterations. Reporter cell fluorescence levels after co-encapsulation with either activating mIL-3 wt-, or non-
activating mIL-3-secreting yeast cells should be measured and co-culturing conditions should be optimized for 
effective FACS-selection of active mIL-3 variants. Mixing experiments and functional selection using different 
ratios of yeast cells secreting the active mIL-3 wt variant with an excess of non-activating mIL-3 mutant-secreting 
yeast cells should be conducted in order to demonstrate the feasibility of the concept for function-based 
screening. Furthermore, a small randomized mIL-3 library should be generated and secreted from yeast cells. 
Functional selection for regain of cytokine function should be performed by co-encapsulation in hydrogel 
microbeads with Ba/F3 reporter cells and FACS-based selection.  
In case of NF-B/Jurkat/GFP reporter cell line, co-encapsulation with hTNF-secreting yeast cells should be 
performed and sufficient reporter cell activation should be achieved. In order to assess the applicability of the 
system for yeast-based screening of functional antibodies, anti-CD3 antibody (muromonab or OKT3) should be 
secreted from yeast cells and T cell activation of the reporter cell line should be tested by cocultivation of yeast 
and reporter cells in microdroplets.  
In summary, the presented work aimed at development and validation of a novel functional screening platform 
in an ultra-high-throughput manner. Such technology is high-in-demand in the biotechnological field and we 
believe it could contribute for the accelerated discovery of new functional biologics, including cytokines, 
agonistic or internalizing antibodies.  
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3. Materials 
3.1. Bacterial Strains  
The following Escherichia coli strains with corresponding genotypes were used: 
• DH5 - F- Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–, mK+) phoA supE44 λ– thi-1 
gyrA96 relA1 
• Top10 - F- mcrA (mrr-hsdRMS-mcrBC) 80lacZ M15 lacX74 recA1 ara139 (ara-leu)7697 galU galK rpsL 
(StrR) endA1 nupG 
 
3.2. Yeast Strains  
S. cerevisiae EBY100 - MATa URA3-52 trp1 leu2Δ1 his3Δ200 pep4:HIS3 prb1Δ1.6R can1 GAL (pIU211:URA3) 
 
3.3. Mammalian Cell Lines  
 Cell line Cultivation medium 
Reporter 
cell lines 
Ba/F3-CIS-d2EGFP 
murine pro B cell line 
RPMI-1640 + 10 % (v/v) FBS + 1 % (v/v) Pen/Strep 
mix + 10 ng/ml murine interleukin 3 (mIL-3) 
NF-κB/Jurkat/GFP 
human T cell acute lymphoblastic leukemia  
RPMI-1640 + 10 % (v/v) FBS + 1 % (v/v) Pen/Strep 
mix  
Cancer 
cell lines 
HeLa 
human adenocarcinoma epithelial cells 
DMEM + 10 % (v/v) FBS + 1 % (v/v) Pen/Strep mix 
SK-BR-3  
human epithelial breast cancer cells  
DMEM + 10 % (v/v) FBS + 1 % (v/v) Pen/Strep mix 
MDA-MB 468 
human mammary gland adenocarcinoma 
cancer cells 
DMEM + 10 % (v/v) FBS + 1 % (v/v) Pen/Strep mix 
 CHO-KI 
Chinese hamster ovary 
DMEM/F12 Ham + 10 % (v/v) FBS + 1 % (v/v) 
Pen/Strep mix  
Protein 
expression 
CHO-FlipIn-hTNFα 
Chinese hamster ovary cell, stably 
expressing and secreting human TNFα 
DMEM/F12 Ham + 10 % (v/v) FBS + 1 % (v/v) 
Pen/Strep mix + 0.8 mg/ml hygromycin  
Expi293F 
human embryonic kidney cells optimized 
for antibody production 
Expi293™ Expression Medium with 4 mM 
L-glutamine, cultivation as suspension cultures 
with 110 rpm orbital shaking 
Expi293F-C225 
human embryonic kidney cells, stably 
expressing and secreting cetuximab (C225) 
Expi293™ Expression Medium with 4 mM 
L-glutamine + 1 µg/ml puromycin  
Expi293F-SP34 
human embryonic kidney cells, stably 
expressing and secreting anti-CD3 antibody 
(clone SP34) 
Expi293™ Expression Medium with 4 mM 
L-glutamine + 1 µg/ml puromycin 
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3.4. Plasmids 
3.4.1. Plasmids for secretion from yeast S. cerevisiae  
(1) pYD-app8-mIL-3wt-T2A-mCherry  
 
 
 
 
 
Figure 8. Vector map of pYD-app8-mIL-3-T2A-
mCherry. Important components are annotated. AmpR: 
beta-lactamase-mediated ampicillin resistance, pUC ori: 
origin of replication for E. coli, CEN/ARS: origin of 
replication for yeast (S. cerevisiae CEN6 centromere 
fused to an autonomously replicating site), LEU2: beta-
isopropylmalate dehydrogenase (IMDH) for leucine 
biosynthesis, GAL1 promoter: yeast promoter with 
upstream activating sequence mediating Gal4-dependent 
induction217, app8: leader sequence for secretion from S. 
cerevisiae218, mIL3: gene for mature murine interleukin 
3 (D33-C166), T2A: ribosome skipping peptide219, 
mCherry: red fluorescent protein, constitutively 
fluorescent. 
 
 
(2) pYD-app8-mIL-3_ E49G-T2A-mCherry 
 
 
 
 
 
Figure 9. Vector map of pYD-app8-mIL-3_E49G-T2A-
mCherry. Important components are annotated. AmpR: 
beta-lactamase-mediated ampicillin resistance, pUC ori: 
origin of replication for E. coli, CEN/ARS: origin of 
replication for yeast (S. cerevisiae CEN6 centromere fused 
to an autonomously replicating site), LEU2: beta-
isopropylmalate dehydrogenase (IMDH) for leucine 
biosynthesis,  GAL1 promoter: yeast promoter with 
upstream activating sequence mediating Gal4-dependent 
induction217, app8: leader sequence for secretion from S. 
cerevisiae218, mIL3 E49G: gene for mature murine 
interleukin 3 (D33-C166) with a single amino acid 
substitution E49G, T2A: ribosome skipping peptide219, 
mCherry: red fluorescent protein, constitutively 
fluorescent. 
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(3) pYD-app8-hTNFα-T2A-mCherry 
 
 
 
 
 
 
Figure 10. Vector map of pYD-app8- hTNFα-T2A-
mCherry. Important components are annotated. AmpR: 
beta-lactamase-mediated ampicillin resistance, pUC ori: 
origin of replication for E. coli, CEN/ARS: origin of 
replication for yeast (S. cerevisiae CEN6 centromere fused 
to an autonomously replicating site), LEU2: beta-
isopropylmalate dehydrogenase (IMDH) for leucine 
biosynthesis, GAL1 promoter: yeast promoter with 
upstream activating sequence mediating Gal4-dependent 
induction217, app8: leader sequence for secretion from S. 
cerevisiae218, hTNFα: gene for human tumor necrosis 
factor alpha, T2A: ribosome skipping peptide219, 
mCherry: red fluorescent protein, constitutively 
fluorescent. 
 
 
(4) pYD-app8-OKT3-HC-T2A-mCherry 
 
 
 
 
Figure 11. Vector map of pYD-app8-OKT3-HC-T2A-
mCherry. Important components are annotated. AmpR: 
beta-lactamase-mediated ampicillin resistance, pUC ori: 
origin of replication for E. coli, CEN/ARS: origin of 
replication for yeast (S. cerevisiae CEN6 centromere fused 
to an autonomously replicating site), LEU2: beta-
isopropylmalate dehydrogenase (IMDH) for leucine 
biosynthesis, GAL1 promoter: yeast promoter with 
upstream activating sequence mediating Gal4-dependent 
induction217, app8: leader sequence for secretion from S. 
cerevisiae218, OKT3 VH: gene for the humanized heavy 
chain of murine anti-CD3 antibody (muromomab), CH1: 
gene for human IgG1 CH1 domain, Fc: gene for human 
IgG1 Fc fragment , T2A: ribosome skipping peptide219, 
mCherry: red fluorescent protein, constitutively 
fluorescent. 
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(5) pCT-app8-OKT3-LC 
 
 
 
 
 
Figure 12. Vector map of pCT-app8-OKT3-LC. 
Important components are annotated. KanR: 
aminoglycosidase kinase (APH(3’))-mediated kanamycin 
resistance, pUC ori: origin of replication for E. coli, 
CEN/ARS: origin of replication for yeast (S. cerevisiae 
CEN6 centromere fused to an autonomously replicating 
site), TRP1: phosphoribosylanthranilate isomerase for 
tryptophan biosynthesis, GAL1 promoter: yeast promoter 
with upstream activating sequence mediating Gal4-
dependent induction217, app8: leader sequence for 
secretion from S. cerevisiae218, OKT3 VL: gene for the 
humanized light chain of murine anti-CD3 antibody 
(muromomab), κCL: gene for human kappa constant 
region, cmyc: gene for c-Myc tag peptide. 
 
 
3.4.2. Plasmids for antibody expression in mammalian cells  
(6) pTT5-Trastuzumab-HC-wt 
 
 
 
 
 
 
 
 
Figure 13. Vector map of pTT5-Trastuzumab-HC-wt. 
Important components are annotated. AmpR: beta-
lactamase-mediated ampicillin resistance, pUC ori: origin 
of replication for E. coli, CMV promoter: 
cytomegalovirus promoter for high level expression in 
eukaryotes, leader SP: leader sequence for secretion into 
the culture medium from mammalian cells, VH, CH1, CH2, 
CH3: domains of the heavy chain of the humanized anti-
HER2 antibody trastuzumab, LLQG: recognition tag for 
site specific conjugation using microbial 
transglutaminase. 
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(7) pTT5-hT4-LC 
 
 
 
 
 
 
 
 
Figure 14. Vector map of pTT5-hT4-LC. Important 
components are annotated. AmpR: beta-lactamase-
mediated ampicillin resistance, pUC ori: origin of 
replication for E. coli, CMV promoter: cytomegalovirus 
promoter for high level expression in eukaryotes, leader 
SP: leader sequence for secretion into the culture 
medium from mammalian cells, hT4 VL: gene sequence 
for the variable domain of the light chain of the 
engineered murine autoantibody hT4, κCL: gene for 
human kappa constant region. 
 
 
(8) pTT5-Trastuzumab-LC 
 
 
 
 
 
 
 
 
Figure 15. Vector map of pTT5-hT4-LC. Important 
components are annotated. AmpR: beta-lactamase-
mediated ampicillin resistance, pUC ori: origin of 
replication for E. coli, CMV promoter: cytomegalovirus 
promoter for high level expression in eukaryotes, leader 
SP: leader sequence for secretion into the culture 
medium from mammalian cells, Trastuzu-VL: gene 
sequence for the variable domain of the humanized anti-
HER2 antibody trastuzumab, κCL: gene for human kappa 
constant region. 
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(9) pTT5-Trastuzumab-HC-3×(GFP11) 
 
 
 
 
 
 
 
Figure 16. Vector map of pTT5-Trastuzumab-HC-
3×(GFP11). Important components are annotated. AmpR: 
beta-lactamase-mediated ampicillin resistance, pUC ori: 
origin of replication for E. coli, CMV promoter: 
cytomegalovirus promoter for high level expression in 
eukaryotes, leader SP: leader sequence for secretion into 
the culture medium from mammalian cells, VH, CH1, CH2, 
CH3: domains of the heavy chain of the humanized anti-
HER2 antibody trastuzumab, GFP11: gene for 11th β-sheet 
of GFP (a 16 aa long split GFP tag), yellow: 15 aa long  
glycine-serine linker 
 
 
(10) pQCXIP-spGFP1-10 
 
 
 
 
 
 
 
 
Figure 17. Vector map of pQCIP-spGFP1-10. Important 
components are annotated. AmpR: beta-lactamase-
mediated ampicillin resistance, pUC ori: origin of 
replication for E. coli, CMV promoter: cytomegalovirus 
promoter for high level expression in eukaryotes, 
spGFP(1-10): gene for superfolder green fluorescent 
protein β-sheets 1 to 10. IRES: viral internal ribosome 
entry site for translation of polycistronic constructs. 
PuroR: puromycin N-acetyl-transferase (PAC)-mediated 
puromycin resistance.  
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3.5. Oligonucleotides 
3.5.1. Sequencing primers 
Name Sequence (5’ – 3’) 
pTT5 seq up CTGCGCTAAGATTGTCAGT 
pTT5 seq lo  CCATATGTCCTTCCGAGTG 
app8 seq up GCCATTGTCCAACAGCACAAATAAC 
pYD seq lo TACGAGCTAAAAGTACAGTGGGAAC 
mCherry seq lo CTCCTTGATGATGGCCATG 
  
 
3.5.2. Cloning primers 
Name Sequence (5’ – 3’) 
app8-mIL3wt up GAAGAAGGGGTACAACTCGATAAAAGAGATACCCACCGTTTAAC 
mIL3wt-T2A lo CAGCAGGCTGCCGCGGCCCTCACATTCCACGGTTCCACGGTTAGGAG 
mIL3wt-T2A up TCTCCTAACCGTGGAACCGTGGAATGTGAGGGCCGCGGCAGCCTGCTG 
mCherry-pYD lo CACTGTTGTTATCAGATCAGCGGGTTTAAACTCACTATTACTTGTACAGCTCGTCCATG 
app8-mIL3-E49G up 
GAAGAAGGGGTACAACTCGATAAAAGAGATACCCACCGTTTAACCAGAACGTTGAATT
GCAGCTCTATTGTCAAGGGTATTATAGG 
mIL-3 degenerative up GTTGAATTGCAGCTCTATTGTCNNRNNHHNNATAGGGAAGCTCCCAGAAC 
app8-hTNFα1 up CAGATCATCTTCTCGAACCCCGAGTGACAAGCCTGTGGCCCACGTGGTGGC 
app8-hTNFα2 up AAGAAGGGGTACAACTCGATAAAAGAGTCAGATCATCTTCTCGAACCCCG 
 
3.5.3. Next generation sequencing and single clone screening primers 
 
 Primer  Sequence  
mIL-3 initial 
library 
NGS IL3 Bib fwd ACACTCTTTCCCTACACGACGCTCTTCCGATCTACATCAC
GTCTACACCACGACtgctgctaaagaagaagggg 
NGS IL3 Bib rev GACTGGAGTTCAGACGTGTGCTCTTCCGATCTGTCGTGG
TGTAGACGTGATGTgataacgtatctgtcctcaggatc 
mIL-3 library 
R1 
NGS IL3 Bib R1 fwd ACACTCTTTCCCTACACGACGCTCTTCCGATCTCATCTGCA
TCACTCTtgctgctaaagaagaagggg 
NGS IL3 Bib R1 rev GACTGGAGTTCAGACGTGTGCTCTTCCGATCTAGAGTGA
TGCAGATGgataacgtatctgtcctcaggatc 
mIL-3 library 
R2 
NGS IL3 Bib R2 fwd ACACTCTTTCCCTACACGACGCTCTTCCGATCTCATCTGCA
TCACGCGtgctgctaaagaagaagggg 
NGS IL3 Bib R2 rev GACTGGAGTTCAGACGTGTGCTCTTCCGATCTCGCGTGA
TGCAGATGgataacgtatctgtcctcaggatc 
 
mIL-3 library 
R3 
NGS IL3 Bib R3 fwd ACACTCTTTCCCTACACGACGCTCTTCCGATCTCATCTGCA
TCACGTGtgctgctaaagaagaagggg 
NGS IL3 Bib R3 rev GACTGGAGTTCAGACGTGTGCTCTTCCGATCTCACGTGA
TGCAGATGgataacgtatctgtcctcaggatc 
1:10,000 mix 
NGS IL3 Mix fwd ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCTATATCGACA
CTGAGTtgctgctaaagaagaagggg 
NGS IL3 Mix rev GACTGGAGTTCAGACGTGTGCTCTTCCGATCTACTCAGTGTCG
ATATAGAgataacgtatctgtcctcaggatc 
NGS IL3 MixR1 fwd ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCTATATCGCAC
TCTtgctgctaaagaagaagggg 
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1:10,000 mix 
R1 
NGS IL3 MixR1 rev  GACTGGAGTTCAGACGTGTGCTCTTCCGATCTAGAGTGCGATA
TAGAgataacgtatctgtcctcaggatc 
1:10,000 mix 
R2 
NGS IL3 MixR2 fwd ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCTATATCGCAC
GCGtgctgctaaagaagaagggg 
NGS IL3 MixR2 rev GACTGGAGTTCAGACGTGTGCTCTTCCGATCTCGCGTGCGATA
TAGAgataacgtatctgtcctcaggatc 
mIL-3 wt 
specific  
IL3 wt E23 fwd  CAGCTCTATTGTCAAGGAG 
IL3 rev  ACATTCCACGGTTCCACG 
 
3.6. Chemicals 
Compound Supplier 
1H,1H,2H,2H-Perfluorooctanol (PFO) Sigma-Aldrich, St. Louis, USA 
2-Mercaptoethanol  Carl Roth GmbH, Karlsruhe, Germany  
Acetic acid  Carl Roth GmbH, Karlsruhe, Germany  
Acrylamide/Bisacrylamide (37.5:1)  Carl Roth GmbH, Karlsruhe, Germany  
Agar-agar  Carl Roth GmbH, Karlsruhe, Germany  
Agarose  Carl Roth GmbH und Co KG, Karlsruhe  
Agarose (ultra-low gelling temperature) Sigma-Aldrich, St. Louis, USA 
Ammonium acetate  Carl Roth GmbH, Karlsruhe, Germany  
Ammonium persulfate (APS)  Carl Roth GmbH, Karlsruhe, Germany 
Ammonium sulfate Carl Roth GmbH, Karlsruhe, Germany 
Ampicillin, sodium salt  Carl Roth GmbH, Karlsruhe, Germany  
Bromophenol blue  Carl Roth GmbH, Karlsruhe, Germany  
Citric acid  Carl Roth GmbH, Karlsruhe, Germany  
Coomassie Brilliant Blue-G250  Carl Roth GmbH und Co KG, Karlsruhe  
Coomassie Brilliant Blue-R250  Carl Roth GmbH, Karlsruhe, Germany  
D-Galactose  Carl Roth GmbH, Karlsruhe, Germany  
D-Glucose  Carl Roth GmbH, Karlsruhe, Germany  
Dimethyl sulfoxide (DMSO)  Thermo Fisher Scientific, Waltham, USA  
EDTA (disodium salt)  Carl Roth GmbH und Co KG, Karlsruhe  
Ethanol  Carl Roth GmbH, Karlsruhe, Germany  
Glycerol  Carl Roth GmbH, Karlsruhe, Germany  
Glycine  Carl Roth GmbH und Co KG, Karlsruhe  
HCl  Carl Roth GmbH, Karlsruhe, Germany  
HDGreen™ DNA/RNA staining reagent Intas Science Imaging, Göttingen, Germany 
HFE-7500 3M™ Novec™ engineered fluid Fluorochem, Hadfield, Derbyshire, UK  
Imidazole  Carl Roth GmbH, Karlsruhe, Germany  
Isopropanol  Carl Roth GmbH und Co KG, Karlsruhe  
Isopropyl β-D-1 thiogalactopyranoside(IPTG)  Carl Roth GmbH und Co KG, Karlsruhe 
Light Mineral Oil Sigma-Aldrich, St. Louis, USA  
Magnesium chloride  Carl Roth GmbH, Karlsruhe, Germany  
Meliseptol  B. Braun Melsungen AG, Melsungen  
Nickel chloride  Merck KGaA, Darmstadt, Germany  
PicoSurf™ fluorosurfactant  Sphere Fluidics, Cambridge, UK 
Polyethylenimine, 25 kDa, linear (PEI)  Polysciences, Eppelheim, Germany  
Potassium chloride  Carl Roth GmbH, Karlsruhe, Germany  
Potassium dihydrogen phosphate  Carl Roth GmbH, Karlsruhe, Germany  
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Potassium hydrogen phosphate  Carl Roth GmbH, Karlsruhe, Germany  
Potassium hydroxide  Carl Roth GmbH, Karlsruhe, Germany  
Sodium azide  Sigma-Aldrich, St. Louis, USA  
Sodium chloride  Carl Roth GmbH, Karlsruhe, Germany  
Sodium dihydrogen phosphate dihydrate  Carl Roth GmbH, Karlsruhe, Germany  
Sodium dodecyl sulfate (SDS)  Carl Roth GmbH, Karlsruhe, Germany  
Sodium hydroxide  Carl Roth GmbH, Karlsruhe, Germany  
Sorbitan oleate (Span 80) Sigma-Aldrich, St. Louis, USA 
TEMED  Merck KGaA, Darmstadt, Germany  
Tris(hydroxymethyl)aminomethan (Tris)  Carl Roth GmbH und Co KG, Karlsruhe  
Trisodium citrate  Carl Roth GmbH, Karlsruhe, Germany  
Triton X-100  Carl Roth GmbH, Karlsruhe, Germany  
Tryptone/Peptone  Carl Roth GmbH, Karlsruhe, Germany  
TWEEN-20  Carl Roth GmbH, Karlsruhe, Germany  
Yeast extract  Carl Roth GmbH und Co KG, Karlsruhe 
Yeast nitrogen base w/o amino acids and 
ammonium sulfate (BD Difco™)  
Fischer Scientific, Waltham, Massachusetts, USA 
 
3.7. Mammalian Cell Culture Media and Reagents  
Component Supplier 
Dulbecco’s Modified Eagle’s Medium high glucose 
(DMEM, D6429) 
Sigma-Aldrich, St. Louis, USA 
Dulbecco’s Modified Eagle’s Medium/Nutrient 
Mixture F-12 Ham (DMEM/F12 Ham, D6421) 
Sigma-Aldrich, St. Louis, USA 
Expi293™ Expression Medium Thermo Fisher Scientific Inc., Waltham, USA 
Fetal bovine serum superior (FBS) Biochrom GmbH, Berlin, Germany 
Hygromycin B (50 mg/mL) Thermo Fisher Scientific Inc., Waltham, USA 
L-Glutamine 200 mM Sigma-Aldrich, St. Louis, USA 
Opti-Prep™ density medium Sigma-Aldrich, St. Louis, USA 
Penicillin-Streptomycin (100x) (P4333) Sigma-Aldrich, St. Louis, USA 
Puromycin Dihydrochloride (10 mg/ml)  Thermo Fisher Scientific Inc., Waltham, USA 
RPMI-1640 (R8758) Sigma-Aldrich, St. Louis, USA 
Trypan Blue Solution, 0.4 % Thermo Fisher Scientific Inc., Waltham, USA 
Trypsin-EDTA solution  Sigma-Aldrich, St. Louis, USA 
 
3.8. Solutions and Buffers 
Solution/buffer Composition 
Agarose solution for encapsulation  
3 % (w/v) ultra-low gelling temp. agarose 
50 % RPMI-1640 
50 % DMEM-F12 Ham 
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Alginate solution for encapsulation  
2 % (w/v) sodium alginate 
300 mM D-mannitol 
50 mM CaCl2 
50 mM EDTA  
pH 8  
Ampicillin stock solution  100 mg/mL ampicillin  
APS stock solution  10 % APS  
Coomassie de-staining solution 1  
10 % (v/v) acetic acid  
25 % (v/v) isopropanol  
Coomassie de-staining solution 2  10 % (v/v) acetic acid  
Coomassie staining solution  
0.2 % (w/v) Coomassie Brilliant Blue R-250  
0.2 % (w/v) Coomassie Brilliant Blue G-250  
30 % (v/v) isopropanol  
7.5 % (v/v) acetic acid  
dNTP mixture  
 
5 mM dATP  
5 mM dCTP  
5 mM dGTP  
5 mM dTTP  
dYT medium 
 
1 % (w/v) yeast extract,  
1.6 % (w/v) tryptone  
0.5 % (w/v) NaCl  
1.5 % (w/v) agar-agar (for agar plates)  
SD medium 
5.4 g/L Na2HPO4 
8.6 g/L NaH2PO4xH2O 
20 g/L glucose  
5 g/L ammonium sulfate 
1.6 g/L yeast nitrogen base (w/o amino acids) 
5 g/L Bacto casamino acids 
SG medium 
5.4 g/L Na2HPO4 
8.6 g/L NaH2PO4xH2O 
20 g/L galactose  
5 g/L ammonium sulfate 
1.6 g/L yeast nitrogen base (w/o amino acids) 
5 g/L Bacto casamino acids 
Kanamycin stock solution  50 mg/mL kanamycin  
Phosphate buffered saline (PBS) 
137 mM NaCl  
2.7 mM KCl  
10 mM Na2HPO4  
1.8 mM KH2PO4  
pH 7.4  
Protein A elution buffer  
100 mM citric acid  
20 mM trisodium citrate  
pH 3.0  
 Materials   42 
Protein A neutralizing buffer  
50 mM M Tris-HCl (pH 9)  
150 Mm NaCl  
Protein A binding buffer  
4 mM NaH2PO4 
6 mM Na2HPO4 
pH 7  
Protein denaturing loading buffer 
0.25 M Tris-HCl pH 8 
7.5 % (w/v) SDS 
25 % (v/v) glycerin 
0.25 mg/mL bromphenol blue 
12.5 % (v/v) 2-mercaptoethanol 
TAE buffer (50×)  
2 M Tris  
1 M acetic acid  
0.1 M EDTA  
YPD medium  
20 g/L dextrose 
20 g/L tryptone 
10 g/L yeast extract 
 
3.9. Consumables and Kits 
Consumable Supplier 
Amicon® Ultra Centrifugal Filters (3000 NMWL)  Merck Millipore, Darmstadt, Germany 
Cell culture 96 well plates Carl Roth GmbH, Karlsruhe, Germany 
Centrifuge Tubes, 15/50 ml  Sarstedt AG, Nümbrecht, Germany  
Centrifuge tubes, 50 ml (up to 15.500 g)  Carl Roth GmbH, Karlsruhe, Germany  
Corning cell culture flasks (25 or 75 cm2)  Sigma-Aldrich, St. Louis, USA  
Corning Erlenmeyer cell culture flasks  Sigma-Aldrich, St. Louis, USA  
Elektroporation cuvettes  BioRad, Munich, Germany  
  
Nunc MaxiSorp ELISA plates  eBioscience, San Diego, USA  
Petri dishes, 92x16 mm und 150x20 mm  Sarstedt AG, Nümbrecht, Germany  
Reaction vessels, 1,5/2 ml  Sarstedt AG, Nümbrecht, Germany  
ZelluTrans® dialysis membran T3  Carl Roth GmbH, Karlsruhe, Germany  
  
HiTrap Protein A HP, 1 ml column  GE Healthcare, Little Chalfont, UK  
PD-10 Desalting Columns  GE Healthcare, Little Chalfont, UK  
  
PureYield™ Plasmid Midiprep System  Promega, Fitchburg, USA  
Wizard Plus® SV Minipreps DNA Purification System  Promega, Fitchburg, USA  
Wizard® SV Gel and PCR Clean-Up System  Promega, Fitchburg, USA  
Zymoprep™ Yeast Plasmid Miniprep II Zymo Research Europe, Freiburg, Germany 
  
PDMS microfluidic devices Wunderlichips GmBH, Zurich, Switzerland 
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3.10. Instruments  
Device Manufacturer 
Accuri C6 flow cytometer  Becton Dickinson, New Jersey, USA 
Äkta Purifier UPC-900 P900 Frac-920, Unicorn 5 
software 
GE Healthcare, Little Chalfont, UK 
Äkta Start, Unicorn start software GE Healthcare, Little Chalfont, UK 
Arpege 110, TP100 liquid nitrogen storage system  Air Liquide, Paris, France  
BioSpec-nano Micro-volume UV-Vis 
Spectrophotometer 
Shimadzu, Kyoto, Japan 
Influx™ Fluorescence-Activated Cell Sorter (FACS) Becton Dickinson, New Jersey, USA 
GelDoc-It 2 Imaging System UVP, LLC, Upland, USA 
Gene Pulser und pulse controller Bio-Rad Laboratories, Hercules, USA 
Infinite M1000 Tecan, Männedorf, Switzerland 
Leica TCS SP8 with LAS AF software Leica Microsystems, Wetzlar, Germany 
MCO-19AICUV CO2 incubator Panasonic, Kadoma, Japan 
Mr. Frosty™ isopropanol freezing container Thermo Fisher Scientific Inc., Waltham, USA 
New BrunsWick S41i Eppendorf, Hamburg, Germany 
PCR Cycler Eppendorf Mastercycler Eppendorf, Hamburg, Germany 
TC20™ Automated Cell Counter Bio-Rad Laboratories, Hercules, USA 
µEncapsulator microfluidic system Dolomite Bio, Royston, UK 
Ultra-Turrax® dispersing device IKA, Staufen im Breisgau, Germany 
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4. Methods 
4.1. Microbiological Methods 
4.1.1. Transformation and culturing of bacteria 
Escherichia coli strains were cultivated in dYT medium, or grown on dYT agar plates. Liquid cultures were 
incubated at 37 °C and 180 rpm orbital shaking. Agar plates were incubated overnight in static incubator at 37 °C.  
For transformation with plasmid, electrocompetent E. coli were generated. To this end, cells were inoculated in 
50 mL dYT medium at an OD600 of 0.1. Cells were expanded until OD600 of 0.5-0.8 was reached (exponential 
growth phase). Cells were pelleted at 4 °C, 4000 × g, for 10 min and washed three times with 50 mL ice-cold 
dH20. Bacterial cells were subsequently separated in 5 × 100 µL aliquots and transferred to electroporation 
cuvettes where 100 ng plasmid were mixed. Electroporation was performed at 200 Ω, 2.5 kV, 25 µF on Gene 
Pulser II device. Following electroporation, cells were resuspended in 1 mL fresh dYT medium and recovered for 
1 h at 37 °C. Finally, the cells were plated on dYT agar plates containing selective antibiotics and incubated 
overnight at 37 °C.  
Plasmid extraction from E. coli was performed using PureYield™ Plasmid Miniprep or Midiprep System according 
to manufacturer’s protocol. Plasmid concentration was determined on BioSpec-nano Micro-volume UV-Vis 
Spectrophotometer. 
4.1.2. Transformation and culturing of yeast  
Saccharomyces cerevisiae was transformed according to the protocol of Benatuil et. al (2010)40. Briefly, 1 µg 
purified plasmid backbone was mixed with 300 ng DNA insert (for gap repair cloning) and added to 100 µL 
electrocompetent S. cerevisiae cells. Yeast cells were electroporated as described in 4.1.1 and recovered for 2 h 
in 2 mL YPD medium at 30 °C, 180 rpm. Subsequently, the cells were pelleted by centrifugation at 4000 × g for 
3 min and washed once with sterile PBS. Finally, the yeast was plated on minimal SD agar and incubated for 48-
72 h at 30 °C in a static incubator.  
Transformed yeast cells were propagated in liquid medium (SD) at 30 °C, 180 rpm. Expression induction was 
performed by cell harvesting and transfer in minimal SG medium and incubation overnight at 30 °C, 180 rpm. 
Alternatively, single yeast clones were inoculated in a mixture of 75 % SD + 25 % SG for simultaneous propagation 
and induction overnight.  
 
4.2. Mammalian Cell Culture  
4.2.1. Culturing adherent cell lines  
Adherent cell lines were cultured under standard sterile conditions in a humidified atmosphere with 5 % CO2 in 
T75 culture flasks. Cells were passaged twice a week after reaching over 90 % confluency. For this purpose, 
culture medium was aspirated and cells were washed with 10 ml sterile PBS. Next, 1 mL Trypsin-EDTA solution 
was added and the cells were incubated for 5-10 min at 37 °C until complete detachment of the cells could be 
optically observed (light microscopy). Trypsin reaction was stopped by adding 4-6 mL serum-containing culture 
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medium and the cells were diluted according to the grow rates of the corresponding cell line (in the range of 1:2 
to 1:10). The flask was finally filled up to 10 mL with fresh pre-warmed medium and the cells were further 
incubated.  
4.2.2. Culturing suspension cell lines  
Reporter cell lines (Ba/F3-CIS-d2EGFP and NF-κB/Jurkat/GFP) were cultured in T75 culture flasks at 37 °C in a 
humidified atmosphere with 5 % CO2. Cells were passaged three times a week after reaching a maximal cell 
density of 3 × 106 cells/mL. To this end, the cell density was determined using dead cell stain (Trypan Blue) and 
TC20™ Automated Cell Counter. Next, cells were diluted with fresh pre-warmed medium to reach a final cell 
density of 0.2 × 106 cells/mL for Ba/F3-CIS-d2EGFP and 0.3 × 106 cells/mL for NF-κB/Jurkat/GFP using 10-15 ml 
end volume medium. 
Expi293F™ cells were used for recombinant antibody expression. Those cells were cultured in 30 mL serum-free 
medium in 125 mL shaker flasks on an orbital shaker at 110 rpm, 37 °C, 8 % CO2. Cells were passaged every 3-4 
days after reaching a cell density of 4-7 × 106 cells/mL. Cell density was determined as described above and cells 
were seeded at a density of 0.5 × 106 cells/mL in fresh pre-warmed medium.  
4.2.3. Antibody expression in mammalian cells 
Expi293F™ cells were transiently co-transfected with the corresponding vectors coding for the trastuzumab 
heavy and light chains using polyethylenimine (PEI). To this end, the cells were diluted in 30 ml serum-free 
expression medium to a cell density of 2.5 × 106 viable cells/mL. Plasmid DNA (30 µg in total) were mixed with 
90 µg of PEI (dissolved in dH2O) in 3 mL expression serum-free medium and were incubated for 15 min at room 
temperature. Subsequently, the pre-complexed DNA-PEI mixture was added dropwise to the cell suspension. 
After 24 h incubation at standard conditions, 0.5 % (w/v) tryptone was added to the cell suspension and antibody 
expression was performed for 3-4 days at standard culturing conditions. Finally, culture supernatant was 
harvested by centrifugation, filtered using 0.45 µm sterile filter, and subjected to protein A chromatography.  
4.2.4. Cryopreservation of mammalian cell lines  
For cryopreservation in the vapor phase of liquid nitrogen, cells were harvested and at least 5 × 106 viable cells 
were resuspended in 1 mL growth medium supplemented with 10 % (v/v) DMSO and 20 % (v/v) FBS. 
Resuspended cells were transferred into cryogenic storage vials and placed into a Mr. Frosty™ isopropanol 
freezing container for slow temperature decrease at - 80 °C. The following day, the vials were transferred to the 
liquid nitrogen tank.  
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4.3. Molecular Biology Methods 
4.3.1. Polymerase chain reaction (PCR) 
PCR was used for amplification and generation of DNA fragments for gap repair cloning and plasmid ligation. 
Furthermore, colony PCR screening of transformed bacterial and yeast cells, harbouring desired plasmids was 
performed. For PCR amplification different polymerases were utilized: Q5 DNA polymerase (NEB) was used for 
amplification of longer DNA fragments and for generation of gene fragments for cloning, OneTaq DNA 
polymerase (NEB) and Taq DNA Polymerase (Qiagen) were utilized for colony PCR screening. All PCR samples 
were performed according to supplier’s standard protocol and primer annealing temperatures were calculated 
using NEB Tm calculator tool (https://tmcalculator.neb.com/#!/main).  
Overlap extension (OE)-PCR was performed for introduction of extended desired sequence by multiple 
oligonucleotides. To this end, PCR containing the first primer pair (with partially complementary region to the 
template) was performed for 10 cycles, and subsequently the second primer pair (with complementary region 
only to the first oligonucleotides) was added and PCR was performed for further 30 cycles.  
Colony PCR screen was performed after lysis of the cells of interest (bacteria or yeast) in 50 µL H2O or 10 mM 
NaOH, respectively, by heating at 98 °C for 10-15 min. After centrifugation of the cell debris, 1 µL cell lysate was 
used as template for the PCR. 
4.3.2. Restriction digest 
Restriction digest of plasmids and DNA fragments prior to cloning was performed using specific high-fidelity 
restriction enzymes (NEB). Digest reactions were performed according to NEB’s standard protocols and sample 
volumes were scaled up accordingly, if necessary.  
4.3.3. DNA ligation  
For generation of a Trastuzumab heavy chain plasmid, harboring a triple GFP11 sequence at the C-terminus, DNA 
ligation was performed. Therefore, 100 ng digested plasmid backbone were mixed with 20 ng DNA fragment 
containing the triple GFP11 sequence. T4 DNA ligase (NEB) and the corresponding reaction buffer were added 
according to the standard protocol. Ligation was performed for 30 min at room temperature or overnight at 
16 °C and was directly used (5 µL) for transformation of E. coli. 
4.3.4. Agarose gel electrophoresis  
Analysis of DNA amplification, restriction digest, and plasmid preparation was performed via agarose gel 
electrophoresis. To this end, 1 % (w/v) agarose solution in TAE buffer was mixed with HDGreen™ DNA staining 
reagent and was poured into an agarose gel chamber. DNA samples were mixed with 6 × loading dye (NEB) and 
applied in the agarose gel pockets, as a standard 1 kb plus (NEB) DNA ladder was used. Electrophoresis was 
performed at 110 V for 20 – 30 min in TAE buffer. Finally, agarose gel was irradiated with UV light and analysed 
on a GelDoc-It2 device with a 535 nm emission filter. 
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4.3.5. DNA purification  
DNA fragments (PCR amplification products or restriction digest products) were purified using Wizard® SV Gel 
and PCR Clean-up System either directly from the reaction mix, or after separation by agarose gel electrophoresis 
and excision of the desired band from the gel. The purification was performed according to manufacturer’s 
protocol.  
4.3.6. Antibody purification and characterization  
Antibodies were purified by protein A chromatography using a HiTrap Protein A HP column. To this end, 
mammalian culture supernatants (after heterologous expression in Expi293F™ cells) were mixed with 50 % (v/v) 
protein A binding buffer and loaded on the pre-equilibrated column. Following a wash step with 10 mL binding 
buffer, antibodies were eluted isocratic with protein A elution buffer and collected in 1 mL fractions with 200 µL 
protein A neutralizing buffer. 
Collected fractions were analysed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
under reducing conditions, using 10 % polyacrylamide gels. Therefore, 10 µL of each fraction were mixed with 
5 µL protein denaturing loading buffer and heated up to 98 °C for 10 min. Protein samples were loaded onto the 
gel and protein marker was used as a size standard. Electrophoretic protein separation was performed for 
40 min at 40 mA and maximum voltage. Protein bands were stained with Coomassie staining solution and 
background staining was removed by incubation in de-staining solutions 1 and 2, until distinct protein bands 
were observable. 
Fractions, containing the desired protein were pooled and dialyzed overnight in 5 L PBS at 4°C. On the following 
day, protein concentration was determined by absorption measurement at 280 nm and calculation with the 
corresponding extinction coefficient (ɛ) of each antibody, according to the Lambert-Beer law (Equation 3). If 
necessary, antibody solutions were concentrated using Amicon® Ultra Centrifugal Filters with a molecular cut-
off of 3000 Da.   
Equation 3. Lambert-Beer Law  
𝐴 =  ɛ × c × d 
𝐴 = absorption at 280 nm 
ɛ = molar extinction coefficient (M-1cm-1) at 280 nm  
c = concentration (M) 
d = path length (cm)  
 
4.4. Generation of Hydrogel Microbeads 
4.4.1. Microfluidic cell encapsulation  
Microfluidic cell encapsulation was performed on µEncapsulator System, consisting of three pressure pumps, 
three respective flow rate sensors, a temperature control unit (TCU), microfluidic sample chip, and a two-
reagent flurophilic droplet-generation chip with an etch depth of 50 µm at the junction. Fluorinated oil (Novac 
7500) with 2 % PicoSurf™ surfactant was used as a continuous phase, plain Novac 7500 was used as a running 
fluid for the pressure pumps. Samples to be co-encapsulated were pipetted on the sample chip (100 µL each) 
and the microfluidic device was closed. Encapsulation process was started by turning-on the pressure pumps for 
the two aqueous channels, followed by the pump for the continuous phase. Flow rates between 3-5 µL/min for 
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the dispersed phases and 30-50 µl/min for the continuous phase were used. Target flow rates were set using 
the software and were adjusted until stable droplet formation was observable. Depending on the samples, the 
TCU was set either to 37.5 °C or to 4 °C, 15 min prior encapsulation start. Droplet-containing emulsion was 
collected in sterile 1.5 mL reaction vessels, placed in the tempered collection container holder of the device. 
Following complete encapsulation of the samples on the sample-chip, the microfluidic device was paused, 
running fluid was removed from the sample chip, new samples were applied, and encapsulation process was 
restarted.  
4.4.2. Alginate microbeads 
For encapsulation of cells in calcium alginate hydrogel microbeads, alginate solution was prepared as described 
in 3.8 and was filtered using a 0.45 µm sterile filter. Cell encapsulation medium was prepared as listed in Table 
2  and was pre-warmed at 37 °C. Mammalian reporter cells and secretor yeast cells were centrifuged, washed 
twice with sterile PBS, and were separately resuspended in the alginate-containing cell encapsulation medium. 
Cells were co-encapsulated as described above (4.4.1) and w/o emulsion was incubated at 37 °C, 8 % CO2 at 
110 rpm orbital shaking. Alginate was solidified by addition of 0.05 % (v/v) acetic acid to the emulsion for 2 min. 
After vortexing, the emulsion was centrifuged shortly (100 × g, 10 s) and the excess fluorinated oil under the 
emulsion was removed. Emulsion was broken by addition of approx. 1 volume of PFO and inverting carefully. 
After phase separation (centrifugation for 10 s at 100 × g), the lower phase containing PFO and remaining 
fluorinated oil was removed, and alginate microdroplets were resuspended in alginate curing Tris buffer. 
Following a centrifugation step (10,000 × g, 5 min), alginate microbeads were filtered using a 70 µm cell strainer 
and were further processed by FACS.  
4.4.3. Matrigel microbeads  
Matrigel was stored as 1 mL aliquots at -20 °C. Prior usage (10 – 24 h) Matrigel was placed in a refrigerator at 
4 °C where it liquefied. Cell encapsulation solution was prepared as described in Table 2, and all components 
were cooled on ice the entire time in order to prevent hydrogel solidification. Microfluidic system was tempered 
at 4 °C during the whole encapsulation process (4.4.1). After incubation overnight at 37 °C, 8 % CO2, 110 rpm, 
the emulsion was broken as described above and the Matrigel microbeads were recovered in PBS.  
4.4.4. Agarose microbeads   
Ultra-low gelling temperature agarose (3 % w/v) was dissolved in 50 % DMEM-F12 Ham and 50 % RPMI-1640 
medium mix using a microwave. The agarose solution was then placed in a water bath at 37 °C. Cell 
encapsulation medium consisted of the components listed in Table 2 and all components were pre-warmed at 
37 °C in order to avoid agarose solidification. Prior to cell resuspension, the cell encapsulation medium was 
sterile filtered using a 0.2 µm sterile filter. The TCU of the µEncapsulator was set to 37.5 °C and 15 min later cells 
were co-encapsulated as described in 4.4.1. Following incubation step overnight at 37 °C, 8 % CO2, 110 rpm, the 
emulsion was placed on ice for 15 min or at 4 °C for 30 min in order to let the agarose solidify. Next, the emulsion 
was broken as described in 4.4.2 and agarose microbeads were resuspended in cold sterile PBS. Prior FACS, 
agarose microbeads were filtered using a 70 µm cell strainer to prevent clogging of the sample line and nozzle 
of the device.  
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Table 2. Composition of cell encapsulation media, containing different hydrogel-building molecules.  
Components 
Alginate (2 % w/v) Matrigel® Agarose (3 % w/v) 
End concentration 
Volume 
for 4 mL 
End 
concentration 
Volume 
for 4 mL 
End 
concentration 
Volume 
for 4 mL 
Hydrogel solution 0.5 % 1 mL 40 % 1.6 mL 0.75 % 1 mL 
FBS 20 % 800 µL × × 20 % 800 µL 
Opti-Prep™ density gradient medium 20 % 800 µL 16 % 640 µL 20 % 800 µL 
Galactose (20 % in medium mix) 2 % 400 µL 2 % 400 µL 2 % 400 µL 
Penicillin-Streptomycin solution 1 % 40 µL 1 % 40 µL 1 % 40 µL 
Medium Mix (50 % RPMI-1640 + 
 50 % DMEM-F12 Ham) 
 1 mL  1.3 mL  1 mL 
 
 
4.5. Cell-Based Experiments 
4.5.1. Cell internalization assay with cytotransmab HerT4 
For investigation of cellular internalization and distribution of HerT4 cytotransmab, three different cell lines with 
different Her2 expression level were chosen: SK-Br-3 (Her2high), CHO-KI (Her2int) and MDA-MB 468 (Her2low). Cells 
were seeded on glass cover slides in 6-well culturing plates at a cell density of 3 × 105 cells/well for SK-BR-3 and 
MDA-MB 468, and 2 × 105 cells/well for CHO-KI. Cells were propagated for 36 h at 37 °C, 5 % CO2 for reaching a 
sufficient confluency (70-80 %). Cells were treated with 1 µM antibodies (trastuzumab wt or HerT4) diluted in 
culture medium without serum for 8 h at 37 °C, 5 % CO2. Subsequently, cells were washed with PBS and fixed 
with 4 % PFA in PBS for 15 min at room temperature. Next, cells were permeabilized using 0.3 % Triton X-100 in 
PBS for 10 min and blocked overnight with 2 % BSA in PBS at 4 °C. Cells were stained with anti-human IgG-Alexa 
488 conjugate, diluted 1:500 in 1 % BSA + 0.3 % Triton X-100 in PBS for 1 h at room temperature. Detection 
antibodies were washed 3 times with PBS and cells were mounted on microscopic slides. Cellular internalization 
was analysed on Leica confocal microscope.  
4.5.2. GFP complementation assay with cytotransmab HerT4 
Cytoplasm-penetration properties of HerT4 were investigated using split GFP complementation assay as 
described by Kamiyama et al. (2016)220.  For this purpose, CHO-KI cells were seeded in an 8-well chamber slide 
at a cell density of 8000 cells/well. Cells were propagated for 36 h at standard culturing conditions and were 
transfected with 300 ng/well pQCIX-spGFP1-10 plasmid (Fig. 17), complexed with 900 ng PEI. Treatment with 
antibodies was performed 24 h post-transfection. To this end, Trastuzumab-3×(GFP11) and HerT4-3×(GFP11) were 
diluted at a concentration of 2 µM in fresh culture medium without FBS and GFP complementation was analysed 
6, 8, and 10 h after treatment on Leica confocal microscopy.  
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4.5.3. Optimization mammalian medium for growth and induction of yeast 
Yeast cells were inoculated at a cell density of 5 × 106 cells/mL in 3 mL of different standard mammalian media 
(DMEM high glucose, RPMI-1640, DMEM-F12 Ham, or mix of 50 % RPMI-1640 + 50 % DMEM-F12 Ham). Cells 
were cultivated at 30 °C or 37 °C, 180 rpm and OD600 was measured every 60 min for a time span of 10 h. Yeast 
induction was determined by measuring the fluorescence intensity of the intracellular expression marker 
(mCherry) by flow cytometry after 24 h of cultivation in the corresponding mammalian medium, supplemented 
with 2 % galactose. The percentage of mCherry-fluorescent cells was used as a measure of yeast induction.  
4.5.4. Co-cultivation of yeast and mammalian cells  
Yeast cells were expanded and induced overnight at 30 °C, 180 rpm. 1 × 107 yeast cells were mixed with 1 × 106 
reporter cells in 1 mL mammalian medium mix (50 % RPMI-1640 + 50 % DMEM-F12 Ham), supplemented with 
10 % FBS, 2 % galactose, and 1 % Pen/Strep. Cells were transferred to a 50 mL centrifugation tubes, which were 
sealed with a gas-permeable membrane in order to prevent evaporation of the medium. Cells were cocultured 
overnight at 37 °C, 110 rpm in a humidified atmosphere with 8 % CO2 or at 30 °C, 180 rpm. Activation of the 
reporter cells was estimated based on the GFP fluorescence, measured on BD Influx™ cell sorter. 
4.5.5. Co-encapsulation of yeast and reporter mammalian cells in microdroplets 
Yeast cells were expanded and induced overnight at 30 °C, 180 rpm. 4 × 107 yeast cells were pelleted by 
centrifugation at 500 × g for 3 min and were washed with sterile PBS. Cells were resuspended in 1 mL 
encapsulation medium and tempered according to the used hydrogel-forming polymer (37 °C for agarose and 
alginate and 4°C for Matrigel). 2 × 107 viable reporter cells were harvested by centrifugation at 800 × g for 5 min 
at room temperature and were washed twice with sterile PBS. Cells were resuspended in 1 mL encapsulation 
medium and were tempered as well. 
Co-encapsulation was performed as described in 4.4.1 and resulting emulsions were placed into a rotating 
incubator and incubated for 17-18 h at 37 °C, 110 rpm, in a humidified atmosphere and 8 % CO2. 
4.5.6. FACS of gel microdroplets  
Prior to analysis and sorting, the emulsion with the co-encapsulated cells was treated accordingly to the type of 
hydrogel (sections 4.4.2, 4.4.3 and 4.4.4) and recovered hydrogel microbeads were transferred to aqueous 
buffer ( Tris buffer with 1 mM CaCl2 for alginate and PBS for agarose and Matrigel microbeads).  
Sorting of hydrogel beads was performed on BD Influx™ Cell Sorter, equipped with a 200-micron nozzle tip (BD 
Biosciences 645895), with a 6 kHz drop frequency. BD FACSFlow™ sheath fluid (Fisher Scientific 10638814) was 
used in case of agarose and Matrigel and Tris buffer with 1 mM CaCl2 was used for alginate, with 3.0 psi sheath 
pressure.  
After each sorting round, the sorted yeast-containing agarose beads were plated on selective SD agar plates and 
incubated for 3 days at 30 °C in a static incubator. The colonies were harvested from the plates using sterile SD 
and stored at 4 °C until further usage. 
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4.5.7. Analysis of yeast cell enrichment  
Monitoring of sorting efficiency was performed using bulk populations after each sorting round. To this end, 
yeast cells of the non-sorted mix and of the corresponding sorting rounds were inoculated at a cell density of 
1 × 107 cells/ml in test tubes containing 2 mL of DMEM-F12 Ham medium, supplemented with 2 % galactose and 
1 % Pen/Strep. Cells were cultivated for 24 – 48 h at 30 °C, 180 rpm and after cell density measurement, the 
yeast cultures were centrifuged for 15 min, 17 000 × rcf in 1.5 mL reaction tubes. The supernatant (1 mL) was 
transferred to a new tube and pH was neutralized with 100 µL 1M HEPES buffer. 1 x 105 reporter cells/sample 
were harvested and washed twice with sterile PBS. Reporter cells were resuspended in 100 µL RPMI medium, 
supplemented with 20 % FBS and 1 % Pen/Strep. The volume of yeast supernatant (max. 100 µL), added to the 
reporter cells, was normalized to the final cell density of the yeast culture. Reporter cells were subsequently 
incubated overnight (15-18 h) at 37 °C, 5 % CO2 in a 96 well plate. Enrichment of functional wt mIL-3-secreting 
yeast cells was verified by the measurement of elevated GFP-fluorescence signal, normalized to background 
fluorescence of non-activated Ba/F3 reporter cells. GFP fluorescence signal (10,000 viable cells/sample) was 
determined using BD Accuri™ C6 flow cytometer. 
Efficiency of the functional screening approach was analysed using NGS of the non-sorted population, as well as 
of the bulk populations after each selection round. To this end, yeast cell populations were propagated for 24 h 
at 37 °C in SD medium. 1 × 108 cells were centrifuged and plasmid preparation was performed using Zymoprep™ 
Yeast Plasmid Miniprep Kit according to the manufacturer’s protocol. Specific oligonucleotides, comprising 
partial Illumina adapters and a DNA barcode were designed (3.5.3). PCR was performed using 0.5 µL plasmid 
preparation from each population as a template utilizing Q5 Polymerase (NEB) according to the standard 
protocol (NEB). PCR amplicons were purified using Wizard® SV Gel and PCR Clean-Up System following the 
manufacturer’s protocol. Samples were sent for NGS to GENEWIZ (Leipzig, Germany) and sequencing data 
analysis was performed using Geneiuos 2020.1. 
Colony PCR with single clones after the second sorting round was performed using a specific primer pair (3.5.3), 
where a 400 bp PCR product indicated the presence of wt mIL-3 coding DNA sequence. For the colony PCR, each 
colony was resuspended in 50 µL 20 mM NaOH and was heated at 98 °C for 15 min in 200 µL PCR tubes. After 
cooling down, the samples were centrifuged to pellet the cell debris and 1 µL supernatant per clone was used 
as a template. PCR was performed utilizing Taq DNA Polymerase (Qiagen) according to the standard 
manufacturer’s protocol. PCR consisted of initial denaturation step (94 °C - 3 min); 30 cycles of denaturation 
(94 °C – 30 s), annealing (60 °C – 30 s), and elongation (72 °C – 30 s); final elongation (72 °C – 5 min). Colony PCR 
was analysed using agarose gel electrophoresis.  
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5. Results and Discussion  
5.1. Generation and Cell Internalization of Cytotransmab HerT4  
A long-term goal of this thesis was the identification and functional characterization of antibodies that are able 
to reach the cell cytoplasm, aimed at addressing intracellular targets. The cytotransmab-technology promises 
versatile generation of cytosol-penetrating full-length antibodies using antibodies with any desired specificity, 
simply by substitution of the original VL domain by the VL domain of a hT4 auto-antibody derived from a lupus 
mouse model91. In order to validate this claim, we generated HerT4 (Fig. 18A): anti-Her2 IgG1 antibody 
trastuzumab (Herceptin®), combined with the hT4 VL domain from Choi et al. (2014) (Figure S1A) and tested its 
cellular internalization and cytoplasmic penetration in comparison to the wildtype trastuzumab antibody. 
5.1.1. Cellular internalization test in Her2 expressing cell lines 
Cellular internalization was assessed in three cell lines with different antigen (Her2) expression levels. In case of 
trastuzumab wt, internalisation is mediated by receptor endocytosis combined with recycling of a significant 
part of the antibodies together with the receptor back to the cell surface221. This process was observable in form 
of gradual decrease in fluorescence intensity in accordance to the lower antigen expression levels of the CHO-
KI and MDA-MB 468 cells, combined with punctual distribution of the fluorescence signals throughout the 
cellular interior, except in the cell nucleus (Fig. 18B), suggesting entrapment in intracellular vesicles. 
 
Figure 18. HerT4 cytotransmab and its cellular internalization and distribution. (A) Generation of trastuzumab-based cytotransmab. 
The trastuzumab VL domain is exchanged for the humanized hT4 VL domain, which facilitates cytoplasm penetration. Image is modified 
from Choi et al. (2014)91. (B) Cellular internalization test with trastuzumab wt and HerT4. Three cell lines with different Her2 expression 
levels (high, intermediate, and low) were treated with 1 µM trastuzumab wt or HerT4 antibodies for 8 h. Cells were stained with anti-
human IgG-Alexa 488 conjugate and analysed using confocal microscopy.   
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In contrast, cellular internalization of the HerT4 antibody did not correlate with the Her2 display levels on the 
different cell lines. Strongest fluorescence intensity was detected in case of CHO-KI cells, where accumulation in 
the nucleus could be assumed (Fig. 18B). Fluorescence distribution in this case seems more homogenous, 
indicating possible release of the cytotransmab in the cytoplasm in accordance to the proposed endosomal 
escape mechanism of hT4-VL-baring antibodies92. Enhanced cellular internalization in CHO-KI cells could be 
explained by higher density of heparan sulfate proteoglycans (HSPG) on the cellular surface222 in comparison to 
the other two cell lines, confirming loss of antigen specificity of the parental antibody through the substitution 
of the VL, as declared by Kim et al. (2018)93.   
5.1.2. Cytoplasmic penetration of HerT4  
In order to examine in detail the capacity of endosomal escape and cytoplasmic release of the trastuzumab-
based cytotransmab, a GFP fragment complementation assay223 was performed. Spontaneous reassembly of 
two non-fluorescent fragments (GFP1-10 and GFP11) of green fluorescent protein results in formation of matured 
fluorophore, with fluorescence properties identical to the native GFP protein224. Cytoplasmic expression of the 
bigger GFP fragment, consisting of -sheets 1 to 10 of the -barrel structure of the protein, is achieved by 
transient transfection of mammalian cells. After treatment with a cytotransmab, carrying the 11th GFP -sheet 
in form of a 16 amino-acid-long protein tag, GFP reassembly occurs only after release of the cytotransmab in 
the cytoplasm, excluding any fluorescence signals from antibodies entrapped in vesicles. This method allows for 
live cell imaging and enables direct verification of cytoplasmic penetration without risk of false-positive signals 
derived from cell permeabilization and antibody staining procedures.  
In order to enhance the GFP complementation signal induced by one antibody molecule and enable time-
resolved analysis of GFP signal increase, a tandem GFP11-tag consisting of three GFP11-sequences in a row, each 
separated by a triple G4S-linker sequence, was genetically fused on the C-terminus of trastuzumab heavy chain 
resulting in six GFP11 peptides per antibody molecule (Fig. 19A). Tandem GFP tags facilitate linear increase of the 
GFP signal intensity depending on the number of the GFP11 moieties by simultaneous reassembly of multiple 
GFP molecules220.  
Incubation of GFP1-10-expressing CHO-KI cells with the HerT4-GFP11 cytotransmab (Figure S1B), resulted in GFP 
fluorescence detectable 6 h after treatment with increased intensity 8 h post-treatment (Fig. 19B). At the same 
time, trastuzumab-GFP11 construct did not show any GFP complementation signal even after 8 h of treatment 
with the same concentration of the construct. This indicates successful cytoplasmic penetration only in case of 
the cytotransmab and demonstrates the suitability of the assay for distinguishing between endosomal 
entrapment and cytosolic localization of the tested constructs.  
Nonetheless, this approach demonstrated a significant shortcoming in the face of limited transfection efficiency 
of the mammalian cells with the split-GFP1-10-carrying plasmid, resulting in a very low number of cytotransmab-
treated cells with detectable GFP complementation. Only 10-15 % of all cells exhibited detectable GFP signal 
after co-transfection with a plasmid coding for actin-fused GFP11 and comparable number of cells were 
fluorescent after transfection with vector coding for EGFP-actin fusion protein (Fig. 19C).  
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Figure 19. GFP complementation assay for proof of cytoplasmic delivery of HerT4. (A) Antibody constructs with C-terminal GFP11 
complementation tags. Three consecutive GFP11 sequences were fused genetically on the C-terminus of the trastuzumab heavy chain. 
GFP11-tags were separated by 15 amino acids long glycine-serine linker in order to ensure flexibility. (B) GFP complementation assay with 
CHO-KI cells transiently transfected with expression vector for GFP1-10. Cells were treated with 2 µM of each antibody construct and were 
analysed via live cell confocal imaging 6 h and 8 h after treatment. (C) Complementation assay positive control with spGFP1-10-expressing 
CHO-KI cells which were co-transfected with actin-GFP11, and a transfection control with CHO-KI wt cells transfected with EGFP-Actin 
plasmid.  
 
The presented experiments demonstrate that implementation of the split GFP complementation system would 
be a feasible and elegant strategy for screening and selection of antibodies or other molecules based on their 
cytosol-penetrating properties. However, significant improvements are required in order to enable efficient 
FACS-based detection and sorting of cells by means of GFP complementation.  
Firstly, reliable and consistent expression levels of the GFP1-10 fragment within the whole mammalian cell 
population should be achieved. In order to avoid variations between the transfection experiments, a stably 
transfected cell line expressing sufficient amount of the GFP1-10 protein should be established. Furthermore, 
since the GFP complementation signal is homogeneously distributed within the cytoplasm of the mammalian 
cells, overall fluorescence intensity of the cells is rather low, representing a limitation for FACS-mediated 
screening. Further enhancement of the GFP signal intensity could be achieved by genetic fusion of the GFP1-10 
fragment to streptavidin leading to tetramerization of the fusion protein. By introducing a peptidic streptavidin 
tag along the GFP11 sequence on the cytotransmab, a spatially proximity of the reassembled GFP molecules is 
accomplished leading to enhanced GFP intensity as demonstrated by Kim et al. (2018)93.  
Secondly, the development of a screening setup for cytosol-penetrating molecules represents further challenges 
regarding the library format and the phenotype-genotype coupling. Since only soluble molecules are able to 
penetrate cellular membranes and undergo GFP complementation, the screened candidates should be secreted 
by the library host (yeast). Microfluidic co-encapsulation of the library-secreting yeast cells together with the 
stably expressing split-GFP1-10 reporter cell line would ensure desired phenotype-genotype linkage and enable 
sorting on basis of cell penetration properties of the library variants (Fig. 20). Establishment of FACS-based 
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selection of desired candidates by generation of hydrogel microbeads and GMD-FACS would enable ultra-high-
throughput screening of a high number of variants, making the approach suitable for yeast-based libraries.  
 
Figure 20. Concept for selection of cytoplasm-penetrating antibodies. Antibody-secreting yeast cells are encapsulated together with 
mammalian reporter cells in microdroplets in w/o emulsion. Secreted antibodies carry GFP11 peptides on the C-terminus and accumulate 
in the microdroplet. Antibody-variants with cytosol penetrating properties localize in the cytoplasm of the mammalian reporter cell, where 
GFP complementation with the cytosolic expressed GFP1-10 takes place leading to enhanced GFP fluorescence signal of the mammalian 
cell. By sorting of the droplets containing GFP-positive mammalian cell, yeast cells secreting the desired cytosol-penetrating antibody 
variants are enriched (phenotype-genotype coupling). Scheme was generated with Biorender.  
 
Since the establishment of a functional screening procedure of this kind represents a versatile tool for selection 
of molecules with desired biological functions not only limited to cytosolic-penetration, this work was focused 
on the development of a novel technical procedure for efficient compartmentalization of living yeast and 
mammalian cells in picolitre-sized droplets and a FACS-compatible selection procedure in form of hydrogel 
microbeads.  
Development of a stable GFP1-10-expressing cell line and an enhanced split GFP complementation system was 
meanwhile object of the master’s thesis work of Janna Sturm and Carolin Dombrowsky.    
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5.2. Generation of Hydrogel Microbeads 
5.2.1. High-throughput generation of hydrogel-containing microdroplets 
Different procedures were tested for the generation of hydrogel-forming microdroplets:  
Bulk emulsification is the simplest method, based on the generation of aqueous droplets dispersed in an oil 
phase by applying shear stress (Fig. 21A). Following the procedure of Fang et al. (2017) for co-encapsulation of 
antibody-secreting Pichia pastoris and fixed mammalian target cells by bulk emulsification of agarose-containing 
medium225, 1.5 % low-melting agarose was emulsified in light mineral oil supplemented with 1.5 % (v/v) Span 80 
surfactant by stirring with an Ultra-Turrax® dispersing device. After cooling at 4 °C by gentle stirring and breaking 
the emulsion by multiple washing steps with light mineral oil and with PBS, the agarose beads were filtered 
through a 70 µm cell strainer and were analysed on a light microscope.  
 
Figure 21. Formation of agarose microbeads by bulk emulsification of agarose-containing medium. (A) Scheme of the bulk 
emulsification procedure in light mineral oil with 1.5 % Span 80 surfactant. Image was generated with Biorender. (B) Microscopical 
analysis of agarose microbeads generated by bulk emulsification at 37 °C and 42 °C.  
 
Bulk emulsification at 37 °C resulted in spherical agarose beads with dense texture (Fig. 21B, on the left), most 
likely due to partially solidification during the dispersing process. Increasing the emulsification temperature to 
42 °C led to highly transparent microbeads, yet the form of the particles was non-uniform (Fig. 21B, on the right). 
In both cases, bead recovery process by washing and filtering resulted in very low yield of agarose microbeads 
containing cells. Additionally, emulsification process at 42 °C is not compatible with living mammalian cells and 
would cause drastic reduction in the cell viability.   
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In order to increase the amount of microbeads with desired size and morphology, microfluidic droplet 
generation was envisaged. Custom-made microfluidic devices consist most commonly of single-use poly-di-
methyl-siloxane (PDMS) microfluidic chips with desired architecture and channel sizes (Fig. 22A) which are 
bonded onto microscopic glass slides. Microfluidic channels are connected through steel fluidic couplers with 
the tubing (Fig. 22B). In the simplest configuration, the fluids are injected with the help of syringes operated by 
peristaltic syringe pumps, enabling control of the flow rates. Adjusting of the flow rates occurs mostly empirically 
until stable droplet formation is observed, where exclusively monodispersed droplets are produced (Fig. 22C). 
 
 
Figure 22. Custom-made microfluidic system. (A) Schematic of the geometry of a flow focusing PDMS microfluidic chip. Image was 
modified from Duarte et al. (2017)226. (B) Image of an PDMS microfluidic chip assembled with channel connectors and tubing. (C) Image 
of droplet generation using a flow-focusing PDMS microfluidic chip.  
 
PDMS microfluidic devices are designed for combination with a microscope (and optionally a high-speed camera) 
for control and observation of the droplet formation. Since reliable tempering of the complete microfluidic 
equipment at 42 °C including the syringe pumps and the microscope was not possible, encapsulation of agarose-
containing medium was not pursued. As an alternative, sodium alginate was chosen since it has found broad 
application in cell encapsulation experiments (see chapter 1.8.1). Two different gelation strategies for 
generation of calcium alginate beads were tested, both leading to generation of a high quantity of alginate 
microbeads. External gelation of a 1 % sodium alginate solution emulsified using the PDMS chip was achieved 
by dripping the emulsified droplets from the outlet tubing directly into Ca2+-containing Tris buffer (100 mg/mL 
CaCl2) combined with gentle shaking of the collection vessel. However, hydrogel microbeads generated in this 
way did not exhibit spherical form and were prone to clumping (Fig. 23A), resulting in dramatic loss of the 
microbeads during the filtering step with a 70 µm cell strainer. Internal gelation method as developed by Utech 
et al. (2015)205 resulted in more homogeneous alginate microbeads with spherical shape, nicely dispersed in the 
aqueous solution after recovery (Fig. 23B). 
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Figure 23. Formation of calcium alginate 
microbeads with the help of PDMS microfluidic 
chip and peristaltic syringe pumps. (A) External 
alginate gelation by dripping of the emulsified 
droplets into calcium-containing solution. (B) 
Internal alginate gelation by addition of Ca-EDTA 
complex to the encapsulation medium.  
 
Although droplet generation using custom-made PDMS microfluidic chips allowed for production of a sufficient 
quantity monodispersed calcium alginate microbeads, encapsulation flow rates were limited to 1-2 µL/min due 
to the high viscosity of the alginate solution. Furthermore, pressure fluctuations from the peristaltic pumps led 
frequently to disturbances in the droplet generation resulting in droplets with varying sizes (Fig. 23B lower 
image). In order to achieve faster and more consistent droplet generation and to enable encapsulation of other 
hydrogels with thermal crosslinking mechanisms (agarose and Matrigel), a commercially available microfluidic 
system (µEncapsulator) was obtained. The µEncapsulator system consists of pressure pumps and flow rate 
sensors for precise control of the flow rates (Fig. 24). It comprises also a temperature controlling unit (TCU), a 
microscope with integrated high-speed camera and is compatible with a variety of reusable microfluidic chips 
made of glass, which makes them long-living and stable to high pressures.  
 
Figure 24. Composition of the µEncapsulator system and images of droplets and hydrogel microbeads generated with the device.  
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Cell encapsulation using the µEncapsulator system and a microfluidic chip with 50 µm junction in combination 
with fluorinated oil with 2 % PicoSurf surfactant as continuous phase resulted in highly homogeneous and stable 
droplets (Fig. 24). The size of the monodispersed droplets was estimated using area calculation of 100 droplets 
(ImageJ). Droplet formation at flow rates of 4 µL/min and 35 µL/min for the aqueous and oil phases, respectively, 
generated microdroplets with 44 µm diameter and 45 pL volume on average. Generation of hydrogel 
microbeads was successful using internal gelation of alginate, as well as thermal crosslinking of ultra-low gelling 
temperature agarose and Matrigel.  
5.2.2. GMD-FACS of agarose and alginate microbeads  
Sorting of hydrogel microbeads using a standard FACS device (BD Influx™) required some technical changes and 
settings optimization. Particle size plays a decisive role in the sorting process, thus standard settings for sorting 
of yeast and mammalian cells needed to be adopted to the significantly bigger hydrogel microbeads. To this end, 
a 200-micron outer nozzle was installed, which enabled sufficient sheathing of the microbeads with sheath 
buffer, required for generation of a stable stream, as well as for effective charging and deflection of the FACS 
drops. Furthermore, in case of alginate hydrogel, the sheath fluid for the FACS device needed to be exchanged 
and optimized, since PBS-based sheath buffer dissolved the microbeads by precipitation of non-soluble calcium 
phosphates. Therefore, Tris buffer with 1 mM CaCl2 was used as sheath fluid for the FACS processing of alginate 
microbeads.  
 
Figure 25. Generation of hydrogel microbeads containing yeast cells. Green fluorescent yeast cells (EBY100-tGFP) were mixed with 
red fluorescent yeast cells (EBY100-mCherry) at a 1:50 ratio. Encapsulation was performed using the µEncapsulator system with cells 
resuspended in medium containing either ultra-low gelling temperature agarose or alginate, dissolved in Ca-EDTA solution. Directly after 
encapsulation the hydrogel was solidified and following emulsion break, the yeast-loaded hydrogel microbeads were sorted by FACS. 
 
The sorting process of hydrogel microbeads was validated using GFP-producing yeast cells mixed with an excess 
of red fluorescent protein (mCherry)-expressing yeast cells, which were together encapsulated in alginate or 
agarose microbeads (Fig. 25). FACS selection of GFP-expressing yeast cells was successful both for agarose and 
alginate, resulting in predominantly green fluorescent yeast populations after a single sorting round (Fig. 26 A 
and B, sort outcome). Moreover, fluorescence microscopy of sorted populations revealed reliable selection of 
desired populations and specific discrimination between beads containing cells with one fluorescent marker or 
both (Fig. 26 on the left).        
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Figure 26. Test of GMD-FACS efficiency using yeast cells encapsulated in (A) agarose and (B) alginate microbeads. Yeast-loaded 
hydrogel microbeads were sorted by FACS. Sorting efficiency was analysed by sorting mCherry-positive (green), GFP-positive (blue), and 
double-fluorescent (magenta) events, followed by fluorescence microscopy (on the left). Analysis of sort outcome was performed after 
propagation of the sorted GFP-positive yeast on agar medium. 
 
5.2.3. Mammalian cell viability and reporter cell activation using different hydrogels  
Since a reporter cell line stably expressing split-GFP1-10 for detection of cytoplasm-penetrating antibodies was 
not available, two other reporter cell lines were utilized for verification of the functional selection concept. 
Ba/F3-CIS-d2EGFP cells were used to demonstrate the suitability of the system for isolation of biologically active 
cytokines (interleukin-3) (chapter 5.3), while NF-B/Jurkat/GFP reporter cells served as a model for establishing 
a functional screening procedure for selection of agonistic antibodies (chapter 5.4). In order to evaluate possible 
negative effects of the encapsulation procedure and droplet microenvironment upon the viability and 
functionality of the mammalian reporter cells, reporter cells were encapsulated in droplets, containing different 
hydrogel-forming agents (agarose, alginate, Matrigel). Hydrogel microbeads were recovered after incubation 
overnight in the w/o emulsion and dead cells were stained with propidium iodide, followed by flow cytometrical 
analysis (Fig. 27A). 
Cell viability measurement revealed minimal negative effects of the encapsulation procedure and incubation 
conditions in emulsion when no hydrogel-forming polymer was added to the encapsulation mix, with over 75 % 
viable cells of both reporter cell lines (Fig. 27B, medium only). By adding alginate, drastic reduction of the cell 
viability could be observed, especially in case of the NF-B/Jurkat/GFP cells. This effect is most likely caused by 
limited nutritional supply inside the microdroplets, where a big portion of the droplet volume is occupied by the 
polymer. Furthermore, in case of alginate, the hydrogel crosslinking procedure involves a short incubation step 
under acidic conditions, which seemed to induce additional negative effects and can be observed as a small cell 
population with high GFP fluorescence, but elevated PI-signal (Fig. 27A, black arrow). In case of Matrigel, Ba/F3-
CIS-d2EGFP cells demonstrated higher cell viability of about 60 %. However, no hydrogel microbeads could be 
recovered from cell-containing droplets incubated overnight, whereas Matrigel-formation was possible by 
solidification and beads recovery directly after encapsulation. This indicated digestion of Matrigel overnight by 
secreted cell proteases, a phenomenon which has been previously reported227. For this reason, Matrigel was not 
further used for encapsulation experiments despite higher viability of the cells in the presence of this matrix. At 
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the same time, encapsulation in agarose microbeads resulted in similar viability of both reporter cell lines, with 
variations in the range of 30-70 %, between different samples. 
 
 
Figure 27. Mammalian cell viability in different hydrogel microbeads. (A) Two-dimensional FACS plots of Ba/F3-CIS-d2EGFP 
reporter cells encapsulated in droplets and incubated overnight in emulsion. Cells were encapsulated in medium with or without addition 
of hydrogel-forming polymers (alginate, Matrigel, and agarose). Water-in-oil emulsion was incubated overnight at 37 °C, 8 % CO2, 
110 rpm. On the following day, hydrogels were solidified and the emulsion was broken. Dead cells were stained with propidium iodide 
(PI) and microbeads (or free cells in case of medium only) were analysed using flow cytometry. Fraction of living cells was defined as the 
population with strong GFP signal and low PI-fluorescence (black box). (B) Cell viability of Ba/F3-CIS-d2EGFP and NF-B/Jurkat/GFP 
reporter cells in droplets containing different hydrogel-forming polymers determined by flow cytometry. Error bars are the result of three 
independent encapsulation experiments. 
 
Next, the expression of the reporter protein (GFP) upon activation of the reporter system in droplets was 
investigated. To this end, the reporter cells were encapsulated in medium containing different hydrogel forming 
polymers with or without addition of reporter activators (murine interleukin-3 (mIL-3) for Ba/F3-CIS-d2EGFP 
(Fig. 30) and human tumour necrosis factor alpha (hTNFα) in case of NF-B/Jurkat/GFP (Fig. 47)). Following 
incubation overnight in emulsion at 37 °C, hydrogel microbeads were gelled and GFP fluorescence was analysed 
by flow cytometry (Fig. 28).    
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Figure 28. Activation of reporter cells encapsulated in droplets containing different polymers. (A) GFP fluorescence signal of Ba/F3-
CIS-d2EGFP cells encapsulated in droplets consisting only of medium with or without addition of murine interleukin-3 (20 ng/mL) and 
incubated in emulsion (black and magenta). For comparison activation of reporter cell in a 96-well plate in the same medium composition 
(blue and green). (B) GFP fluorescence of Ba/F3-CIS-d2EGFP cells encapsulated in alginate-containing (1 % (w/v)) medium, incubated 
overnight in emulsion and crosslinked prior to flow cytometry analysis. (C) Activation of NF-B/Jurkat/GFP cells encapsulated in droplets 
consisting only of medium with or without addition of human tumour necrosis factor alpha (20 ng/mL) and incubated in emulsion. (D) 
GFP fluorescence of NF-B/Jurkat/GFP cells encapsulated in medium, containing 1 % (w/v) alginate, incubated overnight in emulsion and 
crosslinked on the next day prior analysis. (E) Activation of NF-B/Jurkat/GFP cells encapsulated in agarose-containing (0.75 % w/v)) 
medium, incubated overnight in emulsion and solidified prior analysis.  
 
Reporter protein expression was sufficient for both cell lines if encapsulated in droplets without addition of 
hydrogel-forming agent (Fig. 28A and C). In case of Ba/F3-CIS-d2EGFP, 89 % of all analysed cells exhibited 
elevated GFP fluorescence intensity in comparison with cells encapsulated without addition of mIL-3 (black and 
magenta histograms). At the same time incubation in a 96-well plate in the same medium composition resulted 
in slightly higher number of GFP-positive cells (95 %) and increased mean fluorescence intensity ((Fig. 28A blue 
histogram), indicating a weak negative effect of the encapsulation procedure and incubation in the w/o emulsion 
on the mammalian cells. The assessment of reporter cell activation indicates that GFP expression correlates 
tightly with the viability of the reporter cells under the tested conditions. In case of NF-B/Jurkat/GFP, no GFP 
positive cells could be observed after encapsulation in alginate microbeads (Fig. 28D), whereas 60 % of the Jurkat 
cells demonstrated strong GFP expression in medium-only droplets and 10 % in agarose-containing droplets. 
These results are again in accordance with the cell viability measured under the indicated conditions (Fig. 27B). 
Generally, NF-B/Jurkat/GFP demonstrated significantly lower cell viability and activation levels in comparison 
to Ba/F3-CIS-d2EGFP, which seemed more robust and resistant to the process.  
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5.3. Functional Selection of Active Interleukin-3 Variants 
For proof-of-concept verification of the functional selection approach, a cytokine-responsive murine reporter 
cell line was utilized (Fig. 30) in combination with cytokine-secreting S. cerevisiae cells. Cytokines are small 
signalling proteins secreted by immune cells with growth-promoting, pro- or anti-inflammatory effects228. 
Implementation of interleukin-3 for induction of reporter cell activation, was chosen due to the small size, 
monomeric protein structure and high potency of this cytokine. Furthermore, the murine Ba/F3-CIS-d2EGFP 
reporter cells demonstrated higher cell viability and reporter cell activation under the tested conditions in 
hydrogel microdroplets, compared to the second available reporter cell line (NF-B/Jurkat/GFP). Since 
implementation of agarose as hydrogel-forming polymer sustained higher cell viability for both reporter cell 
lines, it was preferred for the further encapsulation experiments and screens over alginate.  
Based on the murine Ba/F3 reporter cell line, a workflow for isolation of biologically active mIL-3 variants was 
designed. The functional screening procedure is illustrated in Figure 29. 
 
Figure 29. Workflow scheme of a functional screening procedure for selection of active mIL-3 cytokine variants. 
 
The mIL-3-responsive mammalian reporter cells are co-encapsulated with cytokine-secreting S. cerevisiae in 
agarose-containing microdroplets (Fig. 29) and are incubated overnight at 37 °C, 110 rpm, 8 % CO2 in the w/o 
emulsion. Actively secreting yeast cells express an intracellular red fluorescence protein (mCherry). Since the 
reporter cells are mIL-3-dependent for cell growth and are propagated in the presence of the cytokine, they are 
fluorescent at beginning of the encapsulation process. However, if a reporter cell is co-encapsulated in a droplet 
with a yeast cell which secretes a non-functional cytokine, the GFP intensity of the reporter cell reduces over 
time. In contrary, in the presence of a yeast cell secreting a biologically active mIL-3 variant, the GFP fluorescence 
intensity remains high. Following the incubation step, the agarose in the droplets is solidified by incubation on 
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ice and agarose microbeads are recovered in PBS. Selection by FACS is conducted by sorting of double-
fluorescent agarose microbeads, containing mCherry-positive yeast and GFP-positive mammalian cells. Sorted 
hydrogel microbeads are plated on selective agar for expansion of yeast cells and the encapsulation and sorting 
process is repeated in multiple rounds until sufficient enrichment of biologically active cytokines is achieved.  
5.3.1. Murine interleukin-3-dependent activation of a reporter cell line 
For the purpose of a proof-of-concept functional screen, a murine Ba/F3 reporter cell line, expressing GFP upon 
stimulation with mIL-3 was used (Fig. 30). Interleukin-3 is an important regulator of hematopoiesis and growth 
factor inducing proliferation of pluripotent stem cells, as well as supports the functional activity of some fully 
differentiated cells229. 
 
Figure 30. Activation of GFP expression in Ba/F3-CIS-d2EGFP reporter cells. Gene for destabilized green fluorescent protein 
(d2EGFP) is placed under the control of the STAT5-inducible CIS promoter. Upon binding of murine interleukin-3 to its receptor, the 
JAK2/STAT5 pathway is activated leading to expression of the reporter protein and strong GFP fluorescence of the reporter cells. Scheme 
was generated with Biorender according to Reddy et al. (2000)230 and Robin et al. (2010)231. 
 
Expression of destabilized green fluorescent protein (d2EGFP) is induced upon binding of mIL-3 to its receptor 
on the reporter cell surface and activation of the JAK2/STAT5 pathway (Fig. 30). Short-lived GFP reporter was 
used in order to enable faster GFP degradation upon mIL-3 deprivation, since mIL-3 is required for propagation 
and cultivation of the reporter cells. D2EGFP is generated by fusion of enhanced GFP to mouse ornithine 
decarboxylase (MODC), which is one of the mammalian proteins with most rapid turnover (most short lived)232. 
This fusion strategy reduces the half-live of the GFP reporter from approx. 15 hours233 to 2 hours232.  
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Figure 31. Reporter activation in Ba/F3-CIS-d2EGFP cell line in dependency to the mIL-3 concentration. (A) Mean GFP 
fluorescence intensity determined by flow cytometry after incubation overnight of reporter cells in a 96-well plate with a dilution row 
(2.5 pg/mL – 41 ng/mL) of recombinant mIL-3 in standard cultivation medium (RPMI-1640) or a medium mix (50 % RPMI-1640 + 50 % 
DMEM-F12 Ham + 2 % w/v galactose). GFP signal was normalized to the negative control (reporter cells incubated without mIL-3). 
Dashed lines represent logarithmic trendlines. Error bars are result of measurement of three biological replicates. (B) Flow cytometry 
histograms of reporter cells activated with different concentrations of rec. mIL-3 obtained on BD Influx™ Cell Sorter.  
 
First, the response of the mIL-3 inducible reporter cell line in relation to the mIL-3 concentration was examined 
and revealed a dose-dependent increase in the GFP fluorescence intensity upon stimulation with recombinant 
mIL-3 with concentrations in the range of 0.01 – 40 ng/ml (Fig. 31A). Additionally, flow cytometry analysis 
confirmed sufficient population separation of the non-activated (0 ng/mL rec. mIL-3) and weakly-activated 
(0.625 ng/mL rec. mIL-3) reporter cells (Fig. 31B), which proves the compatibility of the reporter system with a 
FACS-based positive selection.  
 
5.3.2. Generation of a non-functional mIL-3 mutant 
A non-activating mIL-3 variant with minimal sequence alterations (single amino acid substitution) was desired 
for verification of the functional screening approach. Based on the study of Klein et. al (1997) regarding the 
receptor-binding site of human IL-3, one amino acid substitution (E22G) in human IL-3 was determined as 
suitable for our purposes, since it resulted in >300 fold reduction in growth-promoting activity, while retained 
the relative binding to the  receptor subunit of human IL-3 receptor234. In order to identify the corresponding 
position in the murine mIL-3 ortholog, a structural alignment with human mIL-3 was performed, revealing a 
conserved glutamate at position 49 in the murine IL-3 sequence (Fig. 32B) with a similar spatial orientation to 
E22 in hIL-3 (Fig. 32A).   
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Figure 32. Structural and sequential comparison of human and murine IL-3. (A) Protein structures were obtained from PDB and 
aligned using PyMol. (B) Amino acid sequences were obtained and aligned using UniProt data base. 
 
Sequences of wildtype mIL-3 and the mutant E49G were constructed for secretion by S. cerevisiae as illustrated 
in Figure 33. Galactose-induced transcription (GAL1 promoter) leads to generation of a single mRNA transcript, 
comprised of the transcripts of mIL-3 and red fluorescent protein (mCherry). Ribosomal skipping peptide (T2A) 
between the two genes facilitates the translation of two separate proteins: mIL-3 with N-terminal secretion 
signal (app8218) is secreted in the culture medium, while mCherry remains trapped intracellularly and 
accumulates in a correlation to the expression rate of the cytokine219, serving as an expression control. This 
construct enabled the detection of agarose microbeads containing an actively secreting yeast cells during the 
selection process by FACS.  
 
Figure 33. Gene construct for the expression and secretion of mIL-3 in S. cerevisiae. 
 
5.3.3. Reporter cell activation by mIL-3 in yeast culture supernatant 
A reporter cell activation assay using yeast supernatant was performed in order to verify successful secretion of 
mIL-3 wt and E49G mutant from S. cerevisiae and to prove the functionality of the cytokine with respect to the 
reporter system. To this end, yeast cells were cultured under expression conditions (2 % w/v galactose in 
medium) until sufficient cell density and mCherry-fluorescence were reached (Fig. 34C). Cytokine-containing 
yeast supernatant was then harvested and added to the reporter cells (Fig. 34A). In case of sufficient secretion 
of the wt mIL-3, GFP expression in the mammalian cells is induced and the cells remain fluorescent, while in case 
of the non-functional E49G mutant a decrease in the fluorescence intensity over time is expected. 
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Figure 34. Reporter cell activation assay using yeast supernatant. (A) Scheme of the assay components. (B) Flow cytometry histograms 
of Ba/F3-CIS-d2EGFP reporter cells incubated with yeast supernatant after expression and secretion of mIL-2 wt or mIL-3 E49G from 
S. cerevisiae. (C) Mean mCherry fluorescence in rFU of yeast cells before and after induction with galactose. Error bars are result of two 
flow cytometry measurements of the corresponding samples.  
 
Reporter cell activation assay was analysed by flow cytometry after 16-18 h of treatment of the reporter cells 
with the yeast supernatant (Fig. 34B). Ba/F3-CIS-d2EGFP cells incubated with the culture supernatant of the 
mIL-3 wt- secreting yeast exhibited strong GFP fluorescence (blue histogram), while yeast supernatant 
containing the mutated mIL-3 variant induced GFP expression levels comparable to the negative control (red 
and black histograms). Simultaneously, mCherry fluorescence intensity was identical for both mIL-3 variants 
(Fig. 34C) and the discrepancy in the yeast culture densities was negligible, indicating similar expression rates of 
both proteins. This result confirms successful cytokine secretion and accumulation in the yeast supernatant and 
at the same time verifies our assumption, that the single amino acid substitution E49G leads to strongly 
diminished reporter cell activation.   
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5.3.4. Growth of S. cerevisiae in different mammalian culture media 
Investigation of reporter cell viability and activation levels revealed a thight correlation between cell viability 
and GFP expression rates (chapter 5.2.3). For a functional read-out by combination of yeast secretor and 
mammalian reporter cells, culturing conditions (O2, CO2, humidity, medium, temperature, etc.) suitable for both 
species should be identified. Generally, S. cerevisiae prefers 30 °C and slightly acidic cell extract-based media235, 
while mammalian cells need to be cultured by strict conditions – 37 °C, 5 % CO2, in defined synthetic media with 
complex composition. In order to address this problem, yeast cell growth in three standard mammalian culture 
media (DMEM, RPMI-1640, and DMEM-F12 Ham) was compared at two different temperatures (Fig. 35). 
 
 
Figure 35. Growth curve of S. cerevisiae EBY100 in different mammalian culture media. (A) Culturing at 30 °C with 180 rpm orbital 
shaking. (B) Culturing at 37 °C with 180 rpm orbital shaking. Cell density was measured photometrically every hour for 10 h. Error bars 
are result of three photometrical measurements of the corresponding sample.  
 
Cell proliferation was observed only at 30 °C (Fig. 35A), while at 37 °C no increase in the optical density even 
after 10 h could be measured for all samples (Fig. 35B). Moreover, sufficient cell growth was detected only in 
case of DMEM-F12 Ham medium (Fig. 35A, yellow curve), most likely due to the inorganic microelements 
contained in the F12 nutrition mix (e.g. cupric sulfate, ferric sulfate, zinc sulfate). Since the Ba/F3 reporter cells 
are commonly cultured in RPMI-1640 medium, but no significant yeast growth was observed in this medium 
(Fig. 35A, blue curve), a 1:1 mixture of RPMI-1640 + DMEM-F12 Ham was tested, resulting in slightly reduced, 
but sufficient yeast cell growth and viability (Fig. 35A, green curve). Furthermore, the activation of the reporter 
cells by rec. mIL-3 was not impaired in this medium mix, but stronger GFP fluorescence was measured (Fig. 31A, 
red curve) and reporter cell viability remained over 90 % in the 50 % RPMI-1640 + 50 % DMEM-F12 Ham medium 
mix (Fig. 36, red curve). Nevertheless, induction of yeast cells and protein expression seemed to correlate to the 
growth rates of the S. cerevisiae, which reduced drastically by lowering the proportion of the DMEM-F12 Ham 
in the medium mix (Fig. 36). Thus, in order to achieve a sufficient induction level, yeast cells were induced in 
minimal SG medium prior to co-encapsulation and coculturing experiments with mammalian reporter cells.  
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Figure 36. Medium-dependent yeast cell growth and induction rates, as well as mammalian reporter cell viability. DMEM-F12 Ham 
medium was mixed with RPMI-1640 in different ratios (0 % – 100 %) and supplemented with 2 % galactose and 1 % Pen/Strep. Yeast cell 
density (OD600) was determined photometrically after 24 h of incubation at 30 °C, 180 rpm and induction levels were determined as fraction 
mCherry positive cells (%) by flow cytometry. Reporter cell viability was measured after staining with propidium iodide (PI) by flow 
cytometry and percent viable cells was plotted on the graph for each medium composition.  
 
5.3.5. Cocultivation of mIL-3-secreting yeast cells and reporter cells in test tubes  
Next, the activation of the reporter cells in the presence of live cytokine-secreting yeast cells was tested. Since 
no yeast cell growth could be observed at 37 °C (Fig. 35B), а concern regarding the cytokine secretion rates at 
37 °C arose. In order to estimate which temperature is suitable for the purposes of coculturing in microdroplets, 
mammalian reporter cells were mixed with pre-induced cytokine-secreting yeast cells in medium and incubated 
at 37 °C and at 30 °C overnight, respectively (Fig. 37). Activation of the reporter cells was measured by means of 
flow cytometry (GFP fluorescence) and was used as a factor to determine the conditions supporting sufficient 
cytokine secretion from the yeast and high cell viability of the mammalian cells.  
 
Figure 37. Cocultivation of live mammalian reporter (Ba/F3-CIS-d2EGFP) and yeast (S. cerevisiae EBY100) cells. Both cell types 
were suspended in 1 mL medium mix (50 % RPMI-1640 + 50 % DMEM-F12 Ham), supplemented with 2 % w/v galactose and 1 % 
Pen/Strep and were cocultured in 50 mL reaction tubes. Negative and positive controls represent reporter cells alone, without addition of 
cytokine, or reporter cells mixed with yeast cells and 20 ng/mL rec. mIL-3, respectively. (A) Incubation at 37 °C. (B) Incubation at 30 °C. 
Flow cytometry analysis was performed after 18 h of cocultivation. Histograms depict the GFP fluorescence signal of the mammalian 
reporter cells only. 
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Significant GFP fluorescence signal separation between the Ba/F3 reporter cells cocultured with the non-
activating E49G mutant and the wildtype mIL-3 could be observed at 37 °C (Fig. 37A). Furthermore, the mIL-3 
wt secretion level from the yeast cells was sufficient to induce maximal reporter cell activation, which could not 
be enhanced further by the addition of recombinant mIL-3 (Fig. 37A, positive control). In contrast, coculturing 
at 30 °C resulted in high reporter cell mortality, leading to insufficient activation of the mammalian cells, even 
after stimulation with rec. mIL-3 (Fig. 37A, positive control). With the aid of this experiments, coculturing at 
37 °C, 8 % CO2 in humidified atmosphere in a medium consisting of 50 % RPMI-1640 + 50 % DMEM-F12 Ham + 
2 % galactose w/v + 1 % Pen/Strep, was determined as optimal for the means of functional screening procedure 
in microdroplets.  
5.3.6. Activation of reporter cells by co-encapsulation with cytokine-secreting yeast  
Activation of the mammalian reporter cells by secreted cytokines from yeast cells in agarose microdroplets was 
tested by co-encapsulation of the Ba/F3-CIS-d2EGFP cells together with yeast cells secreting either mIL-3 wt or 
the non-functional E49G mIL-3 mutant. Both samples were handled identically (as illustrated in Fig. 29) and were 
incubated as emulsion for 18 h at 37 °C. Microscopical analysis of the droplets in emulsion was performed 
directly after encapsulation  and after the incubation period (Fig. 38).  Directly after co-encapsulation with mIL-3 
wt-, or mIL-3 E49G-secreting yeast cells, the mammalian cells in both samples showed strong GFP fluorescence 
(due to cultivation in presence of rec. mIL-3 for cell expansion), while no fluorescence background in the droplets 
could be observed (Fig. 38, 0 h). After incubation of the droplet- w/o-emulsion overnight, the droplets containing 
the non-functional mIL-3 variant exhibited diffuse fluorescence, spread throughout the whole droplet, implying 
cell lysis and release of the remaining GFP in the droplet (Fig. 38A, 18 h). In case of the activating mIL-3 wt- 
secreting yeast, significantly more mammalian cells appear intact, leading to mainly cell-concentrated GFP 
fluorescence with higher intensity when yeast cells are colocalised in the droplet. (Fig. 38B, 18 h).  
 
Figure 38. Microscopical analysis of co-encapsulated reporter and yeast cells. (A) Ba/F3-CIS-d2EGFP cells were co-encapsulated 
with mIL-3 E49G- secreting yeast. (B) Ba/F3-CIS-d2EGFP cells were co-encapsulated with mIL-3 wt- secreting yeast. Cells were co-
encapsulated in agarose-containing droplets in w/o emulsion and were analysed on a confocal fluorescence microscope without 
solidification directly after emulsification (0 h) and after 18 h incubation at 37 °C, 8 % CO2. Black arrows indicate droplets with yeast and 
mammalian cells in the same droplet.  
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These observations were confirmed by flow cytometry analysis of the solidified agarose microbeads (Fig. 39). 
While the mCherry fluorescence intensity of both samples remains identical, indicating the same cytokine 
expression levels (Fig. 39B), the GFP fluorescence in case of co-encapsulation with wt mIL-3 is significantly 
stronger (Fig. 39C). By comparison of the GFP intensity of the double-fluorescent agarose microdroplets, the 
mIL-3 wt-containing microbeads exhibited noticeably stronger GFP fluorescence (Fig. 39D) with 1 % lying in the 
high-stringency sorting gate (Fig. 39A P2-Q2).  
 
 
Figure 39. Flow cytometry of agarose microbeads containing mammalian reporter cells and cytokine- secreting yeast cells (mIL-3 
E49G and mIL-3 wt) after 18 h incubation in emulsion at 37 °C. (A) Two-dimensional FACS plot: x-axis represents GFP fluorescence 
of reporter cells and y- axis depicts the mCherry fluorescence of yeast cells. Gating strategy (blue) represents the double-fluorescent 
hydrogel microbeads identified as positive events during sorting (P2-Q2). (B) Overlay of the mCherry fluorescence signals of both samples. 
(C) Overlay of the GFP fluorescence signals of both samples. (D) Overlay of the GFP fluorescence intensity of the agarose microbeads 
containing mammalian and yeast cells (black box) from both samples. (E) Two-dimensional overlay of both samples (generated with 
FlowJo).   
 
The number of agarose microbeads with significantly enhanced GFP signal (1 %) is limited by multiple factors 
including mammalian and yeast cell viability, cell distribution in the droplets, and co-encapsulation efficiency. 
Cell distribution in the droplets is dependent on the cell density of the encapsulated suspension and on the 
droplet size and can be predicted by Poisson’s equation (Equation 2). Thus, optimal occupancy (one yeast and 
one mammalian cell) occurs only in a fraction of all droplets, affecting directly the FACS selection. In case low 
cell density of both cell types is used for co-encapsulation, the co-encapsulation efficiency drops drastically, 
resulting in a very high number of useless droplets. On the other side, high cell density leads to encapsulation 
of multiple yeast/mammalian cells in one droplet, and sorting of multiple yeast clones based on mammalian 
response induced by a single yeast cell (false positive). However, during subsequent co-encapsulation and 
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selection cycles, the enriched false-positive yeast cells are eliminated to a large extend. Since our functional 
screen approach enables multiple screening rounds for specific enrichment of activating variants, more than 
one yeast cell per droplet is tolerated. Cell densities of 4 × 107 yeast cells/mL (= 0.9) and 2 × 107 mammalian 
cells/mL ( = 0.45) were used for co-encapsulation. In order to determine the actual distribution of cells in the 
droplets, co-encapsulated cells in w/o emulsion were analysed microscopically (Fig. 38, 0 h). While about 55 % 
of all droplets were empty, approx. 23 % of the occupied droplets contained one yeast and 50 % one mammalian 
cell (Fig. 40B). Generally, yeast cells are prone to flocculation236, which reflects the higher number of droplets 
with more than one yeast cell (38 %) in comparison to the fraction of droplets with more than one mammalian 
cell (19 %). Based on the microscopical analysis of 226 droplets, an average of 0.6 yeast and 0.41 mammalian 
cells per droplet were estimated, resulting in a theoretical co-encapsulation probability of about 15 % 
(Equation 4). On account that only about 70 % of the yeast cells exhibited sufficient mCherry fluorescence, the 
fraction of droplets containing an actively secreting yeast cell and a viable mammalian cell was determined by 
flow cytometry to be in the range between 8 % and 10 % of all droplets (Fig. 40A). Furthermore, since nutrition 
and space are limited inside the picolitre-volume droplets, co-encapsulation of a yeast cell with multiple 
mammalian cells could lead to false negative signals, due to reduced viability of the mammalian cells during the 
incubation step. To avoid losing desired variants due to false negative events, oversampling the yeast diversity 
during the co-encapsulation step at least 100 times is necessary. Nevertheless, with a generation speed of about 
8 × 106 droplets/h using the µEncapsulator system, at least 8 × 105 yeast cells could be successfully co-
encapsulated with a mammalian reporter cell in just one hour, making this system feasible for the screening of 
yeast-based libraries. 
 
 
Equation 4. Calculation of co-encapsulation probability using Poisson’s law.  
𝑃(𝑥1; 𝑥2)  =  
𝑒−𝜆1 × 𝜆1
𝑥1
𝑥1!
× 
𝑒−𝜆2 × 𝜆2
𝑥2
𝑥2!
 
 
𝑃(𝑥1 ≥ 1; 𝑥2 ≥ 1)  = (1 −  𝑒
−𝜆1) × (1 −  𝑒−𝜆2)  
𝑃 = co-encapsulation probability 
𝑥1  = number of mammalian cells in a droplet  
𝜆1  = average number of mammalian cells per droplet 
𝑥2  = number of yeast cells in a droplet 
𝜆2  = average number of yeast cells per droplet 
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Figure 40. Analysis of cell distribution in the microdroplets and co-encapsulation efficiency of reporter and yeast cells. (A) Flow 
cytometrical analysis of co-encapsulation efficiency directly after co-encapsulation (0 h). Agarose containing droplets were generated by 
co-encapsulation of mammalian reporter cells with either mIL-3 wt- or mIL-3 E49G-secreting yeast cells, which were priorly induced 
overnight in autoinduction medium. Directly after encapsulation the w/o emulsion was cooled for 15 min on ice for agarose microbeads 
formation. Agarose microbeads were subsequently analysed on BD Influx™ FACS. Population in the blue gate represents double positive 
agarose microbeads, containing at least one mCherry-positive yeast and one GFP-positive reporter cell. (B) Distribution of yeast and 
mammalian cells inside the droplets. 226 droplets were analysed based on fluorescence microscopy images, 100 of the droplets contained 
cells and 126 were empty. Number of yeast and mammalian cells per corresponding droplet were estimated optically with help of the 
fluorescence signal of the cells (mCherry for yeast and GFP for mammalian reporter cells). Percentage of droplets with defined number of 
cells of a given cell type (0 to 6) per droplet was plotted.  
 
5.3.7. Mixing experiments with an excess of the non-functional mutant and FACS-selection 
In order to demonstrate the applicability of our system for a mammalian-based functional screen, the mIL-3 wt-
secreting yeast cells were mixed with the yeast cells secreting the non-functional E49G mutant at different ratios 
(1:10, 1:100, 1:1,000, and 1:10,000). The mixed yeast cells were then co-encapsulated with the Ba/F3-CIS-
d2EGFP reporter cells as illustrated in Figure 29 and only double-fluorescent agarose microbeads with strong 
GFP fluorescence were sorted (Figure S2). Enrichment of yeast cells secreting the functional mIL-3 wt cytokine 
was monitored by reporter cell activation assay using supernatants of the sorted populations, as well as by single 
yeast clone analysis by PCR with mIL-3 wt- specific primer (Figure S3), followed by verification of positive clones 
via reporter cell activation assay with supernatants from the corresponding single clone.  
In case of the 1:10 and 1:100 mixing experiments, enrichment of mIL-3 wt-secreting yeast cells was detected 
after a single selection round (Fig. 41). Supernatant from bulk populations, after the selection procedure and 
yeast expansion, induced enhanced activation of the reporter cells (Fig. 41A and B), with a significant increase 
in the mean GFP fluorescence signal in case of the 1:100 mix. PCR screen of random single clones indicated 3 
and 2 single clones with wildtype mIL-3 sequence from 13 tested clones after the first-round of the selection of 
the 1:10 and 1:100 mix, respectively (Figure S3A and B). Reporter cell activation assay with supernatants from 
the corresponding single clones confirmed biological activity of the secreted cytokines for all PCR-positive 
clones, except one (Fig. 41C). Nonetheless, the low reporter cell activation in case of clone 13 from the 1:10 mix 
lies with high probability on the very low cell density of the yeast culture, from which the supernatant was 
harvested.  
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Figure 41. Analysis of enrichment of reporter cell-activating yeast (mIL-3 wt) after a single functional screening round of a 1:10 
and 1:100 dilution with a non-functional mutant (mIL-3 E49G). (A) Flow cytometry histograms of reporter cell activation assay with 
supernatants (sn) of the populations before and after functional screening. (B) Mean GFP fluorescence of mammalian reporter cells after 
treatment with sn from the populations before and after functional screening in agarose microbeads. Statistical significance was analysed 
by One-way ANOVA, followed by Tukey HSD post-hoc test and was depicted with asterisks (*** P<0.001). (C) Reporter cell activation 
assay (mean GFP fluorescence) with sn from single clones after R1 of functional screening of the 1:10 and 1:100 mix. Single clones 
identified as mIL-3 wt by PCR screen are marked with an asterisk.  
 
In case of 1:1,000 and 1:10,000 mixing experiments, two consecutive functional screening rounds were 
performed leading to gradual enrichment of reporter cell-activating yeast in the sorted populations from both 
samples (Fig. 42A and B). PCR screening after the second selection round revealed about 26 % mIL-3 wildtype 
clones for the 1:1,000 mixing experiment (Figure S3C) and about 17 % in case of the 1:10,000 sample (Figure S4). 
All of those clones demonstrated secretion of biologically active cytokine, confirmed by a reporter cell activation 
assay with supernatants from the respective positive clones (Fig. 42A and C). This corresponds to a 259- and 
1666-times enrichment of mIL-3 wt-secreting yeast in the sorted populations, respectively (Table 3).  
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Figure 42. Analysis of enrichment of reporter cell-activating yeast (mIL-3 wt) after two consecutive functional screening rounds of 
a 1:1,000 and 1:10,000 dilution with a non-functional mutant (mIL-3 E49G). (A) Reporter cell activation assay with supernatants from 
bulk populations after the first and second sorting round of the 1:1,000 mixing experiment, as well as sn from single clones after the R2 
functional selection, which were identified as mIL-3 wt in a PCR screen. (B) Reporter activation with supernatants from the bulk 
populations from the 1:10,000 mixing experiments after the R1 and R2 of functional screening. (C) Reporter activation using supernatants 
from single clones after second functional selection round of 1:10,000 mixed yeast (mIL-3 wt : mIL-3 E49G). Tested single clones were 
identified as positive in a PCR screen using mIL-3 wt- specific primer. Statistical significance was analysed by One-way ANOVA, followed 
by Tukey HSD post-hoc test. GFP signals from relevant samples were statistically compared and the statistical significance was marked 
with asterisks (* P<0.05; ** P<0.01; *** P<0.001).   
 
All mixing experiments using an excess of yeast cell secreting the non-functional mIL-3 mutant, resulted in 
enrichment of yeast cells secreting the wildtype mIL-3 cytokine with biological activity. This proves the feasibility 
of the demonstrated selection approach based on functionality of secreted molecules from yeast cells, paired 
with mammalian reporter cell-based fluorescent readout through compartmentalisation in droplets with 
picolitre volume and FACS of hydrogel microbeads. The mixing experiments demonstrated one limitation of the 
process, regarding the enrichment degree to a maximum of 15-26 % (Table 3) of activating clones. However, this 
is compatible with most screening campaigns, since sufficient number of functionally active single clones could 
easily be identified by single clone analysis. If necessary, further increase in the enrichment degree could be 
achieved by decreasing the yeast cell density used for the co-encapsulation process. This would minimize 
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encapsulation of multiple yeast cells in the same droplet and thus, sorting of false positive yeast cells would be 
avoided.  
 
Table 3. Overview of the results of the mixing experiments with the non-functional mIL-3 E49G mutant. 
Ratio  
(wt : mutant) 
Round 1 Round 2 
Wildtype Clones Wildtype Enrichment  Wildtype Clones Wildtype Enrichment  
1:10 3 of 13 (23.1 %) 2.3 times not performed 
1:100 2 of 13 (15.4 %) 15.4 times not performed 
1:1,000 2 of 52 (3.85 %) 38.5 times 14 of 54 (25.9 %) 259.3 times 
1:10,000 not analysed 9 of 54 (16.7 %) 1666.6 times 
 
 
5.3.8. Generation of a mIL-3 randomized library and screening for active variants 
Functional screening procedure using mIL-3 + Ba/F3-CIS-d2EGFP activator-reporter system was verified using 
different ratios of yeast secretor cells producing the biologically active wildtype cytokine mixed with an excess 
of the non-functional mutant (E49G). Next, in order to test the functional screening approach in the context of 
yeast-based library comprising different cytokine variants, a small library was constructed by randomization of 
the knockout position (E49G) and the two surrounding amino acids (K48 and I50) (Fig. 43). Using a degenerative 
primer with NNR NNH HNN sequence (Fig. 43), a library with a theoretical diversity of 74,000 DNA sequences 
and 4,000 proteins was generated. Statistically, formation of only one mIL-3 wildtype molecule (1:4,000) was 
allowed and only generation of sequences with a codon distinct from the original glutamate codon (GAA instead 
of GAG)) at the position 49 was possible.  
 
 
Figure 43. Randomization site in the mIL-3 E49G gene.  
 
Randomization was performed by PCR and the library was transformed in S. cerevisiae (EBY100) using gap-repair 
cloning. Correct randomization was verified by Sanger sequencing, confirming desired distribution of the 
mutations (Figure S5A). Functional screening was performed in the same manner as the mixing experiments, by 
co-encapsulation of the library-secreting yeast cells together with the Ba/F3-CIS-d2EGFP reporter cells in 
agarose containing microdroplets (Fig. 29), followed by incubation overnight and FACS sorting of double-
fluorescent agarose microbeads (Figure S5B). Although four consecutive selection rounds were performed, no 
significant enrichment of reporter cells-activating yeast in the expanded populations could be observed 
(Fig. 44A). Moreover, testing reporter cell activation with supernatants of 50 single clones after the third 
selection round did not reveal GFP expression induction by any of the tested clones (Fig. 44B). Functional 
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selection, using the randomized library was repeated in three more rounds, starting with the initial library, 
however again without success in enrichment of biologically active mIL-3 variants.  
 
 
Figure 44. Analysis of enrichment of reporter cell-activating yeast after four consecutive functional screening rounds with yeast 
cells secreting the randomized mIL-3 library. (A) Reporter cell activation assay with supernatants from bulk yeast populations from 
each selection round (R1 – R4). (B) Reporter activation assay with supernatants from 50 randomly picked single yeast clones after R3 of 
functional selection. 
 
5.3.9. Next generation sequencing  
In order to gain an insight into the composition of the randomized library and to investigate the possible reasons 
for the failed enrichment of biologically active interleukin-3 variants, next generation sequencing (NGS) of the 
initial library, as well as of the yeast populations after selection rounds one to three was performed. For 
comparison, NGS of the 1:10,000 mIL-3 wt + mIL-3 E49G mixing experiments and of the corresponding enriched 
populations was performed, as well.  To this end, barcoded primer were designed for each yeast population 
(chapter 3.5.3) consisting of a partial Illumina sequence (capital letters), a specific barcode (bold letters) and a 
gene complementary region (small letters). Plasmids were isolated from each sample and PCR was performed 
for amplification of the randomized region with the specific NGS primer. PCR products were mixed and sent for 
next generation sequencing.  
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Figure 45. Analysis of NGS results. (A) Fold enrichment of mIL-3 wt NGS reads in the populations of the first and second rounds of 
functional screening of the 1 to 10,000 mixture of mIL-3 wt- and mIL-3 E49G-secreting yeast. (B) Relative abundance of wildtype mIL-3 
sequence in the initial randomized mIL-3 library and in the yeast populations after functional selection rounds one to three. Sequence 
analysis was performed with Geneious 2020.0.5. 
 
Over 120,000 NGS reads were obtained for the samples of both mIL-3 library and 1:10,000 mixing experiment. 
Analysis of the obtained sequences confirmed the gradual increase of wildtype mIL-3 sequences following each 
functional screening cycle of the 1:10,000 mixing experiment (Fig. 45A). However, in case of the randomized 
library, no enrichment of wildtype mIL-3 sequences could be observed (Fig. 45B). Although, statistically the 
frequency of wildtype cytokine clones should be 1 of 4,000 (0.025 %), the abundance of mIL-3 wt sequences in 
the initial library is only 0.012 % of all NGS reads, meaning the biologically active cytokine variant was twice as 
rare, as assumed. Furthermore, no significant enrichment of specific amino acid (aa) residues could be observed 
after detailed analysis of the NGS results (Fig. 46). Investigation of the relative frequency of all amino acid 
residues at the randomized positions (aa48, aa49, and aa50) revealed only minimal variation in the aa 
abundance between the selection rounds. Gradual enrichment of a specific residue throughout the selection 
process could only be observed for serine at position 49. However, in this case a fold enrichment of only 0.4 
times could be achieved within the three consecutive selection rounds, which is too low to interpret as 
significant.  After R2, valine is approx. 8 times more abundant at position 50 than in the initial library, however 
the relative frequency of this amino acid residue increased from 0.01 % to 0.08 % and dropped again to 0.01 % 
after the third selection cycle, indicating this result more likely as a sequencing artefact.  
NGS analysis of the randomized library enabled a deep investigation of the library composition before and during 
the functional selection process. The abundance of wt mIL-3 clones in the initial library was lower than expected, 
which could represent one explanation for the unsuccessful enrichment of biologically active cytokine variants 
from the randomized library. Nevertheless, even if the frequency of the wildtype clone was only 0.012 % 
(meaning 1 of 8,000 yeast clones), it is still higher than the wildtype frequency in the 1:10,000 mixing 
experiment. Since the applicability of the functional screening procedure was demonstrated using the same 
yeast and reporter cells for a row of mixing experiments, which all resulted in a rapid enrichment of the 
functional wildtype cytokine, the low mIL-3 wt frequency in the initial library should not represent a huge 
limitation for the selection process, as long as enough yeast cells were used for the encapsulation procedure.  
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Figure 46. Next generation sequencing (NGS) analysis of sorted populations after rounds one to three of functional selection of the 
mIL-3 randomization library. On the left: frequencies (%) of amino acid (aa) residues at the corresponding randomized position (aa48, 
aa49 and aa50) for each selection round. Amino acids are sorted alphabetically. On the right: relative fold enrichment of the aa residue at 
the corresponding position. Residues are sorted, starting with the highest enrichment factor. Sequence analysis was performed with 
Geneious 2020.0.5. 
 
Additionally, the randomization of the region which seems to be in high degree responsible for the functionality 
of the cytokine, could have unexpected negative effects on the properties of the molecules. On the one side, it 
was expected that additional amino acid combinations would also retain functionality of the cytokine. Klein et 
al. (1997) demonstrated that in the human IL-3 ortholog, the amino acid before the knockout position (D21) is 
involved in the interaction with the  subunit of the hIL-3 receptor, whereas the E22 is responsible for binding 
to the common  subunit (c)234. This means that both positions are sensitive to amino acid exchange and a 
random combination of amino acid side chains would rarely result in a functional protein. Furthermore, a 
mutational analysis of hIL-3 performed by Lambert et al. (1991), identified a row of cytokine mutants with 
significantly increased binding affinity to the IL-3 receptor, but with reduced stimulation activity237. High binding 
affinity of some mIL-3 variants in combination with co-encapsulation of multiple yeast cells in one droplet could 
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have led to false negative sorting events due to competition of the different mIL-3 mutants for the receptors on 
the reporter cell surface, which did not represent an issue during the mixing experiments. In this case if a mutant 
possesses a higher receptor binding affinity, but does not activate reporter response, a biologically active 
cytokine variant secreted by a yeast cell in the same droplet would not be capable of sufficient reporter 
induction. 
However, since the human and mouse interleukin-3 and the associated receptors share relatively low homology, 
no direct extrapolation of hIL-3 mutation sites and their effects on the cytokine functionality could be 
performed. Unfortunately, no studies regarding the binding mechanism of murine IL-3 to its receptors are 
available, thus the influence of the two E49-neighboring amino acids on the functionality of mIL-3 could only be 
speculated. Further deep investigation would be necessary in order to identify the reason why the functional 
selection of the randomized library did not result in enrichment of reporter-activating yeast cells. However, since 
the mIL-3 cytokine in combination with the Ba/F3-CIS-d2EGFP reporter cells was used as a proof-of-concept 
system, and the performance of the functional screening approach was validated with help of the mixing 
experiments, screening of the randomized library was not further pursued.  
 
5.4. Functional Selection of Agonistic anti-CD3 Antibodies 
As described in chapter 5.3, the functional screening approach proved suitable for the enrichment of yeast cells 
secreting a biologically active wildtype mIL-3 cytokine. However, the feasibility of this novel approach could not 
be directly extrapolated for applications involving much more complex and larger molecules such as antibodies. 
Since the long-term aim of this study is to establish a system for selection of functional antibodies (agonistic, 
antagonistic, or cytosol-penetrating antibodies), the functional screening procedure needed to be validated also 
in the context of antibody molecules.  
As a model system for selection of agonistic antibodies, a second reporter cell line – NF-B/Jurkat/GFP, was 
used. This cell line is based on leukemic human T lymphocytes and expresses high levels of mature T cell receptor 
(TCR) and low levels of CD4, but no CD8 or MHC class II238. Due to its cancerous origin and easy propagation and 
expansion, Jurkat cells are often used as a T cell model system for testing of diverse immunomodulators and T 
cell activators239. In vivo, T cells are activated by interaction of the TCR ( and  domains) with an antigen bound 
to the major histo-compatible complex (MHC) on antigen-presenting cells. Signal transduction is carried out by 
the CD3 (T3) molecular complex, which is noncovalently associated with the TCR240 (Fig. 47). Some CD3-specific 
antibodies have demonstrated T cell activation properties241 by ligation of the TCR-CD3 complex with synergistic 
effects in combination with anti-CD28 antibodies. Stimulation of primary T cells in this manner leads to cell 
proliferation and has been utilized for cell expansion protocols242, 243. 
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Figure 47. Activation of GFP expression in NF-B/Jurkat/GFP reporter cell line.  
 
5.4.1. NF-B/Jurkat/GFP reporter cell line activation mechanisms 
Signal transduction upon T cell activation results in initiation of a phosphorylation cascade involving 
phosphoinositide-3 kinase (PI-3 kinase)244, leading to the activation of transcription factors (NF-AT, NF-B, and 
AP-1)245. Regulation of reporter gene expression (GFP) in the NF-B/Jurkat/GFP cell line is mediated by multiple 
NF-B response elements (Fig. 47) resulting in GFP expression upon T cell activation by anti-CD3 antibodies. By 
co-stimulation with anti-CD28 antibodies, more transcription activators are released, leading to increased GFP 
expression and stronger fluorescence signal (Fig. 48). The NF-B pathway is involved in signal transduction 
cascades induced by multiple receptors, under which tumor necrosis factor receptor 1 (TNFR1)246. Thus, 
activation of reporter gene expression can also be triggered by stimulation with the cytokine TNF (Fig. 47), 
resulting in GFP fluorescence with medium intensity (Fig. 48). 
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Figure 48. Mean GFP fluorescence intensity upon 
stimulation of NF-B/Jurkat/GFP reporter cells. Cells 
were stimulated with 50 ng/mL rec. hTNF, 1 µg/mL anti-
CD3 monoclonal antibody (OKT3), or a mix of 1 µg/mL 
OKT3 + 1 µg/mL anti-CD28 monoclonal antibody. Cells were 
analysed by flow cytometry after 24 h of treatment.  
 
5.4.2. Reporter cell line activation using secreted hTNFα from yeast 
For investigation of NF-B/Jurkat/GFP fluorescence signal intensity in dependence to the hTNF-concentration, 
reporter cells were incubated with a dilution series of recombinant cytokine (0.15 – 10 ng/mL). Mean GFP 
fluorescence of the reporter cells increased in a dose-dependent manner with increasing hTNF-concentration 
(Fig. 49A) and the reporter cells exhibited strong GFP signal after treatment with cytokine in the range of 5-
10 ng/mL.  
A gene construct for expression and secretion of hTNF from S. cerevisiae yeast was generated (Fig. 50A) with 
the same composition as the construct for secretion of mIL-3 (secretion signal (app8), followed by the gene 
sequence of the cytokine, ribosomal skipping peptide (T2A) and intracellular expression control (mCherry)). 
Expression and secretion of hTNF by the yeast cells was validated by reporter cell activation assay with yeast 
culture supernatant. A significant increase in the GFP fluorescence of Jurkat reporter cells, incubated with the 
supernatant from hTNF-secreting yeast could be observed (Fig. 49B) in comparison to untreated reporter cells. 
As positive control, the reporter cells were treated with 10 ng/mL rec. hTNF and exhibited slightly stronger but 
still comparable GFP fluorescence intensity than the cells treated with the yeast supernatant.  
 
Figure 49. (A) Reporter activation in NF-B/Jurkat/GFP cell line in dependency to the hTNF concentration. Mean GFP 
fluorescence intensity determined by flow cytometry after incubation overnight of reporter cells in a 96-well plate with a dilution row 
(156 pg/mL – 10 ng/mL) of recombinant hTNF in standard cultivation medium (RPMI-1640). Dashed line represents a logarithmic 
trendline. (B) Flow cytometry histograms of NF-B/Jurkat/GFP reporter cells incubated with yeast supernatant after expression 
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and secretion of from hTNF from S. cerevisiae. Controls represent the GFP fluorescence signals of cells incubated with or without 
addition of rec. hTNF.    
 
5.4.3. Generation of OKT3-antibody secreting yeast  
Gene constructs for expression and secretion of anti-CD3 antibody (OKT3) from S. cerevisiae were generated in 
order to test in vitro T cell activation in the context of functional screening using the NF-B/Jurkat/GFP reporter 
cell line. Two plasmids carrying the gene sequences for the humanized OKT3 heavy (Fig. 11) and humanized 
OKT3 light chain (Fig. 12) were generated and yeast cells were co-transformed with both plasmids. Intracellular 
expression control was enabled by genetic fusion of a T2A ribosomal skipping peptide and mCherry fluorescent 
protein C-terminally to the heavy chain of the antibody (Fig. 50). 
 
 
 
Figure 50. Gene constructs for expression and 
secretion from S. cerevisiae. (A) Construct for 
secretion of human tumor necrosis factor alpha 
(hTNF). (B) Constructs for the heavy and light 
chains of humanized anti-CD3 antibody 
muromonab (OKT3). 
 
Secretion of functional OKT3 mAb was verified by treatment of Jurkat cells with supernatant from induced yeast 
cells, carrying the plasmids for OKT3 mAb. Bound OKT3 antibodies were detected using specific fluorescently 
labeled detection antibodies against the -light chain and the Fc domain of the antibody (Fig. 51). A significant 
shift of the Jurkat cells treated with the supernatant from OKT3-secreting yeast could be observed upon 
detection of the light chain of the antibody (Fig. 51A) indicating successful secretion of the antibody and binding 
to the target cells. Detection of the heavy chain with anti-Fc antibody resulted in a slight fluorescence shift 
compared to the negative control (cells treated only with the detection antibody) (Fig. 51B). Overall, these 
results indicate successful secretion of the anti-CD3 antibody from the yeast cells. However, the marginal shift 
in case of anti-human Fc-PE detection antibody implies low concentration of the antibody in the yeast 
supernatant.  
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Figure 51. Analysis of secretion and binding of anti-CD3 mAb OKT3 from S. cerevisiae. NF-κB/Jurkat/GFP cells were treated with 
supernatant from OKT3-secreting yeast (after 24 h of expression at 30 °C, 180 rpm) for 2 h on ice. Bound OKT3 antibody was detected 
with (A) anti-κ light chain-Alexa Fluor647 conjugate and (B) anti-human Fc-PE (phycoerythrin) conjugate. As negative control, 
NF-B/Jurkat/GFP cells were treated with the corresponding detection antibody.  
Next, in vitro T cell activation using supernatant from OKT3-secreting yeast was tested. Secreted hTNF from 
yeast cells at identical conditions (cell density etc.) was used as a control. Supernatants from both yeast cell 
cultures producing TNF or OKT3, respectively, were harvested and the same volume supernatant was added 
to the NF-B/Jurkat/GFP reporter cells. While reporter cell activation was detectable in case of the yeast 
supernatant from hTNF-secreting yeast cells (Fig. 52), very low increase of the GFP fluorescence signal was 
observable after treatment with supernatant from OKT3-secreting yeast in comparison to the negative control 
(untreated reporter cells). Again, this result points out a very low concentration of the secreted antibody in the 
yeast supernatant, insufficient to induce significant reporter cell activation.  
 
 
Figure 52. Reporter cell activation assay with yeast culture supernatants from OKT3 mAb- and hTNF-expressing yeast cells. 
Protein expression and secretion was carried out for 48 h at 30 °C, 180 rpm. Cell supernatant was harvested and 25 µL were added to 
100 µL reporter cell suspension (1 × 105 cells) in RPMI-1640 medium. Positive control represents reporter cells treated with 50 ng/mL rec. 
hTNF.   
 
5.4.4. Cocultivation of yeast and reporter cells in test tubes  
Reporter cells were cocultured with hTNF- and OKT3-secreting cells in order to investigate GFP expression rate 
under the coculturing conditions optimized for the Ba/F3-CIS-d2EGFP reporter cell line in combination with mIL-
3-secreting yeast cells. Reporter cells cocultured with hTNF-secreting yeast cells exhibited strong GFP 
fluorescence signal, which was comparable to the positive control (Fig. 53A). However, in vitro T cell activation 
by secreted OKT3 antibody from yeast cells was unsuccessful and no increase in the GFP fluorescence signal of 
the treated cells could be observed (Fig. 53B), although the cells were co-stimulated with anti-CD28 mAb. On 
the other side using 1 µg/mL commercially available OKT3 antibody in combination with the anti-CD28 mAb, 
resulted in an efficient T cell activation of the reporter cells, detected in form of increased GFP fluorescence 
intensity. This indicates that the culturing conditions under which the experiment was carried out are suitable 
for activation of the reporter cells both via the TNFR1 and CD3-receptors. Failed reporter cell activation by OKT3-
secreting yeast cells most probably result from insufficient expression and/or secretion of the full-length 
antibody in S. cerevisiae. Furthermore, while in case of the cytokine, concentration of only 0.5 nM (10 ng/mL) is 
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sufficient to induce strong GFP expression, in case of the antibody-mediated T cell activation by anti-CD3 mAb, 
a concentration of 6 nM (1 µg/mL) was required for moderate reporter cell activation. 
 
 
Figure 53. Cocultivation of live NF-B-Jurkat-GFP reporter reporter cells and S. cerevisiae cells secreting (A) hTNF or (B) anti-
CD3 mAb (OKT3). Both cell types were suspended in 1 mL medium mix (50 % RPMI-1640 + 50 % DMEM-F12 Ham), supplemented 
with 2 % w/v galactose and 1 % Pen/Strep and were cocultured in 50 mL reaction tubes. Negative control represents untreated reporter 
cells. As positive controls rec. hTNF (100 ng/mL) or a commercially available OKT3 antibody (1 µg/mL) were mixed to the cell medium. 
In case of antibody-mediated reporter cell activation assay, a co-stimulation was performed by addition 1 µg/mL anti-CD28 antibody to 
all samples. Flow cytometry analysis was performed after 20 h of cocultivation. Histograms depict the GFP fluorescence signal of the 
mammalian reporter cells only 
 
5.4.5. Cocultivation of anti-CD3 antibody-producing Expi293F cells and reporter cells  
To investigate, whether the observed low level of T cell activation was due to very low yeast secretion levels, we 
used Expi293F mammalian secretor cells which are known to produce and secrete significant amounts of 
antibodies. Hence, in vitro T cell activation by coculturing was further examined using a stably transfected 
Expi293F cell line which secretes another anti-CD3 antibody (SP34). In order to exclude false positive effects 
induced by the Expi293 cell line or the cultivation medium, a negative control with Expi293F cells stably 
expressing cetuximab (Expi-C225) was analysed. The stably transfected antibody-secreting Expi293F cells carry 
an intracellular mCherry fluorescent marker for transfection control and appear in the mCherry fluorescence 
channel as a separate population (Fig. 54). T cell activation of the reporter cells was observed by cocultivation 
with the SP34-secreting Expi293F cells (Expi-SP34) with about 9 % GFP positive Jurkat reporter cells. Co-
stimulation with the anti-CD28 antibody further increased the fraction of activated reporter cells to about 32 %, 
while positive control with yeast cells secreting hTNF resulted in approx. 36 % NF-B/Jurkat/GFP cells 
expressing the reporter protein (Fig. 54).   
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Figure 54. Reporter cell activation by cocultivation with anti-CD3 antibody (SP34)-secreting Expi293F cells. NF-B/Jurkat/GFP 
cells were resuspended in 1 mL of a medium mix, consisting of 50 % RPMI-1640 + 50 % Expi293 Expression medium. Expi293F cell 
stably expressing and secreting either anti-EGFR mAb cetuximab (C225) or anti-CD3 mAb (SP34) were added to the cell suspension. 
Anti-CD28 antibody was added at concentration at 1 µg/mL for co-stimulation of the T cell activation. As a positive control, reporter cells 
were cocultured with hTNF-secreting yeast cells as described above.  
 
5.4.6. Co-encapsulation experiments with NF-B/Jurkat/GFP reporter cells 
Activation of reporter cells in droplets was investigated by co-encapsulation with OKT3- and hTNF-secreting 
yeast cells, as well as with SP34-secreting Expi293F and hTNF-secreting CHO cells. Since the NF-B/Jurkat/GFP 
cell line demonstrated strong reduction of the cell viability by addition of hydrogel-forming polymers (alginate 
or agarose) to the encapsulation medium (Fig. 27B), these experiments were performed by encapsulation in 
droplets without addition of hydrogel-forming polymers.  
While no GFP expression could be observed in reporter cells co-encapsulated with the OKT3-secreting S. 
cerevisiae cells, a low induction level of GFP fluorescence of the NF-B/Jurkat/GFP cells co-encapsulated with 
hTNF-secreting yeast was observed (Fig. 55A). Notably, the positive control consisting of reporter cells co-
encapsulated with hTNF-secreting yeast in presence of recombinant hTNF, also resulted in a comparable low 
level of GFP production. This indicates that not the co-encapsulation efficiency of yeast and reporter cells is the 
reason for the limited reporter cell activation, but rather reduced reporter cell viability under the tested 
conditions may account for this finding. Interestingly, when NF-B/Jurkat/GFP cells were encapsulated alone in 
droplets in absence of any activator of reporter response, a fraction of the reporter cells still exhibited induced 
GFP expression, while this was not the case during the cocultivation experiments in test tubes (Fig. 53 and 
Fig. 54).  Activation of the NF-B pathway under stress conditions in the microdroplets could be an explanation 
for this phenomenon, since NF-B upregulation was reported in relation to serum deprivation and oxidative 
stress247.  
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Figure 55. Co-encapsulation experiments with NF-B/Jurkat/GFP reporter cells in microdroplets. (A) Reporter cells were co-
encapsulated in droplets without hydrogel with yeast cells secreting anti-CD3 antibody (OKT3) or hTNF. As negative control, reporter 
cells were encapsulated alone in microdroplets. As positive control, reporter cells were co-encapsulated with hTNFα-secreting yeast and 
50 ng/mL rec. hTNF were added to the encapsulation medium. Following a 20 h incubation at 37 °C, 8 % CO2, 110 rpm, the emulsion 
was broken, cells were resuspended in PBS and analysed by flow cytometry. (B) Reporter cells were co-encapsulated in droplets together 
with stably transfected mammalian cells secreting either hTNF (CHO-hTNF) or anti-CD3 antibody (Expi-SP34). Following a 20 h 
incubation at 37 °C, 8 % CO2, 110 rpm, the emulsion was broken, cells were resuspended in PBS and analysed by flow cytometry. As 
negative control, reporter cells were co-encapsulated with CHO-KI (wt) cells.     
Co-encapsulation with CHO cells stably expressing and secreting hTNF resulted in the strongest activation of 
the reporter cells (Fig. 55B) in this row of experiments. In case of co-encapsulation with SP34-secreting Expi293F 
cells, a fraction of the Jurkat reporter cells also exhibited elevated GFP signal. Nevertheless, the negative control 
(reporter cells co-encapsulated with wt CHO-KI cells) revealed induced GFP expression in some Jurkat cells as 
well. This hampers the estimation of the activation grade of the reporter cells in the context of functional 
selection of agonistic anti-CD3 antibodies. Therefore, further optimizations regarding the coculturing conditions 
in microdroplets and the secretion host for the anti-CD3 antibodies need to be carried out to enable the 
implementation of the NF-B/Jurkat/GFP cell line for functional selection purposes by encapsulation in 
microdroplets. 
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6. Conclusion and Outlook 
With the rapid expansion of the biopharmaceutical market, the demand for straightforward, cost-effective and 
time-saving discovery technologies for the generation of potent functional biologics has increased 
tremendously. The interest in the establishment of novel high-throughput functional screening methods, which 
surpass the limitations of the current state of the art technologies has raised, leading to the development of 
commercial platforms like Cyto-Mine® from Sphere Fluidics248, Beacon® Optofluidic Platform from Berkeley 
Light, and xPloration™ Screening Platform from xCella Biosciences249. All three systems exploit different 
compartmentalization strategies and aim to perform sophisticated single-cell screening and selection.  
In case of Cyto-Mine®, a microfluidic system is utilized for generation of picolitre-volume droplets and 
encapsulation of up to 40 million mammalian cells per day. The platform is optimized for detection of B cells or 
hybridomas, secreting an antibody of interest, which binds with high affinity to a soluble antigen and selection 
occurs in the same device by fluorescence-activated droplet-sorting (FADS). While easy to handle and with a 
user-friendly interface, this platform also brings certain disadvantages regarding detection only in a single 
fluorescence channel and limited incubation time of the emulsified cells. Furthermore, any kind of processing of 
the w/o emulsion off-chip is not possible, which limits the implementation of the device for some applications.  
The Beacon® Optofluidics System is developed for a broader spectrum of applications including antibody 
discovery, cell line development, cell therapy development (by selection, validation and characterisation of CAR 
T cells), as well as for synthetic biology and gene editing. The platform is based on compartmentalization of 
single cells into nanocavities (250 pL) by light impulses (optofluidics). Isolated single cells in NanoPen chambers 
can be cultured, expanded, assayed and exported for further analysis. Comprehensive fluorescent imaging of 
each cell enables the analysis and selection of desired cells, based as well on binding affinity of secreted 
immunoglobulins, as on biological functionality250. Although the Beacon® Optofluidics System promises to 
reduce drastically the development time and costs for cell-based therapies and antibody discovery and 
development, it comes with a high price tag both for the device and the consumables. Hence, the platform is 
mainly oriented on the big pharma industry, with Pfizer, Novartis, Roche, Amgen, and Sanofi, being some of the 
first customers which purchased the technology251.  
Another player in the field of single-cell functional screening is xCella Biosciences. The xPloration™ Screening 
Platform aims at complete coverage of the immune repertoire with screening throughput of 106 B cells in less 
than 4 hours. The system should enable selection of rare antibodies against challenging targets like GPCRs (G-
protein coupled receptors) and ion channels. B cells are compartmentalised in 40-µm-wide microcapillaries 
together with the target of interest (immobilized on beads) or with target/reporter cells. Antibody-target 
interaction and functionality are assayed over a period of time by time-lapse imaging249. Furthermore, the 
platform can be directly coupled to a next-generation sequencing (NGS) workflow for genotype analysis of hits.  
Although the described platforms operate with high precision and are optimized for specific applications, they 
remain unreachable for academic purposes due to very high device and material costs. Furthermore, these 
systems comprise integrated devices with no or limited modularity, making an alteration of the system and 
adaptation to alternative applications not readily achievable. Nevertheless, with the advantages of sample 
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miniaturization and encapsulation in distinct microdroplets, microfluidic-assisted screening has emerged as a 
promising next-generation approach. Fortunately, alternative, module-based microfluidic systems have become 
commercially available for reasonable price. Modular microfluidic systems enable controlled and efficient cell 
encapsulation under flexible conditions, allowing for a broader application range. 
In search of a screening approach for selection of cytoplasm-penetrating molecules in the scope of this doctoral 
research, a novel strategy for mammalian cell-based functional screening was developed by co-encapsulation of 
viable mammalian reporter cells with yeast secretor cells in millions of agarose-containing microdroplets. 
Encapsulation of cells in picolitre-volume droplets combines sample miniaturization and compartmentalization 
for phenotype-genotype coupling. Furthermore, the implementation of hydrogel-building polymers (e.g. 
agarose and alginate) makes the approach compatible with an ultra-high-throughput selection using a 
commercially available FACS device.  
S. cerevisiae was chosen as a secretion host since it combines the advantages of a microbial expression system, 
characterized by high-transformation efficiencies and fast growth, with those of eukaryotes which possess an 
unfolded protein response machinery for elimination of misfolded proteins prior to secretion252. In addition, in 
our lab both immune and combinatorial libraries have been generated in S. cerevisiae with high efficiency 
enabling the specific selection of desired proteins37, 253. As the glycosylation pattern has proven to have a 
significant influence upon the bioactivity, physicochemical properties, and pharmacokinetics of the majority of 
biologics254-256, S. cerevisiae brings further advantages in the context of functional screening, because human 
like N-glycosylation could successfully be engineered in this yeast257. Lastly, during this study S. cerevisiae has 
proven as a robust organism, capable of fast expansion after encapsulation in w/o emulsion and sorting of 
agarose microbeads. This enables functional screening in multiple rounds or different setups without risk of 
losing desired candidates due to low cell viability.  
While yeast surface display in combination with FACS represents a powerful technology for fast and efficient 
isolation of protein variants with desired specificities, secretion of the molecules of interest was inevitable for 
the purposes of functional screening of cell-penetrating antibodies. However, secretion of a library of molecules 
in the culture medium brings up challenges regarding the phenotype-genotype coupling, as well as makes sorting 
by FACS not feasible for pre-selection of the library in an affinity-based format, which would be necessary for 
selection of agonistic or antagonistic antibodies. Nevertheless, this limitation can be surpassed by simultaneous 
secretion and display of the library variants on the yeast surface by utilizing an inefficient ribosomal skipping 
motif (F2A) as described by Cruz-Teran et al. (2017)258. This strategy could enable alternating affinity-based and 
functional selection. Since it utilizes live mammalian cells, our system could also be applicable for selection of 
molecules with defined biological function against non-soluble membrane-associated targets like GPCRs and ion 
channels. The screening process in this case could consist of an initial pre-selection of the variants displayed on 
the yeast surface using a biopanning procedure with the target mammalian cells as demonstrated by Yang et al. 
(2019)259 for enrichment of target-specific variants. The enriched library would then be subjected to an ultra-
high-throughput phenotypic screening by co-encapsulation with the reporter cells, followed by FACS of hydrogel 
microbeads for isolation of hits with desired biological function.  
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In comparison, several similar screening approaches have been published recently, which once again emphasizes 
the high demand in the field of high-throughput functional selection. In 2017, Fang et al. proposed an affinity-
based antibody screening platform, based on co-encapsulation of antibody-secreting Pichia pastoris and fixed 
mammalian target cells in agarose microdroplets225. This study demonstrated that GMD-FACS is a reliable 
selection method and classical antibody staining procedures can be applied for the specific fluorescent detection 
of target-bound antibodies in the agarose microbeads. However, since this procedure was not optimized for 
viable mammalian cells, functional antibody screening would not be feasible.  
Another system for microfluidic-based functional antibody selection was introduced by Zheng et al. in 2018. In 
this study, the authors co-encapsulated phage-secreting E. coli and mammalian reporter cells in medium-
containing aqueous droplets and were able to detect reporter cell activation by agonist antibody fragment (scFv) 
presented on the phage surface260. This work expands the compatibility of droplet-based functional screening 
towards one of the best-established screening approaches, phage display261. However, the authors have not 
performed selection of agonistic antibodies in w/o emulsion and discussed the necessity of establishing a double 
emulsion-generation protocol to combine the procedure with FACS selection. We are convinced that in 
combination with a straightforward ultra-high-throughput GMD-FACS (by addition of agarose to the 
encapsulation medium) this approach would be feasible for phage display-based selection of agonistic antibody 
variants, bypassing the need of double emulsion generation, addressed by the authors.  
A further example, demonstrating the versatility of droplet-based functional screening utilizing mammalian 
reporter cells is the study of Yaginuma et al. (2019). In a similar to our system fashion, they co-encapsulated 
peptide-secreting S. cerevisiae with mammalian reporter cells, responding to activation of the G-protein coupled 
receptor hGLP1R262. The fluorescence readout, in this case, was achieved by expression and secretion of β-
galactosidase (LacZ) as a reporter enzyme, which converts a non-fluorogenic substrate, added to the droplets, 
into a fluorescent molecule. Selection of agonistic peptide variants from a randomized peptide library was 
performed by co-encapsulation of the peptide-secreting yeast with the reporter cells and manual microscopical 
observation of the droplets, followed by isolation of the highly fluorescent droplets by a micromanipulator. This 
study illustrates the applicability of droplet-based cocultivation screens utilizing viable mammalian cells for 
addressing challenging targets as GPCRs, where the generation of reliable soluble protein for standard affinity-
based screens is not trivial. However, the throughput of this system is mainly limited by the microscope-assisted 
isolation of fluorescent droplets. 
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6.1. Summary  
A novel functional screening procedure was developed based on co-encapsulation of viable mammalian reporter 
cells with yeast secretor cells in millions of agarose-containing microdroplets. This generic approach is 
compatible with an ultra-high-throughput screening utilizing a commercially available FACS device without need 
of extensive optimization and adaptation and may be implemented for selection of new functional biologics, 
including cytokines, agonistic or internalizing antibodies, and soluble receptors. 
During this doctoral research, commonly used emulsification strategies (bulk emulsification and microfluidic-
assisted droplet generation) were tested and resulting hydrogel microbeads were compared. Droplet generation 
utilizing a microfluidic system showed superiority for production of monodispersed and homogeneous droplets 
with desired size. Microdroplet generation was optimized using a µEncapsulator microfluidic system and fast 
and efficient encapsulation of cells in a high number of hydrogel microbeads was achieved. Furthermore, 
gelation conditions of three different hydrogel-forming substances (agarose, Matrigel and alginate) were tested. 
Thermal gelation of agarose and Matrigel was possible resulting in stable microbeads, which could readily be 
recovered in an aqueous buffer. However, upon cultivation of mammalian cells in Matrigel-containing droplets, 
no hydrogel gelation took place, suggesting degradation of the matrix by secreted proteases. External and 
internal crosslinking of alginate was tested and resulting calcium alginate microbeads were compared. Internal 
gelation by addition of chelated Ca2+ to the encapsulation solution and following Ca2+-release under acidic 
conditions yielded uniform and homogeneous alginate microbeads. Reporter cell viability in the hydrogel 
microbeads was investigated revealing enhanced reporter cell mortality in presence of hydrogel-forming 
polymers, especially in case of alginate. Expression of reporter protein (GFP) upon stimulation of reporter cells 
was highly dependent on the cell viability in the microdroplets, being high in medium-only droplets and strongly 
impaired in alginate-containing microdroplets. Hence, agarose was used as a hydrogel-of-choice, since it enabled 
sufficient cell viability and reporter cell activation.  
In a proof-of-concept model study the functional selection procedure was validated. Therefore, activation of a 
murine reporter cell line (Ba/F3-CIS-d2EGFP) by murine interleukin-3 secreted by yeast cells, was extensively 
characterized and a non-functional mIL-3 mutant was designed and secreted from yeast cells. Mixing 
experiments with different ratios of “activating” mIL-3 wt-secreting yeast in an excess of yeast cells secreting 
the non-functional (E49G) mutant resulted in rapid enrichment of the biologically active cytokine after functional 
selection by co-encapsulation with the reporter cells and FACS. Selection progress in each screening round was 
monitored by reporter cell activation assays using supernatants from the enriched yeast populations, revealing 
gradual enrichment of functional cytokine after each functional selection cycle. A randomized library was 
generated for regain-of-function screening experiments. NGS analysis of the generated library confirmed the 
presence of wt-mIL-3 sequence, however it was twice as rare in the yeast population, as expected. No 
enrichment of reporter cell-activating yeast variants could be observed after four consecutive cycles of 
functional selection, raising uncertainty whether the randomization of the protein site have had unexpected 
negative effects.  
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For adaptation of the functional selection system towards screening of agonistic antibodies, an immortalized T 
cell reporter cell line was used. Induction of reporter protein expression (GFP) was possible using secreted 
hTNF from yeast cells, but was not successful by secretion of agonistic anti-CD3 antibody (OKT3). Secretion of 
another anti-CD3 antibody variant (SP34) from stably transfected mammalian cells resulted in strong T cell 
activation of the reporter cells after co-stimulation with an anti-CD28 antibody in cell suspension, but was 
limited in w/o emulsion. Furthermore, unspecific activation of the reporter cell line was observed after 
encapsulation in microdroplets, implying reporter gene expression under stress conditions and nutrient 
deprivation. 
 
6.2. Outlook  
In conclusion, a novel concept for selection of biomolecules, based on their biological function in an ultra-high-
throughput manner was developed and validated. Co-encapsulation and cocultivation of reporter mammalian 
cells and secretor yeast cells in picolitre-volume droplets containing hydrogel-forming polymers was challenging 
with respect to retaining the viability and functionality of both cell types. Reduced reporter cell viability was 
observed in presence of alginate and agarose polymers, hence, further optimization of the composition of the 
encapsulation medium would be beneficial. Since the co-encapsulation efficiency of both cell types plays an 
important role for the throughput of the system, and flocculation of the yeast demonstrated negative effects 
upon the distribution of the yeast cells in the generated droplets, a deeper investigation of the encapsulation 
medium composition and its effects on yeast cell flocculation should be performed. Additives like EDTA or sugars 
(mannose)263 should be tested for dispersion of yeast flocs and their influence on the protein secretion rate of 
the yeast and reporter cell viability should be carefully evaluated.  
Using a murine reporter cell line (Ba/F3-CIS-d2EGFP) which expresses GFP upon stimulation with murine 
interleukin-3, the functional selection approach was validated. Mixing experiments in different ratios (1:10, 
1:100, 1:1,000, and 1:10,000) using a non-functional mIL-3 mutant resulted in rapid enrichment of yeast cells 
secreting the biologically active mIL-3 wildtype cytokine. The extent of mIL-3 wt-enrichment was limited to 15-
25 % in the yeast population, which was sufficient to identify multiple positive clones by testing single yeast 
clones. However, further efforts of optimizing the screening conditions should be invested aimed at improving 
the enrichment factor by performing additional selection rounds with decreased yeast cell density in the 
encapsulation medium during droplet generation, since this would minimize sorting of false positive yeast 
clones.  
Since the aim of the research was to establish a screening platform for functional antibodies (e.g. cell-
internalizing, agonistic or antagonistic properties), the functional selection concept should be optimized for 
selection of antibody-secreting yeast cells. Initial experiments using anti-CD3 agonistic antibody (OKT3), 
secreted from S. cerevisiae revealed new critical aspects, which need to be addressed.  
Firstly, secretion of the OKT3 antibody could be verified by specific binding to the target cells 
(NF-B/Jurkat/GFP), performed by staining with detection antibodies. However, the concentration of the 
antibody in the yeast supernatant was very low and only a slight shift in the fluorescence signal of the target 
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cells with bound antibodies could be observed. This implies very low antibody secretion levels from S. cerevisiae, 
and has been previously reported as an issue in case of large and complex proteins, such as full-length 
antibodies264. For this reason, we envisaged adaptation of the functional screening system to an alternative 
microbial secretion host, which is known for secretion of high amounts of full-length antibodies – Komagataella 
Phaffii (Pichia pastoris)265. As demonstrated by Fang et al. (2017), P. pastoris is a suitable secretion host 
compatible with encapsulation procedures in agarose microbeads and following GMD-FACS selection225. 
Therefore, we are confident that our functional screening approach could be adapted for co-encapsulation with 
antibody-secreting P. pastoris. 
Nevertheless, even very low amounts of secreted OKT3 antibody should be sufficient for induction of T cell 
activation in the microdroplets. In a droplet volume of only 45 pL, secretion of as few as 1.6 × 105 antibody 
molecules would be sufficient to reach a concentration required for T cell activation (6 nM). While anti-CD3 
antibodies in soluble form have demonstrated immunosuppressive properties by blocking the TCR-CD3 complex 
for interaction with antigen-MHC complexes, T cell activation relies on crosslinking of the anti-CD3 antibody by 
Fc-receptors on accessory cells (monocytes)266 which induces T cell proliferation and systemic release of 
cytokines. Multiple reports have evidenced that proliferative effects of OKT3 on T cells depend on the antibody 
subclass and on its affinity to human Fc-receptors267, 268. Furthermore, humanization of OKT3 by CDR-grafting 
onto human IgG1 resulted in reduced mitogenic activity compared to the wildtype OKT3269. In our case, a 
humanized IgG1 OKT3 antibody was secreted from the yeast cells after grafting of the mouse CDRs to a human 
IgG1 framework, whereas recombinant mouse IgG2a OKT3 antibody (wt) was used as a positive control. In order 
to exclude possible decrease in the T cell activation levels due to the format alteration, the humanized OKT3 
variant should be recombinantly produced and reporter cell activation with the purified antibody should be 
tested. Additionally, secretion of the mouse IgG2a-OKT3 variant from yeast cells and reporter cell activation by 
coculturing with the reporter cells should be examined.  
A second aspect, which needs further investigation is the unspecific activation of the NF-B/Jurkat/GFP reporter 
cells after overnight culturing in microdroplets. Enhanced GFP fluorescence signal in approx. 5-10 % of all Jurkat 
cells was detected, although the cells were not treated either with hTNF, nor with anti-CD3 antibodies. Nuclear 
translocation of NF-B was described in Jurkat cells under stress conditions (nutrient deficiency)270 and could 
explain the unspecific GFP expression in the microdroplets, where the nutritional supply is limited. Thus, further 
optimization of the medium composition for droplet formation, as well as of the culturing conditions in the w/o 
emulsion would be necessary in order to increase the reporter cell viability and to reduce the unspecific GFP 
fluorescent signal in the agarose microbeads.  
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8. Appendix 
8.1. Supplementary Figures 
 
 
Figure S1. SDS-PAGE after antibody expression in Expi293F cells and purification by Protein A chromatography. (A) HerT4 
cytotransmab was generated by substitution of the trastuzumab VL by the VL of an autoantibody hT4. (B) Production of antibody constructs 
carrying a triple GFP11 tandem tag for detection of cytoplasmic localization by GFP complementation.  
 
 
 
 
 
Figure S2. FACS plots of first and second selection rounds of the 1:10, 1:100, 1:1,000, and 1:10,000 mIL-3 wt + mIL-3 E49G 
yeast mixtures, co-encapsulated with mammalian reporter cells. 
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Figure S3. PCR screen of single clones after functional screening of 1:10, 1:100, and 1:1,000 mIL-3 wt + mIL-3 E49G mixtures. (A) 
and (B) Colony PCR with 13 random single clones after R1 of functional selection of 1:10 and 1:100 mixtures, respectively. (C) Colony 
PCR with 52 or 54 random single clones after the first (left side) and second (right side) functional selection round, respectively, with 
1:1,000 mixed mIL-3 wt and mIL-3 E49G yeast cells. Colony PCR was performed using a primer specific for the wildtype mIL-3, resulting 
in specific band at approx. 400 bp. Positive single clones are marked with a red arrow.   
 
 
 
 
Figure S4. PCR screen of single clones after second round of functional screening of a 1:10,000 mIL-3 wt + mIL-3 E49G mixture. 
Colony PCR with a mIL-3 wt-specific primer was performed on 54 random single clones. PCR product corresponding to the wildtype mIL-
3 sequence is marked with a red arrow.  
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Figure S5. Generation and selection of randomized mIL-3 library. (A) Sequencing of the randomized region by Sanger sequencing. 
Plasmids from the yeast library populations were extracted and PCR was performed using primer outside the randomized region and PCR 
product was sent for sanger sequencing. (B) Functional selection of the mIL-3 library secreted by yeast cells using co-encapsulation of 
Ba/F3-CIS-d2EGFP reporter cells in agarose microbeads. Functional screening was performed in four consecutive selection rounds 
comprised of co-encapsulation, incubation, FACS sorting and yeast expansion. 
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8.2. Protein Sequences 
Trastuzumab heavy chain:  
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQM
NSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA
LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGLLQG 
 
Trastuzumab light chain: 
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATY
YCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 
 
hT4 light chain: 
DLVMTQSPSSLSASVGDRVTITCKSSQSLFNSRTRKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQP
EDFATYYCQQYYYHMYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESV
TEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 
 
Trastuzumab heavy chain- 3×(GFP11): 
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQM
NSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA
LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGRDHMVLHEYVNAAGITGGGGSGGGGSGGGSSRDHMVLHEYVNAA
GITGGGGSGGGGSGGGSSRDHMVLHEYVNAAGITGGGGSGGKFM 
 
Split turbo GFP1-10 fragment: 
MVSKGEELFTGVVPILVELDGDVNGHKFSVRGEGEGDATIGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDF
FKSAMPEGYVQERTISFKDDGKYKTRAVVKFEGDTLVNRIELKGTDFKEDGNILGHKLEYNFNSHNVYITADKQKNGIKANFTVR
HNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQTVLSKDPVGLVRLINGSGIPPLSLPPP 
 
Split turbo GFP11 fragment: 
RDHMVLHEYVNAAGIT 
 
app8 secretion signal: 
MRFPSIFTAVLFAASSALAAPANTTTEDETAQIPAEAVIDYSDLEGDFDAAALPLSNSTNNGLSSTNTTIASIAAKEEGVQLDKR 
 
T2A ribosomal skipping motif: 
EGRGSLLTCGDVEENPGP 
 
mCherry red fluorescent protein: 
MCVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHP
ADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGAL
KGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK 
 
mIL-3 wildtype: 
DTHRLTRTLNCSSIVKEIIGKLPEPELKTDDEGPSLRNKSFRRVNLSKFVESQGEVDPEDRYVIKSNLQKLNCCLPTSANDSALPGV
FIRDLDDFRKKLRFYMVHLNDLETVLTSRPPQPASGSVSPNRGTVEC 
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mIL-3 E49G: 
DTHRLTRTLNCSSIVKGIIGKLPEPELKTDDEGPSLRNKSFRRVNLSKFVESQGEVDPEDRYVIKSNLQKLNCCLPTSANDSALPGV
FIRDLDDFRKKLRFYMVHLNDLETVLTSRPPQPASGSVSPNRGTVEC 
 
hTNFα: 
VRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIA
VSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL 
 
OKT3 heavy chain (humanized, CDRs marked in bold): 
QVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISRDNSKNTAFL
QMDSLRPEDTGVYFCARYYDDHYCLDYWGQGTPVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG
ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
 
OKT3 light chain (humanized, CDRs are marked in bold): 
DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIAT
YYCQQWSSNPFTFGQGTKLQITRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS
KDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 
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8.5. Abbreviations 
Abbreviation Meaning 
aa amino acid 
AP-1 activator protein 1 
CD28 T cell surface receptor for CD80 and CD86 proteins 
CD3 cluster of differentiation 3 
CDR complementarity determining region 
CH1 antibody constant domain 1 of the heavy chain 
CL antibody constant domain of the light chain 
EGFR, Her1 epidermal growth factor receptor 
Fab fragment variable 
Fab fragment antigen binding of an antibody 
FACS fluorescence activated cell sorter 
FBS fetal bovine serum 
Fc fragment cristallizable of an antibody 
GMD-FACS gel microdroplet fluorescence-activated cell sorting 
GPCR G-protein coupled receptor 
HC antibody heavy chain 
Her2 human epidermal growth factor receptor 2 
hIL-3 human interleukin-3 
HSPG heparan sulfate proteoglycan  
IL-3 interleukin-3 
LC antibody light chain 
mAb monoclonal antibody 
mIL-3 murine interleukin-3 
NF-AT nuclear factor of activated T cells 
NF-κB nuclear factor “kappa-light-chain-enhancer” of activated B-cells 
PDMS poly-di-methyl-siloxane 
Pen/Strep Penicillin – Streptomycin 
rec. mIL-3 recombinant interleukin-3 
scFv single chain variable fragment 
scFv single chain variable fragment 
sn supernatant 
TCR T cell receptor 
VH antibody variable domain of the heavy chain 
VL antibody variable domain of the light chain 
w/o water-in-oil 
w/o/w water-in-oil-in-water 
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